Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAVXR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 02	STN pricing information for 2008 now available
NEWS 3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5	JAN 28	MARPAT searching enhanced
NEWS 6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9	FEB 08	STN Express, Version 8.3, now available
NEWS 10	FEB 20	PCI now available as a replacement to DPCI
NEWS 11	FEB 25	IFIREF reloaded with enhancements
NEWS 12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 29	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 30	JUN 30	AEROSPACE enhanced with more than 1 million U.S.

```
                patent records
 NEWS 31  JUN 30  EMBASE, EMBAL, and LEMBASE updated with additional
                  options to display authors and affiliated
                  organizations
 NEWS 32  JUN 30  STN on the Web enhanced with new STN AnaVist
                  Assistant and BLAST plug-in
 NEWS 33  JUN 30  STN AnaVist enhanced with database content from EPFULL

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:29:06 ON 14 JUL 2008

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 11:29:27 ON 14 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 JUL 2008  HIGHEST RN 1033821-28-1
DICTIONARY FILE UPDATES:  13 JUL 2008  HIGHEST RN 1033821-28-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> e fosphenytoin/CN
E1            1     FOSOR/CN
```

```
E2              1     FOSPAN/CN
E3              1 --> FOSPHENYTOIN/CN
E4              1     FOSPHENYTOIN SODIUM/CN
E5              1     FOSPINOL/CN
E6              1     FOSPIRAT/CN
E7              1     FOSPIRATE/CN
E8              1     FOSPIRATE-ETHYL/CN
E9              1     FOSPIRATE-METHYL/CN
E10             1     FOSPOLIOL/CN
E11             1     FOSPOLIOL 2/CN
E12             1     FOSPOLIOL II/CN

=> e cerebyx/cn
E1              1     CEREBROSTEROL/CN
E2              1     CEREBRUM, DRIED/CN
E3              1 --> CEREBYX/CN
E4              1     CEREC/CN
E5              1     CEREC 3/CN
E6              1     CEREC II VITABLOCK MARK II/CN
E7              1     CEREC MARK II/CN
E8              1     CEREC VITA DUOCEMENT/CN
E9              1     CEREC VITABLOCS MARK II/CN
E10             1     CERECALASE/CN
E11             1     CERECIN (ANTIBIOTIC)/CN
E12             1     CERECLOR/CN

=> e prodilantin/cn
E1              1     PRODIGY PHENYL 3/CN
E2              1     PRODIGY Z 250-3M/CN
E3              0 --> PRODILANTIN/CN
E4              1     PRODILIDINE/CN
E5              1     PRODILIDINE HYDROCHLORIDE/CN
E6              1     PRODIMINE/CN
E7              1     PRODINE/CN
E8              1     PRODIOL/CN
E9              1     PRODIPEPTIDYL-PEPTIDASE I (HUMAN REDUCED)/CN
E10             1     PRODIPINE/CN
E11             1     PRODIPINE HYDROCHLORIDE/CN
E12             1     PRODISTENIDIN B 2/CN

=> e 5,5-diphenylhydantoin/cn
E1              1     5,5-DIPHENYLGLYCOCYAMIDINE/CN
E2              1     5,5-DIPHENYLHEXAHYDROAZEPIN-2-ONE/CN
E3              1 --> 5,5-DIPHENYLHYDANTOIN/CN
E4              1     5,5-DIPHENYLHYDANTOIN COMPD. WITH 1-(4-BROMOPHENYL)-4-DIMETH
                      YLAMINO-2,3-DIMETHYL-3-PYRAZOLIN-5-ONE (1:1)/CN
E5              1     5,5-DIPHENYLHYDANTOIN SODIUM/CN
E6              1     5,5-DIPHENYLHYDANTOIN-3-(Ω-VALERIC ACID)/CN
E7              1     5,5-DIPHENYLHYDANTOIN-3-BUTYRIC ACID/CN
E8              1     5,5-DIPHENYLIMIDAZOLIDINE-4-ONE-2-THIONE/CN
E9              1     5,5-DIPHENYLOCTAFLUOROGERMANTHRENE/CN
E10             1     5,5-DIPHENYLPENTANAL/CN
E11             1     5,5-DIPHENYLPENTANOIC ACID/CN
E12             1     5,5-DIPHENYLPENTYLAMINE/CN

=> d e3
NO L# DEFINED

=> s e3
L1              1 "5,5-DIPHENYLHYDANTOIN"/CN
```

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 57-41-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2,4-Imidazolidinedione, 5,5-diphenyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Hydantoin, 5,5-diphenyl- (8CI)
OTHER NAMES:
CN 5,5-Diphenyl-1H-imidazolidine-2,4-dione
CN 5,5-Diphenyl-2,4-imidazolidinedione
CN 5,5-Diphenylhydantoin
CN Aleviatin
CN Denyl
CN Di-Hydan
CN Di-Lan
CN Dihycon
CN Dilabid
CN Dintoina
CN Diphantoin
CN Diphedan
CN Diphenat
CN Diphenylan
CN Diphenylhydantoin
CN DPH
CN Ekko
CN Hidantal
CN Hydantol
CN Lehydan
CN Lepitoin
CN NSC 8722
CN Phenytoin
CN Phenytoine
CN Sodanton
CN Zentropil
DR 125-59-7
MF C15 H12 N2 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, USPATOLD, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
            7963 REFERENCES IN FILE CA (1907 TO DATE)
             138 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
            7973 REFERENCES IN FILE CAPLUS (1907 TO DATE)
              10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


=> s e5
L2             1 "5,5-DIPHENYLHYDANTOIN SODIUM"/CN

=> d l2

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   630-93-3  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   2,4-Imidazolidinedione, 5,5-diphenyl-, sodium salt (1:1)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   2,4-Imidazolidinedione, 5,5-diphenyl-, monosodium salt (9CI)
CN   Hydantoin, 5,5-diphenyl-, sodium salt (8CI)
OTHER NAMES:
CN   5,5-Diphenylhydantoin sodium
CN   Aleviatin sodium
CN   Antisacer
CN   Danten
CN   Difenin
CN   Difhydan
CN   Dilantin
CN   Diphantoine
CN   Diphenin
CN   Diphenine
CN   Diphenylan sodium
CN   Diphenylhydantoin sodium
CN   Ditoin
CN   Enkefal
CN   Epanutin
CN   Epelin
CN   Epilan D
CN   Epsolin
CN   Eptoin
CN   Fenitoin sodium
CN   Hydantin
CN   Hydantoinal
CN   M-toin
CN   Minetoin
CN   Phenyloin
CN   Phenytoin sodium
CN   Phenytoin soluble
CN   Prompt
CN   Sodium 5,5-diphenyl-2,4-imidazolidinedione
CN   Sodium 5,5-diphenylhydantoin
CN   Sodium diphenylhydantoin
CN   Sodium diphenylhydantoinate
CN   Sodium phenytoin
CN   Solantyl
CN   Soluble Phenytoin
CN   Tacosal
DR   8017-52-5, 143-75-9, 1421-15-4
MF   C15 H12 N2 O2 . Na
CI   COM
LC   STN Files:   ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO,
       CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM,
```

DDFU, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB,
IMSCOSEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, PS, RTECS*,
SPECINFO, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (57-41-0)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2218 REFERENCES IN FILE CA (1907 TO DATE)
14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2221 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> e fosphenytoin/cn
E1            1     FOSOR/CN
E2            1     FOSPAN/CN
E3            1 --> FOSPHENYTOIN/CN
E4            1     FOSPHENYTOIN SODIUM/CN
E5            1     FOSPINOL/CN
E6            1     FOSPIRAT/CN
E7            1     FOSPIRATE/CN
E8            1     FOSPIRATE-ETHYL/CN
E9            1     FOSPIRATE-METHYL/CN
E10           1     FOSPOLIOL/CN
E11           1     FOSPOLIOL 2/CN
E12           1     FOSPOLIOL II/CN

=> s e3
L3            1 FOSPHENYTOIN/CN

=> d l3

L3   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   93390-81-9  REGISTRY
ED   Entered STN:  18 Dec 1984
CN   2,4-Imidazolidinedione, 5,5-diphenyl-3-[(phosphonooxy)methyl]-  (CA INDEX
     NAME)
OTHER NAMES:
CN   (3-Phosphoryloxymethyl)phenytoin
CN   Cerebyx
CN   Fosphenytoin
MF   C16 H15 N2 O6 P
CI   COM
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, CA, CAPLUS,
```

CASREACT, CBNB, CHEMCATS, CIN, DDFU, DRUGU, HSDB*, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

139 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
140 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> e sodium fosphenytoin/cn
E1            1     SODIUM FORMYLCYCLOPENTADIENIDE/CN
E2            2     SODIUM FOSFOMYCIN/CN
E3            0 --> SODIUM FOSPHENYTOIN/CN
E4            1     SODIUM FRUCTOHEPTONATE/CN
E5            1     SODIUM FRUCTOSE 1,6-DIPHOSPHATE/CN
E6            1     SODIUM FRUCTOSE BISULFITE/CN
E7            1     SODIUM FUCIDATE/CN
E8            1     SODIUM FULLERENE (NA2C60)/CN
E9            1     SODIUM FULLERENE (NA3C60)/CN
E10           1     SODIUM FULLERENE (NAC60)/CN
E11           1     SODIUM FULLERIDE (NA0-6C60)/CN
E12           1     SODIUM FULLERIDE (NA0.5C60)/CN

=> e (fosphenytoin sodium)/cn
E1            1     (FORMYLOXY)TRIHEXYLSILANE/CN
E2            1     (FORMYLPHENYL)BORON OXIDE, THIOSEMICARBAZONE/CN
E3            0 --> (FOSPHENYTOIN SODIUM)/CN
E4            1     (FULLERENE-C60)(BIS(TRIPHENYLPHOSPHINE)PALLADIUM)/CN
E5            1     (FUMARATO)BIS(THIOUREA)ZINC/CN
E6            1     (FUMARODINITRILE)(PHTHALOCYANINATO)RUTHENIUM/CN
E7            1     (FUMARODINITRILE)(PHTHALOCYANINATO)RUTHENIUM HOMOPOLYMER/CN
E8            1     (FUMARONITRILE)BIS(TRI-O-TOLYL PHOSPHITE)NICKEL/CN
E9            1     (FUMARONITRILE)BIS(TRIPHENYLARSINE)PALLADIUM/CN
E10           1     (FUMARONITRILE)BIS(TRIPHENYLARSINE)PLATINUM/CN
E11           1     (FURAN-2-YL)(2-METHYL-7-(2,4,6-TRIMETHYLPHENYL)-4,5,6,7-TETR
                    AHYDRO-2H-PYRAZOLO(3,4-B)PYRIDIN-3-YL)METHANOL/CN
E12           1     (FURAN-2-YL)(3-HYDROXYMETHYLPIPERIDIN-1-YL)METHANONE/CN

=> d l1 1 IDE

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   57-41-0  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   2,4-Imidazolidinedione, 5,5-diphenyl-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Hydantoin, 5,5-diphenyl- (8CI)
```

OTHER NAMES:
CN 5,5-Diphenyl-1H-imidazolidine-2,4-dione
CN 5,5-Diphenyl-2,4-imidazolidinedione
CN 5,5-Diphenylhydantoin
CN Aleviatin
CN Denyl
CN Di-Hydan
CN Di-Lan
CN Dihycon
CN Dilabid
CN Dintoina
CN Diphantoin
CN Diphedan
CN Diphenat
CN Diphenylan
CN Diphenylhydantoin
CN DPH
CN Ekko
CN Hidantal
CN Hydantol
CN Lehydan
CN Lepitoin
CN NSC 8722
CN Phenytoin
CN Phenytoine
CN Sodanton
CN Zentropil
DR 125-59-7
MF C15 H12 N2 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, USPATOLD, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7963 REFERENCES IN FILE CA (1907 TO DATE)
138 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
7973 REFERENCES IN FILE CAPLUS (1907 TO DATE)
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 35.87 36.08

FILE 'CAPLUS' ENTERED AT 11:45:37 ON 14 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Jul 2008 VOL 149 ISS 3
FILE LAST UPDATED: 13 Jul 2008 (20080713/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s l1 l2 l3
MISSING OPERATOR L1 L2
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l1
L4         7973 L1

=> s l2
L5         2221 L2

=> s l1 and l2 and l3
           7973 L1
           2221 L2
            140 L3
L6           11 L1 AND L2 AND L3

=> d scan ti hit

L6    11 ANSWERS   CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Composition comprising a tramadol material and an anticonvulsant drug
IT   630-93-3, Phenytoin sodium
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (diphenylan sodium; synergistic combination of tramadol and an
        anticonvulsant)
IT   50-06-6, Phenobarbital, biological studies   50-11-3, Metharbital
     50-12-4, Mephenytoin 57-41-0, Phenytoin   59-66-5, Acetazolamide
     61-56-3, Sulthiame   63-98-9, Phenacemide   77-41-8, Methsuximide
     77-67-8, Ethosuximide   86-34-0, Phensuximide   86-35-1, Ethotoin
     99-66-1, Valproic acid   115-38-8, Mephobarbital   115-67-3,
     Paramethadione   125-33-7, Primidone   127-48-0, Trimethadione   298-46-4,
```

Carbamazepine 1069-66-5, Valproate sodium 1622-61-3, Clonazepam 4350-09-8, L-5-Hydroxytryptophan 7487-88-9, Magnesium sulfate, biological studies 12794-10-4, Benzodiazepine 22316-47-8, Clobazam 62666-20-0, Progabide 76584-70-8, Divalproex sodium 76824-35-6, Famotidine 80456-81-1 93390-81-9, Fosphenytoin 123134-25-8 123154-38-1 144830-14-8 144830-15-9 147441-56-3 147513-51-7 147513-52-8 148553-50-8, Pregabalin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synergistic combination of tramadol and an anticonvulsant)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 11 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
TI Novel drug delivery system
IT 50-02-2, Dexamethasone 50-04-4, Cortisone Acetate 50-06-6, Phenobarbital, biological studies 50-07-7, Mitomycin 50-12-4, Mephenytoin 50-13-5, Meperidine Hydrochloride 50-14-6D, Vitamin D2, hydroxy derivs. 50-18-0, Cyclophosphamide 50-19-1, Hydroxyphenamate 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-33-9, Phenylbutazone, biological studies 50-34-0, Propantheline Bromide 50-35-1, Thalidomide 50-36-2, Cocaine 50-42-0, Adiphenine Hydrochloride 50-44-2, Mercaptopurine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-55-5, Reserpine 50-56-6, Oxytocin, biological studies 50-57-7, Lypressin 50-58-8, Phendimetrazine Tartrate 50-59-9, Cephaloridine 50-65-7, Niclosamide 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-05-8, Procaine Hydrochloride 51-15-0, Pralidoxime Chloride 51-21-8, Fluorouracil 51-30-9, Isoproterenol Hydrochloride 51-40-1, Norepinephrine Bitartrate 51-43-4, Epinephrine 51-52-5, Propylthiouracil 51-55-8, Atropine, biological studies 51-56-9, Homatropine Hydrobromide 51-57-0, Methamphetamine Hydrochloride 51-64-9, Dextroamphetamine 51-74-1, Histamine Phosphate 51-83-2, Carbachol 52-01-7, Spironolactone 52-24-4, Thiotepa 52-28-8, Codeine phosphate 52-43-7, Allobarbital 52-49-3, Trihexyphenidyl Hydrochloride 52-67-5, Penicillamine 52-68-6, Metrifonate 52-76-6, Lynestrenol 52-86-8, Haloperidol 52-88-0, Methylatropine Nitrate 52-89-1, Cysteine Hydrochloride 53-03-2, Prednisone 53-16-7, Estrone, biological studies 53-19-0, Mitotane 53-34-9, Fluprednisolone 53-39-4, Oxandrolone 53-43-0, Dehydroepiandrosterone 53-60-1, Promazine Hydrochloride 53-73-6, Angiotensin Amide 53-79-2, Puromycin 53-84-9, Nadide 53-86-1, Indometacin 54-03-5, Hexobendine 54-05-7, Chloroquine 54-21-7, Sodium Salicylate 54-31-9, Furosemide 54-35-3, Penicillin G Procaine 54-36-4, Metyrapone 54-42-2, Idoxuridine 54-64-8, Thimerosal 54-84-2, Cinanserin Hydrochloride 54-85-3, Isoniazide 54-91-1, Pipobroman 55-03-8, Levothyroxine Sodium 55-06-1, Liothyronine sodium 55-21-0D, Benzamide, N-Substituted 55-48-1, Atropine sulfate 55-63-0, Nitroglycerin 55-86-7, Mechlorethamine Hydrochloride 55-91-4, Isoflurophate 55-98-1, Busulfan 56-41-7, Alanine, biological studies 56-45-1, Serine, biological studies 56-47-3, Desoxycorticosterone Acetate 56-53-1, Diethylstilbestrol 56-59-7, Felypressin 56-75-7, Chloramphenicol 56-84-8, Aspartic Acid, biological studies 56-87-1, Lysine, biological studies 56-89-3, Cystine, biological studies 56-94-0, Demecarium Bromide 57-13-6, Urea, biological studies 57-33-0 57-41-0, Phenytoin 57-47-6, Physostigmine 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol 57-65-8, Thyromedan Hydrochloride 57-66-9, Probenecid 57-68-1, Sulfamethazine 57-83-0, Progesterone, biological studies 57-91-0, 17-α-Estradiol 57-94-3, Tubocurarine Chloride 57-96-5, Sulfinpyrazone 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine 58-18-4, Methyltestosterone 58-22-0, Testosterone

58-25-3, Chlordiazepoxide 58-28-6, Desipramine Hydrochloride 58-32-2, Dipyridamole 58-33-3, Promethazine hydrochloride 58-38-8, Prochlorperazine 58-39-9, Perphenazine 58-54-8, Ethacrynic Acid 58-55-9, Theophylline, biological studies 58-56-0, Pyridoxine hydrochloride 58-61-7, Adenosine, biological studies 58-71-9, Cephalothin Sodium 58-86-6, Xylose, biological studies 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-30-3, Folic Acid, biological studies 59-33-6, Pyrilamine Maleate 59-52-9, Dimercaprol 59-63-2, Isocarboxazid 59-66-5, Acetazolamide 59-87-0, Nitrofurazone 59-92-7, Levodopa, biological studies 59-97-2, Tolazoline Hydrochloride 60-13-9, Amphetamine Sulfate 60-18-4, Tyrosine, biological studies 60-23-1, Cysteamine 60-29-7, Ether, biological studies 60-31-1, Acetylcholine Chloride 60-45-7, Fenimide 60-54-8, Tetracycline 60-56-0, Methimazole 60-80-0, Antipyrine 60-87-7, Promethazine 60-99-1, Methotrimeprazine 61-25-6, Papaverine Hydrochloride 61-56-3, Sulthiame 61-57-4, Niridazole 61-68-7, Mefenamic Acid 61-73-4, Methylene Blue 61-75-6, Bretylium Tosylate 61-76-7, Phenylephrine Hydrochloride 61-90-5, Leucine, biological studies 62-51-1, Methacholine Chloride 62-68-0, Proadifen Hydrochloride 62-90-8, Nandrolone Phenpropionate 63-05-8, Androstenedione 63-12-7, Benzquinamide 63-39-8, Uridine triphosphate 63-45-6, Primaquine phosphate 63-68-3, Methionine, biological studies 63-89-8, Colfosceril Palmitate 63-91-2, Phenylalanine, biological studies 63-92-3, Phenoxybenzamine Hydrochloride 63-98-9, Phenacemide 64-31-3, Morphine Sulfate 64-43-7, Amobarbital Sodium 64-55-1, Mebutamate 64-75-5, Tetracycline hydrochloride 64-77-7, Tolbutamide 64-86-8, Colchicine 65-28-1, Phentolamine mesylate 65-29-2, Gallamine Triethiodide 65-45-2, Salicylamide 66-75-1, Uracil Mustard 66-76-2, DicumaroL 66-81-9, Cycloheximide 67-20-9, Nitrofurantoin 67-43-6, Pentetic Acid 67-45-8, Furazolidone 67-63-0, Isopropyl Alcohol, biological studies 67-68-5, Dimethyl Sulfoxide, biological studies 67-73-2, Fluocinolone Acetonide 67-92-5, Dicyclomine Hydrochloride 67-95-8, Quingestrone 67-96-9, Dihydrotachysterol 68-22-4, Norethindrone 68-23-5, Norethynodrel 68-35-9, Sulfadiazine 68-41-7, Cycloserine 68-89-3, Dipyrone 68-91-7, Trimethaphan Camsylate 68-96-2, 17-Hydroxy progesterone 69-09-0, Chlorpromazine hydrochloride 69-44-3, Amodiaquine Hydrochloride 69-53-4, Ampicillin 69-57-8, Penicillin G Sodium 69-65-8, Mannitol 69-72-7, Salicylic Acid, biological studies 69-74-9, Cytarabine Hydrochloride 70-00-8, Trifluridine 70-10-0, Ticlatone 70-30-4, Hexachlorophene 71-00-1, Histidine, biological studies 71-27-2, Succinylcholine Chloride 71-58-9, Medroxyprogesterone Acetate 71-63-6, Digitoxin 71-68-1, Hydromorphone Hydrochloride 71-73-8, Thiopental Sodium 71-81-8, Isopropamide Iodide 72-18-4, Valine, biological studies 72-19-5, Threonine, biological studies 72-33-3, Mestranol 72-44-6, Methaqualone 73-09-6, Etozolin 73-22-3, Tryptophan, biological studies 73-32-5, Isoleucine, biological studies 73-48-3, Bendroflumethiazide 74-79-3, Arginine, biological studies 75-00-3, Ethyl Chloride 75-19-4, Cyclopropane 76-38-0, Methoxyflurane 76-42-6, Oxycodone 76-43-7, Fluoxymesterone 76-57-3, Codeine 76-90-4, Mepenzolate Bromide 77-21-4, Glutethimide 77-26-9, Butalbital 77-27-0, Thiamylal 77-36-1, Chlorthalidone 77-41-8, Methsuximide 77-46-3, Acedapsone 77-67-8, Ethosuximide 77-86-1, Trometamol 77-92-9, Citric acid, biological studies 78-11-5, Pentaerythritol Tetranitrate 78-44-4, Carisoprodol 79-09-4, Propionic Acid, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel drug delivery system)

IT 466-06-8, Proscillaridin 467-22-1, Carbiphene Hydrochloride 474-25-9, Chenodiol 474-58-8, Sitogluside 474-86-2, Equilin 480-39-7, Pinocembrin 480-49-9, Filipin 483-63-6, Crotamiton 502-54-5,

Monoctanoin 502-85-2, Sodium Oxybate 503-49-1, Meglutol 504-24-5, Fampridine 506-26-3, Gamolenic acid 509-74-0, Methadyl Acetate 511-13-7, Chlophedianol Hydrochloride 513-10-0, Echothiophate Iodide 514-36-3, Fludrocortisone Acetate 514-65-8, Biperiden 517-09-9, Equilenin 518-28-5, Podofilox 520-85-4, Medroxyprogesterone 522-48-5, Tetrahydrozoline Hydrochloride 523-87-5, Dimenhydrinate 524-83-4, Ethybenztropine 525-26-8, Cloperidone Hydrochloride 527-75-3, Berythromycin 528-43-8, Magnolol 528-96-1, Benzoylpas Calcium 530-08-5, Isoetharine 530-78-9, Flufenamic Acid 532-03-6, Methocarbamol 536-33-4, Ethionamide 536-59-4, Perillyl alcohol 536-93-6, Eucatropine Hydrochloride 538-23-8, Tricaprilin 541-15-1, Levocarnitine 541-79-7, Carbocloral 543-82-8, Octodrine 545-80-2, Poldine Methylsulfate 546-88-3, Acetohydroxamic Acid 547-81-9, 16-Epiestriol 548-04-9, Hypericin 548-57-2, Lucanthone Hydrochloride 548-62-9, Gentian Violet 548-68-5, Thiphenamil Hydrochloride 550-70-9, Triprolidine Hydrochloride 550-83-4, Propoxycaine Hydrochloride 550-99-2, Naphazoline Hydrochloride 551-11-1, Dinoprost 551-48-4, Guanoclor Sulfate 552-94-3, Salsalate 554-57-4, Methazolamide 554-92-7, Trimethobenzamide Hydrochloride 555-30-6, Methyldopa 555-43-1, Tristearin 555-44-2, Tripalmitin 555-65-7, Brocresine 555-84-0, Nifuradene 557-04-0, Magnesium stearate 557-08-4, Zinc Undecylenate 566-48-3, Formestane 569-57-3, Chlorotrianisene 579-56-6, Isoxsuprine Hydrochloride 581-88-4, Debrisoquin Sulfate 585-86-4, Lactitol 587-61-1, Propyliodone 590-63-6, Bethanechol Chloride 595-33-5, Megestrol Acetate 595-77-7, Algestone 596-51-0, Glycopyrrolate 599-79-1, Sulfasalazine 604-75-1, Oxazepam 606-05-3, Pyrabrom 609-78-9, Cycloguanil Pamoate 614-39-1, Procainamide Hydrochloride 616-91-1, Acetylcysteine 630-56-8, Hydroxyprogesterone Caproate 630-93-3, Phenytoin sodium 632-00-8, Sulfasomizole 632-99-5, Fuchsin, Basic 635-41-6, Trimetozine 636-54-4, Clopamide 637-07-0, Clofibrate 637-58-1, Pramoxine Hydrochloride 638-23-3, Carbocysteine 638-94-8, Desonide 642-78-4, Cloxacillin Sodium 645-43-2, Guanethidine Monosulfate 651-06-9, Sulfameter 652-67-5, Isosorbide 653-03-2, Butaperazine 655-05-0, Thozalinone 655-35-6, Chromonar Hydrochloride 657-24-9, Metformin 661-19-8, Docosanol 672-87-7, Metyrosine 679-90-3, Roflurane 692-13-7, Buformin 695-53-4, Dimethadione 720-76-3, Fluminorex 723-46-6, Sulfamethoxazole 729-99-7, Sulfamoxole 735-52-4, Cetophenicol 738-70-5, Trimethoprim 739-71-9, Trimipramine 742-20-1, Cyclopenthiazide 747-36-4, Hydroxychloroquine Sulfate 749-02-0, Spiperone 749-13-3, Trifluperidol 751-94-0, Fusidate Sodium 751-97-3, Rolitetracycline 773-76-2, Chloroxine 777-11-7, Haloprogin 797-63-7, Levonorgestrel 801-52-5, Porfiromycin 804-63-7, Quinine Sulfate 808-26-4, Sancycline 811-97-2, Norflurane 826-39-1, Mecamylamine Hydrochloride 827-61-2, Aceclidine 829-74-3, Levonordefrin 830-89-7, Albutoin 846-49-1, Lorazepam 846-50-4, Temazepam 847-25-6, Racephenicol 848-75-9, Lormetazepam 852-19-7, Sulfazamet 852-42-6, Guaiapate 860-22-0 881-17-4 886-38-4, Diphencyprone 886-74-8, Chlorphenesin Carbamate 894-71-3, Nortriptyline hydrochloride 896-71-9, Tigestol 909-39-7, Opipramol Hydrochloride 911-45-5, Clomiphene 914-00-1, Methacycline 955-48-6, Metalol Hydrochloride 956-90-1, Phencyclidine Hydrochloride 959-10-4, Xenbucin 962-02-7, Nitrodan 963-39-3, Demoxepam 965-90-2, Ethylestrenol 967-48-6, Flubanilate Hydrochloride 968-81-0, Acetohexamide 968-93-4, Testolactone 969-33-5, Cyproheptadine Hydrochloride 972-02-1, Diphenidol 976-71-6, Canrenone 977-79-7, Medrogestone 980-71-2, Brompheniramine Maleate 982-24-1, Clopenthixol 983-85-7, Penamecillin 985-16-0, Nafcillin Sodium 987-02-0, Demecycline 990-73-8, Fentanyl Citrate 1018-71-9, Pyrrolnitrin 1021-11-0, Guanoxyfen Sulfate 1038-59-1, Glyoctamide 1050-48-2, Benzilonium Bromide 1070-11-7, Ethambutol hydrochloride 1070-95-7,

Guanoctine Hydrochloride 1094-08-2, Ethopropazine Hydrochloride 1095-90-5, Methadone Hydrochloride 1098-60-8, Triflupromazine Hydrochloride 1104-22-9, Meclizine Hydrochloride 1110-40-3, Cortivazol 1113-10-6, Guancydine 1134-47-0, Baclofen 1143-38-0, Anthralin 1146-98-1, Bromindione 1147-62-2, Pyrovalerone Hydrochloride 1150-20-5, Azabon 1151-11-7, Ipodate Calcium 1155-03-9, Zolamine Hydrochloride 1156-19-0, Tolazamide 1172-18-5, Flurazepam Hydrochloride 1173-88-2, Oxacillin Sodium 1197-18-8, Tranexamic Acid 1197-21-3, Phentermine Hydrochloride 1199-18-4, Oxidopamine 1211-28-5, Prolintane Hydrochloride 1212-72-2, Mephentermine Sulfate 1212-83-5, Guanisoquin Sulfate 1218-35-5, Xylometazoline Hydrochloride 1220-83-3, Sulfamonomethoxine 1225-20-3, Iothalamate Sodium 1225-55-4, Protriptyline Hydrochloride 1227-61-8, Mefexamide 1231-93-2, Ethynodiol 1232-85-5, Elantrine 1234-71-5, Namoxyrate 1235-15-0, Norbolethone 1242-56-4, Stenbolone Acetate 1252-69-3, Piperamide Maleate 1253-28-7, Gestonorone Caproate 1263-89-4, Paromomycin Sulfate 1264-72-8, Colistin Sulfate 1271-19-8, Titanocene dichloride 1314-95-0, Tin sulfide (SnS) 1317-25-5, Alcloxa 1322-14-1, Calcium Undecylenate 1323-83-7, Glycerol distearate 1336-78-3, Imidecyl iodine 1392-21-8, Kitasamycin 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1402-82-0, Amphomycin 1403-17-4, Candicidin 1403-71-0, Hamycin 1403-99-2, Mitogillin 1404-08-6, Neutramycin 1404-15-5, Nogalamycin 1404-20-2, Peliomycin 1404-48-4, Relomycin 1404-64-4, Sparsomycin 1404-88-2, Tyrothricin 1404-90-6, Vancomycin 1405-00-1, Viridofulvin 1405-20-5, Polymyxin B Sulfate 1405-37-4, Capreomycin Sulfate 1405-41-0, Gentamicin Sulfate 1405-52-3, Sulfomyxin 1405-87-4, Bacitracin 1405-97-6, Gramicidin 1414-45-5, Nisin 1420-03-7, Propenzolate Hydrochloride 1420-55-9, Thiethylperazine 1421-14-3, Propanidid 1424-00-6, Mesterolone 1432-75-3, Nitralamine Hydrochloride 1456-52-6, Ioprocemic Acid 1476-53-5, Novobiocin Sodium 1477-40-3, Levomethadyl Acetate 1491-81-2, Bolmantalate 1508-65-2, Oxybutynin chloride 1508-75-4, Tropicamide

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel drug delivery system)

IT 91516-85-7, 2'-Nor-cGMP 91524-15-1, Irloxacin 91524-18-4, Azumolene Sodium 91587-01-8, Pelretin 91618-36-9, Ibafloxacin 91714-94-2, Bromfenac 91832-40-5, Cefdinir 92047-76-2, Tetrachlorodecaoxide 92118-27-9, Fotemustine 92236-42-5, Glutapyrone 92339-11-2, Iodixanol 92623-84-2, Pravadoline Maleate 92623-85-3, Milnacipran 92788-10-8, Rogletimide 92812-82-3, Fluorodopa F 18 92817-10-2, 16-α-Fluoroestradiol 93047-39-3, Etanterol 93135-89-8, Methoxatone 93221-48-8, Levobetaxolol 93390-81-9, Fosphenytoin 93413-69-5, Venlafaxine 93479-97-1, Glimepiride 93738-40-0, Ralitoline 93957-54-1, Fluvastatin 93957-55-2, Fluvastatin Sodium 94168-98-6, Rifametane 94535-50-9, Levcromakalim 94739-29-4, Lemildipine 94820-09-4, Cadexomer iodine 94841-17-5, Spirapril Hydrochloride 95058-81-4, Gemcitabine 95153-31-4, Perindoprilat 95190-13-9, Tetrazolast Meglumine 95232-68-1, Tenosal 95233-18-4, Atovaquone 95399-71-6, Fosinoprilat 95635-55-5, Ranolazine 95671-26-4, Tipentosin Hydrochloride 95734-82-0, Nedaplatin 95751-51-2, Stobadine 95847-70-4, Ipsapirone 96036-03-2, Meropenem 96128-92-6, Clentiazem Maleate 96201-88-6, Brequinar Sodium 96346-61-1, Onapristone 96449-05-7, Rispenzepine 96565-55-8, Ablukast Sodium 96566-25-5, Ablukast 96604-21-6, Ocinaplon 96609-16-4, Lifibrol 96829-58-2, Orlistat 96892-57-8, Hepsulfam 96914-39-5, Actisomide 97048-13-0, Urofollitropin 97068-30-9, Elsamitrucin 97240-79-4, Topiramate 97322-87-7, Troglitazone 97534-21-9, Merbarone 97548-97-5, Quinelorane Hydrochloride 97682-44-5, Irinotecan 97772-98-0, Butedronate Tetrasodium 97938-30-2, Vexibinol 97964-56-2, Lorglumide 98048-97-6, Fosinopril 98079-51-7, Lomefloxacin 98116-53-1, Sulukast 98206-10-1,

Flesinoxan 98319-26-7, Finasteride 98383-18-7, Ecomustine 98569-62-1, Mallotochromene 98631-95-9, Sobuzoxane 99009-20-8, Pyrazoloacridine 99011-02-6, Imiquimod 99107-52-5, Bunaprolast 99149-95-8, Saruplase 99156-66-8, Barmastine 99248-33-6, Seglitide Acetate 99258-56-7, Oxamisole 99283-10-0, Molgramostim 99287-30-6, Equalen 99291-25-5, Levodropropizine 99294-94-7, Teriparatide Acetate 99592-32-2, Sertaconazole 99614-02-5, Ondansetron 99665-00-6, Flomoxef 99705-65-4, Naxagolide Hydrochloride 99759-19-0, Tiqueside 99821-44-0, Nasaruplase 100188-33-8, Piridronate Sodium 100427-26-7, Lercanidipine 100490-36-6, Tosufloxacin 100643-96-7, Indolidan 100981-43-9, Ebrotidine 100986-85-4, Levofloxacin 101001-34-7, Pamicogrel 101197-99-3, Acitemate 101246-66-6, Phenserine 101246-68-8, Eptastigmine 101363-10-4, Rufloxacin 101477-55-8, Lomerizine 101526-83-4, Sematilide 101530-10-3, Lanoconazole 102394-31-0, Otenzepad 102396-24-7, Jasplakinolide 102426-96-0, Paldimycin 102625-70-7, Pantoprazole 102669-89-6, Saterinone 102670-59-7, Batanopride Hydrochloride 102676-47-1, Fadrozole 102767-28-2, Levetiracetam \102822-56-0, Mannostatin A 102916-21-2, Tigemonam Dicholine 103060-53-3, Daptomycin 103222-11-3, Vapreotide 103255-66-9, Pazinaclone 103336-05-6, Ditekiren 103337-74-2, Letrazuril 103379-03-9, Monatepil Maleate 103475-41-8, Tepoxalin 103486-79-9, Belfosdil 103577-45-3, Lansoprazole 103614-76-2, Halichondrin B 103628-46-2, Sumatriptan 103628-48-4, Sumatriptan succinate 103745-39-7, Fasudil 103775-10-6, Moexipril 103878-84-8, Lazabemide 103890-78-4, Lacidipine 103909-75-7, 22-Oxacalcitriol 104054-27-5, Atipamezole 104153-37-9, Rilopirox 104227-87-4, Famciclovir 104340-86-5, Leminoprazole 104344-23-2, Bisoprolol fumarate 104383-17-7, Sabeluzole 104393-00-2, Pirazmonam Sodium 104454-71-9, Ipenoxazone 104456-95-3, Cisconazole 104493-13-2, Adecypenol 104595-79-1, Anaritide Acetate 104719-71-3, Lorcinadol 104775-36-2, Ecabapide 104987-11-3, Tacrolimus 105102-18-9, Tibenelast Sodium 105102-22-5, Mometasone 105118-12-5, Piroxantrone Hydrochloride 105149-04-0, Osaterone 105182-45-4, Fluparoxan 105250-86-0, Ebiratide 105431-72-9, Linopirdine 105462-24-6, Risedronic acid 105567-83-7, Berefrine 105613-48-7, Exametazime 105615-58-5, Oxaunomycin 105687-93-2, Sumarotene 105705-89-3, Vinburnine citrate 105784-61-0, Temafloxacin Hydrochloride 105806-65-3, Efegatran 105851-17-0, Fludeoxyglucose F 18 106243-16-7, Thioperamide 106266-06-2, Risperdal 106282-98-8, Somalapor 106400-81-1, Lometrexol 106463-17-6, Tamsulosin Hydrochloride 106498-99-1, Vintoperol 106516-24-9, Sertindole 106560-14-9, Faropenem 106685-40-9, Adapalene 106730-54-5, Olprinone 106861-44-3, Mivacurium chloride 106941-25-7, Adefovir 107000-34-0, Zanoterone 107167-31-7, Lactivicin 107361-33-1, Enazadrem 107407-62-5, Nelezaprine Maleate 107429-63-0, Lintopride 107703-78-6, Glemanserin 107724-20-9, Epoxymexrenone 107753-78-6, Zafirlukast 107793-72-6, Ioxilan 107868-30-4, Exemestane 107902-67-0, Tazofelone 108310-20-9, Pirodomast 108609-34-3, Lixazinone Sulfate 108612-45-9, Mizolastine 108674-87-9, Sergolexole Maleate 108700-03-4, Teludipine Hydrochloride 108736-35-2, Lanreotide 108778-82-1, Beractant 108852-90-0, Nemorubicin 108945-35-3, Taprostene 109214-55-3, Libenzapril 109229-58-5, Englitazone 109543-76-2, Romazarit 109636-76-2, Prinomide Tromethamine 109889-09-0, Granisetron 110042-95-0, Acemannan 110101-66-1, Tirilazad 110140-89-1, Ridogrel 110311-27-8, Sulofenur 110314-48-2, Adozelesin 110347-85-8, Selfotel 110588-56-2, Noberastine 110588-57-3, Saperconazole 110623-33-1, Suritozole 110690-43-2, Emitefur 110703-94-1, Zopolrestat 110845-89-1, Remiprostol 110871-86-8, Sparfloxacin 110942-02-4, Aldesleukin 111011-63-3, Efonidipine 111025-46-8, Pioglitazone 111073-18-8, Nemazoline Hydrochloride 111149-90-7, Lodelaben 111212-85-2, Ersofermin 111223-26-8, Ceronapril 111406-87-2, Zileuton

111490-36-9, Zeniplatin 111523-41-2, Enloplatin 111672-14-1, Rocastine Hydrochloride 111686-79-4, Remacemide Hydrochloride 111753-73-2, Satigrel 111786-07-3, Prinoxodan 111841-85-1, Abecarnil 111902-57-9, Temocapril 111974-60-8, Ritolukast 111974-69-7, Quetiapine 112018-00-5, Tebufelone 112018-01-6, Bemoradan 112192-04-8, Roxindole 112243-58-0, Gevotroline Hydrochloride 112344-52-2, Flobufen 112515-43-2, Topsentin 112522-64-2, Acetyldinaline 112573-73-6, Ecadotril 112733-06-9, Zenarestat 112809-51-5, Letrozole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel drug delivery system)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 11 ANSWERS CAPLUS COPYRIGHT 2008 ACS on STN
TI Novel dosage form
IT 50-02-2, Dexamethasone 50-04-4, Cortisone Acetate 50-06-6, Phenobarbital, biological studies 50-07-7, Mitomycin 50-12-4, Mephenytoin 50-13-5, Meperidine Hydrochloride 50-18-0, Cyclophosphamide 50-19-1, Hydroxyphenamate 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-33-9, Phenylbutazone, biological studies 50-34-0, Propantheline bromide 50-35-1, Thalidomide 50-36-2, Cocaine 50-44-2, Mercaptopurine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-55-5, Reserpine 50-56-6, Oxytocin, biological studies 50-57-7, Lypressin 50-58-8, Phendimetrazine Tartrate 50-59-9, Cephaloridine 50-65-7, Niclosamide 50-76-0, Dactinomycin 50-78-2, Aspirin 50-91-9, Floxuridine 51-05-8, Procaine Hydrochloride 51-15-0, Pralidoxime Chloride 51-21-8, Fluorouracil 51-30-9, Isoproterenol Hydrochloride 51-40-1, Norepinephrine Bitartrate 51-43-4, Epinephrine 51-52-5, Propylthiouracil 51-55-8, Atropine, biological studies 51-56-9, Homatropine Hydrobromide 51-57-0, Methamphetamine Hydrochloride 51-64-9, Dextroamphetamine 51-74-1, Histamine Phosphate 51-83-2, Carbachol 52-01-7, Spironolactone 52-24-4, Thiotepa 52-49-3, Trihexyphenidyl hydrochloride 52-68-6, Metrifonate 52-76-6, Lynestrenol 52-86-8, Haloperidol 52-88-0, Methylatropine Nitrate 52-89-1, Cysteine Hydrochloride 53-03-2, Prednisone 53-16-7, Estrone, biological studies 53-19-0, Mitotane 53-34-9, Fluprednisolone 53-39-4, Oxandrolone 53-43-0, Dehydroepiandrosterone 53-60-1, Promazine Hydrochloride 53-73-6, Angiotensin Amide 53-79-2, Puromycin 53-84-9, Nadide 53-86-1, Indometacin 54-03-5, Hexobendine 54-05-7, Chloroquine 54-21-7, Sodium Salicylate 54-31-9, Furosemide 54-35-3, Penicillin G Procaine 54-36-4, Metyrapone 54-42-2, Idoxuridine 54-64-8, Thimerosal 54-84-2, Cinanserin Hydrochloride 54-85-3, Isoniazid 54-91-1, Pipobroman 55-03-8, Levothyroxine Sodium 55-06-1, Liothyronine sodium 55-63-0, Nitroglycerin 55-86-7, Mechlorethamine Hydrochloride 55-91-4, Isoflurophate 55-98-1, Busulfan 56-45-1, Serine, biological studies 56-47-3, Desoxycorticosterone Acetate 56-53-1, Diethylstilbestrol 56-59-7, Felypressin 56-75-7, Chloramphenicol 56-84-8, Aspartic acid, biological studies 56-87-1, Lysine, biological studies 56-89-3, Cystine, biological studies 56-94-0, Demecarium Bromide 57-13-6, Urea, biological studies 57-41-0, Phenytoin 57-47-6, Physostigmine 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol 57-65-8, Thyromedan hydrochloride 57-66-9, Probenecid 57-68-1, Sulfamethazine 57-83-0, Progesterone, biological studies 57-83-0D, Pregn-4-ene-3,20-dione, compound with estrogens and leuprolide 57-94-3, Tubocurarine chloride 57-96-5, Sulfinpyrazone 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine 58-18-4, Methyltestosterone 58-22-0, Testosterone 58-25-3, Chlordiazepoxide 58-28-6, Desipramine Hydrochloride 58-32-2, Dipyridamole 58-33-3, Promethazine Hydrochloride 58-38-8,

Prochlorperazine 58-39-9, Perphenazine 58-54-8, Ethacrynic acid 58-55-9, Theophylline, biological studies 58-71-9, Cephalothin Sodium 58-86-6, Xylose, biological studies 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-33-6, Pyrilamine maleate 59-52-9, Dimercaprol 59-63-2, Isocarboxazid 59-67-6, Niacin, biological studies 59-87-0, Nitrofurazone 59-92-7, Levodopa, biological studies 59-97-2, Tolazoline hydrochloride 60-13-9, Amphetamine Sulfate 60-18-4, Tyrosine, biological studies 60-23-1, Cysteamine 60-29-7, Ether, biological studies 60-45-7, Fenimide 60-54-8, Tetracycline 60-56-0, Methimazole 60-80-0, Antipyrine 60-99-1, Methotrimeprazine 61-25-6, Papaverine Hydrochloride 61-56-3, Sulthiame 61-57-4, Niridazole 61-68-7, Mefenamic acid 61-73-4, Methylene Blue 61-75-6, Bretylium Tosylate 61-76-7, Phenylephrine Hydrochloride 61-90-5, Leucine, biological studies 62-51-1, Methacholine Chloride 62-68-0, Proadifen Hydrochloride 62-90-8, Nandrolone Phenpropionate 63-05-8, Androstenedione 63-12-7, Benzquinamide 63-39-8, Uridine triphosphate 63-45-6, Primaquine Phosphate 63-68-3, Methionine, biological studies 63-89-8, Colfosceril Palmitate 63-91-2, Phenylalanine, biological studies 63-92-3, Phenoxybenzamine Hydrochloride 63-98-9, Phenacemide 64-31-3, Morphine Sulfate 64-43-7, Amobarbital Sodium 64-55-1, Mebutamate 64-77-7, Tolbutamide 64-86-8, Colchicine 65-28-1, Phentolamine mesylate 65-29-2, Gallamine Triethiodide 65-45-2, Salicylamide 66-75-1, Uracil mustard 66-76-2, DicumaroL 66-81-9, Cycloheximide 67-20-9, Nitrofurantoin 67-43-6, Pentetic acid 67-45-8, Furazolidone 67-63-0, Isopropyl Alcohol, biological studies 67-68-5, Dimethyl Sulfoxide, biological studies 67-73-2, Fluocinolone Acetonide 67-92-5, Dicyclomine Hydrochloride 67-95-8, Quingestrone 67-96-9, Dihydrotachysterol 68-22-4, Norethindrone 68-23-5, Norethynodrel 68-35-9, Sulfadiazine 68-41-7, Cycloserine 68-89-3, Dipyrone 68-91-7, Trimethaphan camsylate 69-44-3, Amodiaquine Hydrochloride 69-53-4, Ampicillin 69-57-8, Penicillin G Sodium 69-65-8, Mannitol 69-72-7, Salicylic acid, biological studies 69-74-9, Cytarabine Hydrochloride 70-00-8, Trifluridine 70-10-0, Ticlatone 70-18-8D, Glutathione, inhibitors, biological studies 71-00-1, Histidine, biological studies 71-27-2, Succinylcholine Chloride 71-58-9, Medroxyprogesterone Acetate 71-63-6, Digitoxin 71-68-1, Hydromorphone Hydrochloride 71-73-8, Thiopental sodium 71-81-8, Isopropamide Iodide 72-18-4, Valine, biological studies 72-19-5, Threonine, biological studies 72-33-3, Mestranol 72-44-6, Methaqualone 73-09-6, Etozolin 73-22-3, Tryptophan, biological studies 73-32-5, Isoleucine, biological studies 73-48-3, Bendroflumethiazide 74-79-3, Arginine, biological studies 75-00-3, Ethyl Chloride 75-19-4, Cyclopropane 76-38-0, Methoxyflurane 76-42-6, Oxycodone 76-43-7, Fluoxymesterone 76-57-3, Codeine 76-73-3, Secobarbital 76-74-4, Pentobarbital 76-90-4, Mepenzolate Bromide 77-21-4, Glutethimide 77-26-9, Butalbital 77-27-0, Thiamylal 77-36-1, Chlorthalidone 77-41-8, Methsuximide 77-67-8, Ethosuximide 77-86-1, Trometamol 77-92-9, biological studies 78-11-5, Pentaerythritol Tetranitrate 78-44-4, Carisoprodol 79-09-4, Propionic acid, biological studies 79-10-7D, Acrylic acid, polymers 79-17-4, Pimagedine 79-41-4D, Methacrylic acid, copolymers 79-57-2, Oxytetracycline 79-64-1, Dimethisterone 80-08-0, Dapsone 80-50-2, Anisotropine Methylbromide 81-04-9, 1,5-Naphthalenedisulfonic acid 81-23-2, Dehydrocholic acid 81-54-9, Purpurin 82-92-8, Cyclizine 83-43-2, Methylprednisolone 83-73-8, Iodoquinol 83-74-9, Ibogaine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form containing modified-release and immediate-release active ingredients)

IT 520-85-4, Medroxyprogesterone 521-18-6, Dihydrotestosterone 522-48-5,

Tetrahydrozoline hydrochloride 523-87-5, Dimenhydrinate 524-83-4, Ethybenztropine 525-26-8, Cloperidone Hydrochloride 527-75-3, Berythromycin 528-43-8, Magnolol 528-96-1, Benzoylpas Calcium 530-08-5, Isoetharine 530-78-9, Flufenamic acid 532-03-6, Methocarbamol 536-33-4, Ethionamide 536-59-4, Perillyl alcohol 536-93-6, Eucatropine Hydrochloride 538-23-8, Tricaprylin 541-15-1, Levocarnitine 541-79-7, Carbocloral 543-82-8, Octodrine 545-80-2, Poldine Methylsulfate 548-04-9, Hypericin 548-57-2, Lucanthone Hydrochloride 548-62-9, Gentian Violet 548-68-5, Thiphenamil hydrochloride 550-70-9, Triprolidine hydrochloride 550-83-4, Propoxycaine hydrochloride 550-99-2, Naphazoline Hydrochloride 551-11-1, Dinoprost 551-48-4, Guanoclor Sulfate 552-94-3, Salsalate 554-57-4, Methazolamide 554-92-7, Trimethobenzamide hydrochloride 555-30-6, Methyldopa 555-43-1, Tristearin 555-44-2, Tripalmitin 555-65-7, Brocresine 555-84-0, Nifuradene 557-08-4, Zinc Undecylenate 566-48-3, Formestane 569-57-3, Chlorotrianisene 578-95-0D, Acridone, imidazole derivs. 579-56-6, Isoxsuprine Hydrochloride 581-88-4, Debrisoquin Sulfate 585-86-4, Lactitol 586-06-1D, Metaproterenol, Polisterex-coated 587-61-1, Propyliodone 590-63-6, Bethanechol Chloride 595-33-5, Megestrol Acetate 596-51-0, Glycopyrrolate 599-79-1, Sulfasalazine 604-75-1, Oxazepam 606-05-3, Pyrabrom 609-78-9, Cycloguanil Pamoate 614-39-1, Procainamide Hydrochloride 630-56-8, Hydroxyprogesterone Caproate 630-93-3, Dilantin 632-00-8, Sulfasomizole 632-99-5, Fuchsin, Basic 635-41-6, Trimetozine 636-54-4, Clopamide 637-07-0, Clofibrate 637-58-1, Pramoxine Hydrochloride 638-23-3, Carbocysteine 638-94-8, Desonide 645-43-2, Guanethidine Monosulfate 651-06-9, Sulfameter 652-67-5, Isosorbide 653-03-2, Butaperazine 655-05-0, Thozalinone 655-35-6, Chromonar Hydrochloride 657-24-9, Metformin 661-19-8, Docosanol 672-87-7, Metyrosine 679-90-3, Roflurane 692-13-7, Buformin 695-53-4, Dimethadione 720-76-3, Fluminorex 723-46-6, Sulfamethoxazole 729-99-7, Sulfamoxole 735-52-4, Cetophenicol 738-70-5, Trimethoprim 739-71-9, Trimipramine 742-20-1, Cyclopenthiazide 747-36-4, Hydroxychloroquine Sulfate 749-02-0, Spiperone 749-13-3, Trifluperidol 751-94-0, Fusidate sodium 751-97-3, Rolitetracycline 773-76-2, Chloroxine 777-11-7, Haloprogin 797-63-7, Levonorgestrel 801-52-5, Porfiromycin 804-63-7, Quinine Sulfate 808-26-4, Sancycline 811-97-2, Norflurane 826-39-1, Mecamylamine Hydrochloride 829-74-3, Levonordefrin 846-49-1, Lorazepam 846-50-4, Temazepam 847-25-6, Racephenicol 848-75-9, Lormetazepam 852-19-7, Sulfazamet 852-42-6, Guaiapate 860-22-0 881-17-4 886-38-4, Diphencyprone 886-74-8, Chlorphenesin Carbamate 894-71-3, Nortriptyline Hydrochloride 896-71-9, Tigestol 909-39-7, Opipramol Hydrochloride 911-45-5, Clomiphene 914-00-1, Methacycline 955-48-6, Metalol Hydrochloride 956-90-1, Phencyclidine Hydrochloride 959-10-4, Xenbucin 962-02-7, Nitrodan 963-39-3, Demoxepam 965-90-2, Ethylestrenol 967-48-6, Flubanilate Hydrochloride 968-93-4, Testolactone 969-33-5, Cyproheptadine Hydrochloride 972-02-1, Diphenidol 976-71-6, Canrenone 977-79-7, Medrogestone 980-71-2, Brompheniramine Maleate 982-24-1, Clopenthixol 983-85-7, Penamecillin 985-16-0, Nafcillin Sodium 987-02-0, Demecycline 990-73-8, Fentanyl Citrate 1018-71-9, Pyrrolnitrin 1021-11-0, Guanoxyfen Sulfate 1038-59-1, Glyoctamide 1050-48-2, Benzilonium Bromide 1069-66-5, Valproate sodium 1070-11-7, Ethambutol hydrochloride 1070-95-7, Guanoctine Hydrochloride 1094-08-2, Ethopropazine Hydrochloride 1095-90-5, Methadone Hydrochloride 1098-60-8, Triflupromazine hydrochloride 1104-22-9, Meclizine Hydrochloride 1110-40-3, Cortivazol 1113-10-6, Guancydine 1134-47-0, Baclofen 1143-38-0, Anthralin 1146-98-1, Bromindione 1147-62-2, Pyrovalerone Hydrochloride 1150-20-5, Azabon 1151-11-7, Ipodate calcium 1155-03-9, Zolamine Hydrochloride 1156-19-0,

Tolazamide 1172-18-5, Flurazepam Hydrochloride 1173-88-2, Oxacillin Sodium 1197-18-8, Tranexamic acid 1197-21-3, Phentermine Hydrochloride 1199-18-4, Oxidopamine 1211-28-5, Prolintane Hydrochloride 1212-72-2, Mephentermine Sulfate 1212-83-5, Guanisoquin Sulfate 1218-35-5, Xylometazoline Hydrochloride 1220-83-3, Sulfamonomethoxine 1225-20-3, Iothalamate sodium 1225-55-4, Protriptyline hydrochloride 1227-61-8, Mefexamide 1231-93-2, Ethynodiol 1232-85-5, Elantrine 1234-71-5, Namoxyrate 1235-15-0, Norbolethone 1242-56-4, Stenbolone Acetate 1252-69-3, Piperamide Maleate 1253-28-7, Gestonorone Caproate 1263-89-4, Paromomycin Sulfate 1264-72-8, Colistin Sulfate 1271-19-8, Titanocene dichloride 1322-14-1, Calcium Undecylenate 1323-83-7, Glycerol distearate 1336-78-3, Imidecyl iodine 1392-21-8, Kitasamycin 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1402-82-0, Amphomycin 1403-17-4, Candicidin 1403-71-0, Hamycin 1403-99-2, Mitogillin 1404-08-6, Neutramycin 1404-15-5, Nogalamycin 1404-20-2, Peliomycin 1404-48-4, Relomycin 1404-59-7, Rutamycin 1404-64-4, Sparsomycin 1404-88-2, Tyrothricin 1404-90-6, Vancomycin 1405-00-1, Viridofulvin 1405-20-5, Polymyxin B Sulfate 1405-37-4, Capreomycin sulfate 1405-41-0, Gentamicin Sulfate 1405-52-3, Sulfomyxin 1405-87-4, Bacitracin 1405-97-6, Gramicidin 1414-45-5, Nisin 1420-03-7, Propenzolate hydrochloride 1420-55-9, Thiethylperazine 1421-14-3, Propanidid 1424-00-6, Mesterolone 1432-75-3, Nitralamine Hydrochloride 1456-52-6, Ioprocemic acid 1476-53-5, Novobiocin Sodium 1477-40-3, Levomethadyl Acetate 1491-81-2, Bolmantalate 1508-65-2, Oxybutynin chloride 1508-75-4, Tropicamide 1508-76-5, Procyclidine Hydrochloride 1524-88-5, Flurandrenolide 1538-09-6 1553-34-0, Methixene Hydrochloride 1553-60-2, Ibufenac 1597-82-6, Paramethasone Acetate 1605-68-1, Taxane 1605-89-6, Bolasterone 1607-17-6, Pentrinitrol 1622-61-3, Clonazepam 1622-62-4, Flunitrazepam 1639-60-7, Propoxyphene hydrochloride 1642-54-2, Diethylcarbamazine Citrate 1649-18-9, Azaperone 1661-29-6, Meturedepa 1665-48-1, Metaxalone 1684-40-8, Tacrine Hydrochloride 1707-14-8, Phenmetrazine Hydrochloride 1722-62-9, Mepivacaine Hydrochloride 1740-22-3, Pyrinoline 1744-22-5, Riluzole 1764-85-8, Epithiazide 1786-81-8, Prilocaine Hydrochloride 1808-12-4, Bromodiphenhydramine Hydrochloride 1812-30-2, Bromazepam 1841-19-6, Fluspirilene

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form containing modified-release and immediate-release active ingredients)

IT 84290-27-7, Tucaresol 84371-65-3, Mifepristone 84379-13-5, Bretazenil 84392-17-6, Xenalipin 84408-37-7, Desciclovir 84412-94-2, Ruboxyl 84449-90-1, Raloxifene 84485-00-7, Sibutramine Hydrochloride 84490-12-0, Piroximone 84611-23-4, Erdosteine 84625-61-6, Itraconazole 84845-57-8, Ritipenem 84845-75-0, Niperotidine 84878-61-5, Maduramicin 85053-47-0, Suricainide Maleate 85068-76-4 85118-44-1, Minocromil 85136-71-6, Tilisolol 85175-67-3, Zatebradine 85181-38-0, Tropanserin hydrochloride 85197-77-9, Tipredane 85202-17-1, Stobadine 85216-79-1 85441-61-8, Quinapril 85465-82-3, Thymotrinan 85468-01-5, Gusperimus Trihydrochloride 85622-93-1, Temozolomide 85650-52-8, Mirtazapine 85666-17-7, Furegrelate Sodium 85683-41-6, Metipamide 85691-74-3, Pirmagrel 85721-33-1, Ciprofloxacin 85798-08-9, Quinpirole Hydrochloride 85977-49-7, Tauromustine 86015-38-5, Neflumozide Hydrochloride 86048-40-0, Quazolast 86050-77-3, Gadopentetate Dimeglumine 86116-60-1, Azaloxan Fumarate 86160-82-9, Lavoltidine Succinate 86181-42-2, Temelastine 86386-73-4, Fluconazole 86433-40-1, Terflavoxate 86487-64-1, Setoperone 86541-74-4, Benazepril Hydrochloride 86541-78-8, Benazeprilat 86828-07-1, Mallotojaponin 86832-68-0, Carumonam Sodium 86914-11-6, Tolgabide 87005-03-6, Panaxytriol 87051-43-2, Ritanserin 87056-78-8, Quinagolide 87071-16-7, Arclofenin 87173-97-5, Spiradoline Mesylate 87233-61-2,

Emedastine 87248-13-3, Vapiprost hydrochloride 87333-19-5, Ramipril 87359-33-9, Isomazole Hydrochloride 87495-31-6, Disoxaril 87573-01-1, Salnacedin 87679-37-6, Trandolapril 87691-92-7, Tiospirone hydrochloride 87719-32-2, Etarotene 87726-17-8, Panipenem 87760-53-0, Tandospirone 87771-40-2, Ioversol 87784-12-1, Ofornine 87806-31-3, Porfimer Sodium 87810-56-8, Fostriecin 87936-82-1, Tazadolene succinate 88040-23-7, Cefepime 88069-67-4, Pilsicainide 88107-10-2, Tomelukast 88133-11-3, Bemitradine 88296-61-1, Medorinone 88296-62-2, Transcainide 88303-60-0, Losoxantrone 88430-50-6, Beraprost 88637-37-0, Diphenhydramine Citrate 88669-04-9, Trospectomycin 88768-40-5, Cilazapril 88844-73-9, Flestolol Sulfate 89198-09-4, Imazodan Hydrochloride 89226-50-6, Manidipine 89232-84-8, Pelrinone Hydrochloride 89303-64-0, Atiprosin Maleate 89365-50-4, Salmeterol 89371-37-9, Imidapril 89383-13-1, Somidobove 89419-40-9, Mosapramine 89565-68-4, Tropisetron 89651-00-3, Voxergolide 89667-40-3, Isbogrel 89672-11-7, Cioteronel 89778-26-7, Toremifene 89786-04-9, Tazobactam 89797-00-2, Iopentol 89987-06-4, Tiludronic acid 90055-97-3, Tienoxolol 90182-92-6, Zacopride 90243-66-6, Montirelin 90274-23-0, Zaltidine Hydrochloride 90357-06-5, Bicalutamide 90729-41-2, Oxodipine 90729-43-4, Ebastine 90733-42-9, Edifolone Acetate 90779-69-4, Atosiban 90850-05-8, Gloximonam 90898-90-1, Oximonam 90996-54-6, Rhizoxin 91161-71-6, Terbinafine 91296-86-5, Difloxacin Hydrochloride 91296-87-6, Sarafloxacin Hydrochloride 91374-21-9, Ropinirole 91406-11-0, Esuprone 91431-42-4, Lonapalene 91524-15-1, Irloxacin 91524-18-4, Azumolene Sodium 91587-01-8, Pelretin 91618-36-9, Ibafloxacin 91714-94-2, Bromfenac 91832-40-5, Cefdinir 92047-76-2, Tetrachlorodecaoxide 92118-27-9, Fotemustine 92236-42-5, Glutapyrone 92339-11-2, Iodixanol 92623-84-2, Pravadoline Maleate 92623-85-3, Milnacipran 92788-10-8, Rogletimide 92812-82-3, Fluorodopa F 18 93047-39-3, Etanterol 93135-89-8, Methoxatone 93221-48-8, Levobetaxolol 93390-81-9, Fosphenytoin 93413-69-5, Venlafaxine 93479-97-1, Glimepiride 93738-40-0, Ralitoline 93957-54-1, Fluvastatin 93957-55-2, Fluvastatin Sodium 94168-98-6, Rifametane 94535-50-9, Lemakalim 94739-29-4, Lemildipine 94820-09-4, Cadexomer iodine 94841-17-5, Spirapril Hydrochloride 95058-81-4, Gemcitabine 95153-31-4, Perindoprilat 95190-13-9, Tetrazolast meglumine 95232-68-1, Tenosal 95233-18-4, Atovaquone 95399-71-6, Fosinoprilat 95635-55-5, Ranolazine 95671-26-4, Tipentosin hydrochloride 95734-82-0, Nedaplatin 95847-70-4, Ipsapirone 96036-03-2, Meropenem 96128-92-6, Clentiazem Maleate 96201-88-6, Brequinar Sodium 96346-61-1, Onapristone 96449-05-7, Rispenzepine 96604-21-6, Ocinaplon 96609-16-4, Lifibrol 96829-58-2, Orlistat 96892-57-8, Hepsulfam 97048-13-0, Urofollitropin 97068-30-9, Elsamitrucin 97240-79-4, Topiramate 97322-87-7, Troglitazone 97534-21-9, Merbarone 97548-97-5, Quinelorane hydrochloride 97682-44-5, Irinotecan 97772-98-0, Butedronate Tetrasodium 97938-30-2, Vexibinol 97964-56-2, Lorglumide 98048-97-6, Fosinopril 98079-51-7, Lomefloxacin 98116-53-1, Sulukast 98206-10-1, Flesinoxan 98319-26-7, Finasteride 98383-18-7, Ecomustine 98569-62-1, Mallotochromene 98631-95-9, Sobuzoxane 99009-20-8, Pyrazoloacridine 99011-02-6, Imiquimod 99107-52-5, Bunaprolast 99149-95-8, Saruplase 99156-66-8, Barmastine 99248-33-6, Seglitide Acetate 99258-56-7, Oxamisole 99283-10-0, Molgramostim 99287-30-6, Equalen 99291-25-5, Levodropropizine 99294-94-7, Teriparatide acetate 99592-32-2, Sertaconazole 99614-02-5, Ondansetron 99665-00-6, Flomoxef 99705-65-4, Naxagolide Hydrochloride 99759-19-0, Tiqueside 99821-44-0, Nasaruplase 99924-19-3D, complex 100188-33-8, Piridronate Sodium 100324-81-0, Lisofylline 100427-26-7, Lercanidipine 100490-36-6, Tosufloxacin 100643-96-7, Indolidan 100981-43-9, Ebrotidine 100986-85-4, Levofloxacin 101001-34-7, Pamicogrel 101246-66-6,

Phenserine 101246-68-8, Eptastigmine 101363-10-4, Rufloxacin
101477-55-8, Lomerizine 101526-83-4, Sematilide 101530-10-3,
Lanoconazole 102394-31-0, Otenzepad 102396-24-7, Jasplakinolide
102426-96-0, Paldimycin 102625-70-7, Pantoprazole 102669-89-6,
Saterinone 102670-59-7, Batanopride Hydrochloride 102676-47-1,
Fadrozole 102767-28-2, Levetiracetam \102822-56-0, Mannostatin A
102916-21-2, Tigemonam dicholine 103060-53-3, Daptomycin 103222-11-3,
Vapreotide 103255-66-9, Pazinaclone 103336-05-6, Ditekiren
103337-74-2, Letrazuril 103379-03-9, Monatepil Maleate 103475-41-8,
Tepoxalin 103486-79-9, Belfosdil 103577-45-3, Lansoprazole
103614-76-2, Halichondrin B 103628-46-2, Sumatriptan 103745-39-7,
Fasudil 103775-10-6, Moexipril 103878-84-8, Lazabemide 103890-78-4,
Lacidipine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form containing modified-release and immediate-release active
ingredients)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s L6/PREP
FIELD CODES CANNOT BE CHANGED HERE
You may have tried to apply a field code to a term that already has a
field code. You can only add a field code to a term that has no field
code appended to it.

=> s L2/PREP and L2/PREP and L3/PREP
2221 L2
4601799 PREP/RL
13 L2/PREP
(L2 (L) PREP/RL)
2221 L2
4601799 PREP/RL
13 L2/PREP
(L2 (L) PREP/RL)
140 L3
4601799 PREP/RL
6 L3/PREP
(L3 (L) PREP/RL)
L7 0 L2/PREP AND L2/PREP AND L3/PREP

=> s L1/PREP and L2/PREP and L3/PREP
7973 L1
4601799 PREP/RL
151 L1/PREP
(L1 (L) PREP/RL)
2221 L2
4601799 PREP/RL
13 L2/PREP
(L2 (L) PREP/RL)
140 L3
4601799 PREP/RL
6 L3/PREP
(L3 (L) PREP/RL)
L8 0 L1/PREP AND L2/PREP AND L3/PREP

=> s L1/PREP
7973 L1
4601799 PREP/RL
L9 151 L1/PREP
(L1 (L) PREP/RL)

```
=> D L9 ibib abs

L9   ANSWER 1 OF 151  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2008:91080  CAPLUS Full-text
DOCUMENT NUMBER:          148:160147
TITLE:                    Conjugates of psychotropic drugs or GABA agonists with
                          organic acids for treatment of CNS diseases or
                          disorders
INVENTOR(S):              Nudelman, Abraham; Rephaeli, Ada; Gil-Ad, Irit;
                          Weizman, Abraham
PATENT ASSIGNEE(S):       Ramot at Tel Aviv University Ltd., Israel; Bar-Ilan
                          University
SOURCE:                   PCT Int. Appl., 76pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     --------------        ----   --------    -------------------      --------
     WO 2008010223         A2     20080124    WO 2007-IL903            20070717
     WO 2008010223         A3     20080320
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
             MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
             PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.:                       US 2006-831192P     P  20060717
                                             US 2006-831195P     P  20060717
AB   A method of treating pain, addiction or other CNS disorders is claimed using a
     therapeutically effective amount of a chemical conjugate which comprises a
     first chemical moiety covalently linked to a second chemical moiety, wherein
     said first chemical moiety is selected from the group consisting of an
     antidepressant, an antiepileptic drug and a GABA agonist and wherein said
     second chemical moiety is selected from the group consisting of GABA and R-
     C(O)-, whereas R is an alkyl having 3-5-carbon atoms.  The second moiety cas
     also be a GABA agonist.  Pharmaceutical compns. and articles-of-manufacture
     containing the conjugates are also claimed.  Synthetic procedures for
     preparing GABA-oxymethyl-GABA, GABA-oxymethyl-valproate, fluoxetine-GABA, and
     nortriptyline-GABA are exemplified.



=> s L1/SPN
          7973 L1
       2009163 SPN/RL
L10          71 L1/SPN
                (L1 (L) SPN/RL)

=> D L10 ibib abs
```

L10 ANSWER 1 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:91080 CAPLUS Full-text
DOCUMENT NUMBER: 148:160147
TITLE: Conjugates of psychotropic drugs or GABA agonists with organic acids for treatment of CNS diseases or disorders
INVENTOR(S): Nudelman, Abraham; Rephaeli, Ada; Gil-Ad, Irit; Weizman, Abraham
PATENT ASSIGNEE(S): Ramot at Tel Aviv University Ltd., Israel; Bar-Ilan University
SOURCE: PCT Int. Appl., 76pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008010223	A2	20080124	WO 2007-IL903	20070717
WO 2008010223	A3	20080320		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-831192P P 20060717
US 2006-831195P P 20060717

AB A method of treating pain, addiction or other CNS disorders is claimed using a therapeutically effective amount of a chemical conjugate which comprises a first chemical moiety covalently linked to a second chemical moiety, wherein said first chemical moiety is selected from the group consisting of an antidepressant, an antiepileptic drug and a GABA agonist and wherein said second chemical moiety is selected from the group consisting of GABA and R-C(O)-, whereas R is an alkyl having 3-5-carbon atoms. The second moiety cas also be a GABA agonist. Pharmaceutical compns. and articles-of-manufacture containing the conjugates are also claimed. Synthetic procedures for preparing GABA-oxymethyl-GABA, GABA-oxymethyl-valproate, fluoxetine-GABA, and nortriptyline-GABA are exemplified.

=> D L10 2 ibib abs

L10 ANSWER 2 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1215841 CAPLUS Full-text
DOCUMENT NUMBER: 147:455613
TITLE: Halide-free glucosamine-acidic drug complexes
INVENTOR(S): Chopdekar, Vilas M.; Torntore, Michael J.
PATENT ASSIGNEE(S): JF C Technologies, LLC, USA
SOURCE: U.S. Pat. Appl. Publ., 6pp., Cont.-in-part of U.S.

Ser. No. 223,686.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20070249735	A1	20071025	US 2007-731294		20070331
US 20070259043	A1	20071108	US 2005-223686		20050909
PRIORITY APPLN. INFO.:			US 2004-611178P	P	20040917
			US 2005-223686	A2	20050909

AB A complex of glucosamine having a purity of at least about 99 wt.% and a maximum halide content of about 0.01 weight%, and a therapeutic drug having a pKa of less than 7 is provided. Preferably, the complex is stabilized by coating it with at least one pharmaceutically acceptable polymer comprising a water-soluble, water-immiscible and/or water-swellable homopolymer and/or copolymer. Suitable polymers include homopolymers and copolymers of carboxypolymethylene, polyethylene glycol, povidone, polyacrylic acid, polyacrylamide, polysaccharides and mixts. of two or more of the foregoing polymers. The resultant coated complex will be stable upon exposure to ambient temperature and/or the atmospheric Suitable therapeutic drugs fall into the following classes: α- and β-adrenergic agonists; narcotic and non-narcotic analgesics; anorexics; antiallergics; antianginals; antiarrhythmics; antiasthmatics; antibiotics; anticoagulants; anticonvulsants; antidepressants; antidiabetics; antihistaminics; antihypertensives; nonsteroidal anti-inflammatories; antimigraines; antineoplastics; antiparkinsonians; antipsychotics; antipyretics; antispasmodics; antithrombotics; antiulceratives; anxiolytics; decongestants; diuretics; hepatoprotectants; sedatives; and vasodilators. Thus, 3.58 g (0.02 mol) of halide-free glucosamine were added to 4.1 g (0.02 mol) of ibuprofen dissolved in 200 cc of methanol and the mixture was stirred for 1 h at 25-30°, resulting in a clear solution The methanol was evaporated at 50° from the reaction mixture giving 7 g of glucosamine-ibuprofen complex.

=> D L10 3-71 ibib abs

L10 ANSWER 3 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:254742 CAPLUS Full-text
DOCUMENT NUMBER: 147:469270
TITLE: A novel synthesis of some new imidazothiazole and glycocyamidine derivatives and studies on their antimicrobial activities
AUTHOR(S): El-Din, Asmaa A. Magd; Roaiah, Hanaa F.; Elsharabasy, Salwa A.; Hassan, Aisha Y.
CORPORATE SOURCE: Natural Products Department, National Research Centre, Cairo, Egypt
SOURCE: Phosphorus, Sulfur and Silicon and the Related Elements (2007), 182(3), 529-536
CODEN: PSSLEC; ISSN: 1042-6507
PUBLISHER: Taylor & Francis, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:469270
AB 5,5-Diphenyl-2-thioxoimidazolidin-4-one (1) reacted with chloroacetic acid 2a and Et chloroacetate 2b in an alkaline medium to afford 2-(4,5-dihydro-5-oxo-

4,4-diphenyl-1H-imidazol-2-ylthio)acetic acid (3a) and Et 2-(4,5-dihydro-5-oxo-4,4-diphenyl-1H-imidazol-2-ylthio)acetate (3b), resp. Compds. 3a,b were converted to 5,5-diphenylimidazolidine-2,4- dione (4) by boiling in EtOH-HCl. When compds. 3a,b were treated with polyphosphoric acid, cyclization occurred, and 6,6-diphenylimidazo[2,1- b]thiazole-3,5(2H,6H)-dione (5) was obtained. 4-(Furan-2-ylmethylene)-2- (methylthio)-1H-imidazol-5(4H)-one and its thien-2-ylmethylene analog (6a and 6b) reacted with hydrazine hydrate to give the corresponding hydrazones 7a,b. The reaction of the 1-Ph analogs of 6a and 6b with hydrazine hydrate afforded 3-amino-5-[(furan-2-yl/thien-2-yl)methylene]-2- phenyliminoimidazolidin-4-ones 10a,b. The antimicrobial activities of compds. 1, 3a,b, 5, 7a,b, and 10a,b were studied; 5 was the most active.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1125928 CAPLUS Full-text

DOCUMENT NUMBER: 146:274284

TITLE: Evaluating the one-pot synthesis of hydantoins

AUTHOR(S): Mahmoodi, Nosrat O.; Khodaee, Ziba

CORPORATE SOURCE: Department of Chemistry, University of Guilan, Rasht, Iran

SOURCE: ARKIVOC (Gainesville, FL, United States) (2007), (3), 29-36
CODEN: AGFUAR
URL: http://www.arkat-usa.org/ARKIVOC/JOURNAL_CONTENT/manuscripts/2007/EA-1914DP%20as%20published%20mainmanuscript.pdf

PUBLISHER: Arkat USA Inc.

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:274284

GI


I


II


III

AB Re-examn. of the facile one-pot synthesis of hydantoins is considered. An efficient method was utilized for the synthesis of spirohydantoins (I) and (II; n = 4, 5) and hydantoins (III; R = R1 = Ph; R = cyclohexyl, R1 = Ph; R = Ph, R1 = 4-chlorophenyl; R = 4-dimethylaminophenyl, 4-methylphenyl, 4-bromophenyl, 4-chlorophenyl, or Ph, and R = H) starting with ketones such as 9-fluorenone, benzophenone, cyclopentanone, cyclohexanone, cyclohexyl Ph ketone, and 4-chlorobenzophenone, benzoin, benzil, phenanthrene-9,10-dione, and aldehydes such as 4- dimethylaminobenzaldehyde, 4-methylbenzaldehyde, 4-chlorobenzaldehyde, and 4-bromobenzaldehyde. Two main and convenient procedures using either (i) KCN and (NH4)2 CO3 or (ii) urea and NaOH, EtOH were examined Thus, 3 g 9-fluorenone, 2.16 g KCN and 6.38 g (NH4)2CO3 were added to 50 mL 50% aqueous EtOH solution in a 100 mL round bottom flask equipped with a reflux condenser. The reaction mixture was stirred and heated to reflux at 50-65°, by an oil bath for 24 h, cooled to room temperature and filtered. The aqueous filtrate solution was adjusted to pH 2-3 by carefully

adding concentrate HCl so as to facilitate further crystallization and the crude material obtained was recrystd. from 96% EtOH, several times to give 82% I, namely spiro[fluorene-9,4'-imidazolidine]-2',5'-dione.
REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1294782 CAPLUS Full-text
DOCUMENT NUMBER: 144:350594
TITLE: Synthesis of hydantoin, thiohydantoin and desulfuration of thiohydantoin to hydantoin
AUTHOR(S): Dubey, Vijay S.
CORPORATE SOURCE: Department of Chemistry, Hislop College, Nagpur, 440 001, India
SOURCE: Asian Journal of Chemistry (2005), Volume Date 2006, 18(1), 155-158
CODEN: AJCHEW; ISSN: 0970-7077
PUBLISHER: Asian Journal of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:350594
AB Condensation of benzil (or α-diketone obtained from auroneepoxide) with urea, thiourea and substituted thiourea in presence of ethanol in alkaline medium leads to the formation of hydantoin, thiohydantoin and substituted thiohydantoin. All the compds. were purified and analyzed using phys. and chemical methods and were further confirmed by spectral studies. The antimicrobial effect was studied by using cup-plate (nutrient-agar) technique on six different pathogenic microorganisms. The synthesized compds. were screened for their anti-AIDS property.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:570317 CAPLUS Full-text
DOCUMENT NUMBER: 141:410863
TITLE: One-Pot Synthesis of Phenytoin Analogs
AUTHOR(S): Mahmoodi, N. O.; Emadi, S.
CORPORATE SOURCE: Organic Research Laboratory, Department of Chemistry, University of Guilan, Rasht, 1914, Iran
SOURCE: Russian Journal of Organic Chemistry (Translation of Zhurnal Organicheskoi Khimii) (2004), 40(3), 377-382
CODEN: RJOCEQ; ISSN: 1070-4280
PUBLISHER: MAIK Nauka/Interperiodica Publishing
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:410863
GI

I

AB Phenytoin I (R = R1 = Ph) (5,5-diphenylimidazolidine-2,4-dione or 5,5-diphenyl-hydantoin) and a series of phenytoin analogs I (R = R1 = C6H4-4-Me, -

4-OMe; R = C6H4-4-NMe2, -4-OMe, R1 = H) were synthesized in 65-75% yields via cyclocondensation of urea with the corresponding substituted benzils RCOCOR1. The same products were also obtained directly from α-hydroxy ketones via one-pot procedure.

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:281814 CAPLUS Full-text
DOCUMENT NUMBER: 141:33316
TITLE: Block of human NaV1.5 sodium channels by novel α-hydroxyphenylamide analogues of phenytoin
AUTHOR(S): Lenkowski, Paul W.; Ko, Seong-Hoon; Anderson, James D.; Brown, Milton L.; Patel, Manoj K.
CORPORATE SOURCE: Department of Chemistry, University of Virginia, Charlottesville, VA, 22904, USA
SOURCE: European Journal of Pharmaceutical Sciences (2004), 21(5), 635-644
CODEN: EPSCED; ISSN: 0928-0987
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:33316

AB Voltage-gated sodium (Na) channels are a crit. component of elec. excitable cells. Phenytoin (diphenylhydantoin, DPH) is an established sodium channel blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain. In this study, we have synthesized novel α-hydroxyphenylamide analogs of diphenylhydantoin and examined their ability to inhibit human Nav1.5 sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells. Ph ring substitutions were examined including para-Me, para-fluoro, para-chloro, ortho-chloro and meta-chloro. We have found that Ph ring substitutions with electron withdrawing properties resulted in compds. with greater activity. In comparison to diphenylhydantoin, the novel chloro-substituted α-hydroxyphenylamide compds. produced as much as a 20-fold greater tonic and frequency-dependent blockade of Nav1.5 channels with an IC50 value of 14.5 μM. In addition, the chloro-substitutions have position specific state dependent blocking properties. The ortho-, meta- and para-chloro substitutions have an 8-, 13- and 3-fold increased affinity for the inactivated state, resp. Mol. modeling suggests that these differences in affinity are due to a direct interaction with the receptor. Comparing models of diphenylhydantoin to the novel α-hydroxyphenylamide compound suggests that the increased activity may be due to an optimized Ph ring position and increased mol. volume This information may be useful in the development of more potent sodium channel blockers.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:271112 CAPLUS Full-text
DOCUMENT NUMBER: 139:323872
TITLE: Synthesis and characterization of optically active poly(amide-imide)s with hydantoin and thiohydantoin derivatives in the main chain
AUTHOR(S): Faghihi, Khalil; Zamani, Khosrow; Mallakpour, Shadpour
CORPORATE SOURCE: Department of Chemistry, Arak University, Arak, 38156, Iran
SOURCE: Iranian Polymer Journal (2002), 11(5), 339-347
CODEN: IPJOFF; ISSN: 1026-1265
PUBLISHER: Iran Polymer Institute

DOCUMENT TYPE: Journal
LANGUAGE: English

AB Hydantoin and thiohydantoin derivs., i.e., 5,5-di-Ph hydantoin, 5,5-di-Ph thiohydantoin, 5,5-bis(4-chlorophenyl) hydantoin, 5,5-bis(4-chlorophenyl) thiohydantoin, 5,5-bis(4-Me phenyl) hydantoin, and 5,5-dimethylhydantoin (I), were synthesized from the reactions of benzil and benzil derivs. with urea and thiourea. I was synthesized from the reaction of acetone cyanohydrin and ammonium carbonate. Benzil and benzil derivs. were obtained from the oxidation of benzoin and benzoin derivs. with concentrated nitric acid. Benzoin and benzoin derivs. were obtained from benzoin condensation of benzaldehyde and benzaldehyde derivs. The hydantoin and thiohydantoin derivs. were characterized by m.ps., elemental anal., FTIR, 1H NMR and 13C NMR spectroscopy. The hydantoin and thiohydantoin compds. were polycondensed with 4,4-carbonyl-bis(phthaloyl-L-alanine) diacid chloride in DMAc solution in the presence of pyridine. The resulting poly(amide-imide)s, with inherent viscosities about 0.15-0.38 dL/g, were obtained in high yield and were optically active and thermally stable. All of the above compds. were fully characterized by means of FTIR spectroscopy, elemental anal., inherent viscosity (ηinh), solubility tests and sp. rotation. The thermal properties of the polymers were studied using thermal gravimetric anal. (TGA).

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:91629 CAPLUS Full-text
DOCUMENT NUMBER: 139:6807
TITLE: A rapid and efficient microwave-assisted synthesis of hydantoins and thiohydantoins
AUTHOR(S): Muccioli, Giulio G.; Poupaert, Jacques H.; Wouters, Johan; Norberg, Bernadette; Poppitz, Wolfgang; Scriba, Gerhard K. E.; Lambert, Didier M.
CORPORATE SOURCE: Faculte de Medecine, Ecole de Pharmacie, Laboratoire de Chimie pharmaceutique et de Radiopharmacie, Universite catholique de Louvain, UCL-CMFA 7340, Brussels, B-1200, Belg.
SOURCE: Tetrahedron (2003), 59(8), 1301-1307
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:6807
GI

I

AB Studies on the synthesis of the antiepileptic drug phenytoin (I), and of structurally related derivs., are described. First, the influence of the solvent has been investigated in the microwave-assisted synthesis of the drug, resulting in a yield improvement and a cleaner reaction. Second, a two-step reaction is described to synthesize selectively and in high yields phenytoin. The first step consists of microwave activation of the reaction of benzil with

thiourea, the second step includes the conversion of the resulting 2-thiohydantoin to phenytoin using hydrogen peroxide. Moreover, microwave activation is a very convenient method for the synthesis of 3-alkylated phenytoin derivs., resulting in a much more selective method than the previously reported procedure using alkylating agents.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:893101 CAPLUS Full-text

DOCUMENT NUMBER: 138:255591

TITLE: Microwave-assisted rapid synthesis of novel optically active poly(amide-imide)s containing hydantoins and thiohydantoins in main chain

AUTHOR(S): Faghihi, Khalil; Zamani, Khosrow; Mirsamie, Azizollah; Reza Sangi, Mohammad

CORPORATE SOURCE: Department of Chemistry, Arak University, Arak, 38156, Iran

SOURCE: European Polymer Journal (2002), Volume Date 2003, 39(2), 247-254
CODEN: EUPJAG; ISSN: 0014-3057

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:255591

AB Rapid and highly efficient synthesis of novel optically active poly(amide-imide)s (PAIs) 6(a-f) was achieved using microwave irradiation These were made from the polycondensation reactions of 4,4'-carbonyl-bis(phthaloyl-L-alanine) diacid chloride, [N,N'-(4,4'-carbonyldiphthaloyl)] bisalanine diacid chloride 5 with six different derivs. of hydantoin and thiohydantoin compds. 4(a-f) in the presence of a small amount of a nonpolar organic medium that acts as a primary microwave absorber. Hydantoin and thiohydantoin derivs. 4(a-e) were synthesis from the reactions between benzil or benzil derivs. 3(a-e) with urea and thiourea. 5,5-Dimethylhydantoin (4f) was synthesis from the reactions between acetone cyanohydrin (3f) and ammonium carbonate. The polycondensation proceeded rapidly, and was completed within 10 min giving a series of PAIs with an inherent viscosity about 0.25-0.45 dL/g. The resulting PAIs 6(a-f) were obtained in a high yield and were optically active and thermally stable. All of the above compds. were fully characterized by means of Fourier transform IR spectroscopy, elemental analyses, inherent viscosity (ηinh), solubility tests and sp. rotation. Thermal properties of the PAIs 6(a-f) were investigated using thermal gravimetric anal.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:708653 CAPLUS Full-text

DOCUMENT NUMBER: 136:151368

TITLE: Synthesis of hydantocidin and C-2-thioxo-hydantocidin

AUTHOR(S): Shiozaki, M.

CORPORATE SOURCE: Exploratory Chemistry Research Laboratories, Sankyo Co. Ltd., Shinagawa-ku, Tokyo, 140-8710, Japan

SOURCE: Carbohydrate Research (2001), 335(3), 147-150
CODEN: CRBRAT; ISSN: 0008-6215

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:151368

AB Hydantocidin, a naturally occurring strong herbicide, was synthesized in an overall yield of 35.2%, with the accompanying 1'-epi-hydantocidin in overall

9.6% yield from 2,3-O-isopropylidene-D-ribono-1,4-lactone. C-2-thioxo-hydantocidin and its spiro-epimer were also synthesized in an overall yield of 14.4% and 8.5%, resp.
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 12 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:639650 CAPLUS Full-text
DOCUMENT NUMBER: 131:346154
TITLE: The influence of structure and lipophilicity of hydantoin derivatives on anticonvulsant activity
AUTHOR(S): Scholl, S.; Koch, A.; Henning, D.; Kempter, G.; Kleinpeter, E.
CORPORATE SOURCE: Institut fur Organische Chemie und Strukturanalytik, Universitat Potsdam, Postdam, D-14415, Germany
SOURCE: Structural Chemistry (1999), 10(5), 355-366
CODEN: STCHES; ISSN: 1040-0400
PUBLISHER: Kluwer Academic/Plenum Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The lipophilicity of a representative no. of hydantoin derivs. was exptl. determined by RP-HPLC. The stationary phase of RP-HPLC proved a good model to simulate effects of membrane transport. These exptl. values were correlated to theor. estimated lipophilicity values on the basis of global min. structures of the compds. studied. Both these lipophilicity and structure similarities within a proposed pharmacol. model for binding the hydantoin derivs. along the sodium channel were classified with respect to their biol. activity.
REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 13 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:536691 CAPLUS Full-text
DOCUMENT NUMBER: 131:299402
TITLE: 3-Alkyl-(5,5'-diphenyl)imidazolidinediones as new cannabinoid receptor ligands
AUTHOR(S): Kanyonyo, Martial; Govaerts, Sophie J.; Hermans, Emmanuel; Poupaert, Jacques H.; Lambert, Didier M.
CORPORATE SOURCE: Unite de Chimie Pharmaceutique et de Radiopharmacie, Universite Catholique de Louvain, Brussels, 1200, Belg.
SOURCE: Bioorganic & Medicinal Chemistry Letters (1999), 9(15), 2233-2236
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Twenty-four 3-alkyl-(5,5'-diphenyl)imidazolidinediones were synthesized and evaluated as new cannabinoid receptor ligands. Three compds. exhibited a Ki value around 100 nM against [3H]-SR 141716A binding obtained from human CB1 transfected CHO cells membranes. The lack of change of affinity in the presence of a non hydrolyzable GTP analog seems to indicate they are cannabinoid antagonists.
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 14 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:412636 CAPLUS Full-text
DOCUMENT NUMBER: 131:56144
TITLE: Specific binding assay using enzyme inhibitor and

anti-inhibitor antibodies
INVENTOR(S): Contestable, Paul B.; Daiss, John L.; Groth, Holly L.; Grogan, Elizabeth A.; Snyder, Brian A.
PATENT ASSIGNEE(S): Johnson & Johnson Clinical Diagnostics, Inc., USA
SOURCE: U.S., 16 pp., Cont. of U.S. Ser. No. 250,980, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5916757	A	19990629	US 1996-683247	19960717
PRIORITY APPLN. INFO.:			US 1994-250980	B1 19940531

AB Specific binding ligands can be detected with an assay which utilizes an immobilized receptor for the ligand, an immobilized reporter enzyme, an inhibitor antibody and a water-soluble conjugate of the ligand and an anti-inhibitor antibody. Both antibodies are specific for the reporter enzyme, but the antibodies affect enzymic activity differently. The inhibitor antibody effectively shuts down the activity of the reporter enzyme when it is complexed thereto. The anti-inhibitor antibody binds to the reporter enzyme, does not affect the enzymic activity, but prevents the binding of the inhibitor enzyme. This assay provides a direct correlation of the generated signal to the target specific binding ligand. Horseradish peroxidase inhibitor and anti-inhibitor monoclonal antibodies were prepared by the hybridoma method from rats. Anti-inhibitor monoclonal antibody was conjugated with various haptens and used in assays for prostaglandin E2 (as marker for periodontal disease), diphenylhydantoin, phenobarbital, and digoxin.
REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 15 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:527297 CAPLUS Full-text
DOCUMENT NUMBER: 129:161184
ORIGINAL REFERENCE NO.: 129:32803a,32806a
TITLE: Preparation of fatty acyl and alkyl derivatives of drugs and agrochemicals
INVENTOR(S): Myhren, Finn; Borretzen, Bernt; Dalen, Are; Sandvold, Marit Liland
PATENT ASSIGNEE(S): Norsk Hydro Asa, Norway
SOURCE: PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9832718	A1	19980730	WO 1998-NO21	19980123
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

GB 2321455	A	19980729	GB 1997-1441		19970124
ZA 9800579	A	19980723	ZA 1998-579		19980123
CA 2276694	A1	19980730	CA 1998-2276694		19980123
CA 2276694	C	20070522			
AU 9857828	A	19980818	AU 1998-57828		19980123
AU 733370	B2	20010510			
EP 977725	A1	20000209	EP 1998-901593		19980123
EP 977725	B1	20040616			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI					
HU 2000000937	A2	20000928	HU 2000-937		19980123
HU 2000000937	A3	20010129			
HU 225664	B1	20070529			
NZ 336724	A	20010629	NZ 1998-336724		19980123
JP 2001522351	T	20011113	JP 1998-531863		19980123
RU 2227794	C2	20040427	RU 1999-118313		19980123
AT 269292	T	20040715	AT 1998-901593		19980123
ES 2224356	T3	20050301	ES 1998-901593		19980123
IL 130853	A	20050320	IL 1998-130853		19980123
SK 284803	B6	20051103	SK 1999-1003		19980123
TW 231209	B	20050421	TW 1998-87103693		19980313
NO 9903563	A	19990917	NO 1999-3563		19990721
US 20010006962	A1	20010705	US 1999-355111		19990927
US 20030153544	A1	20030814	US 2002-116358		20020405
US 6762175	B2	20040713			
US 20040063677	A1	20040401	US 2003-662441		20030916
PRIORITY APPLN. INFO.:			GB 1997-1441	A	19970124
			WO 1998-NO21	W	19980123
			US 1999-355111	B1	19990927
			US 2002-116358	A1	20020405

AB The properties of biol. active compds., for example drugs and agrochems. which contain in their mol. structure ≥1 functional groups selected from alc., ether, Ph, amino, amido, thiol, carboxylic acid, and carboxylic acid ester groups are modified by replacing one or more of these functional groups by a lipophilic group selected from those of the formula RCOO-, RCONH-, RCOS-, RCH2O-, RCH2NH-, -COOCH2R, -CONHCH2R and -SCH2R, (R = a lipophilic moiety selected from cis-8-heptadecenyl, trans-8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadecenyl). Data for biol. activity of title compds. were given.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 16 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1998:520228 CAPLUS Full-text
DOCUMENT NUMBER:	129:245090
ORIGINAL REFERENCE NO.:	129:49905a,49908a
TITLE:	Superacid-activated condensation of parabanic acid and derivatives with arenes. A new synthesis of phenytoin and 5,5-diarylhydantoins
AUTHOR(S):	Klumpp, Douglas A.; Yeung, Ka Yeun; Prakash, G. K. Surya; Olah, George A.
CORPORATE SOURCE:	Department Chemistry, California State Polytechnic University, Pomona, CA, 91768, USA
SOURCE:	Synlett (1998), (8), 918-920 CODEN: SYNLES; ISSN: 0936-5214
PUBLISHER:	Georg Thieme Verlag
DOCUMENT TYPE:	Journal
LANGUAGE:	English
OTHER SOURCE(S):	CASREACT 129:245090

AB A synthetic route to phenytoin and 5,5-diarylhydantoins is reported. Parabanic acid is converted to 5,5-diarylhydantoins (65-98% yield) from CF3SO3H and

arenes. Deuterium-substituted products are prepared in high yield from parabanic acid, CF3SO3D3, and deuterated arenes.

L10 ANSWER 17 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:488385 CAPLUS Full-text
DOCUMENT NUMBER: 129:85936
ORIGINAL REFERENCE NO.: 129:17633a,17636a
TITLE: Increased Shelf-Life of Fosphenytoin: Solubilization of a Degradant, Phenytoin, through Complexation with (SBE)7m-β-CD
AUTHOR(S): Narisawa, Shinji; Stella, Valentino J.
CORPORATE SOURCE: Department of Pharmaceutical Chemistry and Higuchi Biosciences Center for Drug Delivery Research, University of Kansas, Lawrence, KS, 66047., USA
SOURCE: Journal of Pharmaceutical Sciences (1998), 87(8), 926-930
CODEN: JPMSAE; ISSN: 0022-3549
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Fosphenytoin, a water-sol. prodrug of phenytoin, degrades primarily to phenytoin at pH values <8 during long term storage; phenytoin readily ppts. when formed from fosphenytoin due to its limited aqueous solubility The objective of this study was to develop stable formulations of fosphenytoin in the pH range of 7.4-8.0 by inhibiting the phenytoin precipitation through complexation with a parenterally safe cyclodextrin, (SBE)7m-β-CD. Phase solubility studies at 25° revealed that phenytoin was effectively solubilized by (SBE)7m-β-CD both in the presence and absence of 80.6 mg/mL fosphenytoin (as its dihydrate). The binding consts. for the phenytoin/cyclodextrin complex were 1073 and 792 M-1 at pH 7.4 and pH 8.0, resp. Because of the competitive inclusion between fosphenytoin and phenytoin with (SBE)7m-β-CD, the extent of solubilization of phenytoin was lower, as expected, in the presence of fosphenytoin than in the absence of fosphenytoin, even though the binding consts. for the fosphenytoin/cyclodextrin complex were relatively small (41-45 M-1). Initial rates were used to follow the production of phenytoin from fosphenytoin. Zero-order kinetics were observed under all conditions investigated. Phenytoin production rates were followed at 25, 37, and 50° in the presence of 0.03 or 0.06M (SBE)7m-β-CD. It was projected from the solubility of phenytoin and the kinetic information that fosphenytoin shelf-lives as high as 9 yr at 25° and pH 7.4 in the presence of 60 mM of (SBE)7m-β-CD might be possible while longer shelf-lives might be possible at pH 8.
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:79418 CAPLUS Full-text
DOCUMENT NUMBER: 128:166998
ORIGINAL REFERENCE NO.: 128:32909a,32912a
TITLE: System for multiple simultaneous synthesis of small-molecule organic compounds
INVENTOR(S): Dewitt, Sheila H. H.; Kiely, John S.; Pavia, Michael R.; Schroeder, Mel C.; Stankovic, Charles J.
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: U.S., 67 pp., Cont.-in-part of U.S. Ser.5,612,002.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5714127	A	19980203	US 1995-475559	19950607
US 5324483	A	19940628	US 1993-12557	19930202
US 5324483	B1	19960924		
US 5612002	A	19970318	US 1995-430696	19950428
US 5565173	A	19961015	US 1995-461998	19950605
US 5567391	A	19961022	US 1995-464161	19950605
US 5582801	A	19961210	US 1995-463545	19950605
US 5593642	A	19970114	US 1995-461475	19950605
US 5766556	A	19980616	US 1996-777270	19961231
PRIORITY APPLN. INFO.:			US 1992-958383	B2 19921008
			US 1993-12557	A3 19930202
			US 1994-217347	B1 19940324
			US 1995-430696	A2 19950428

AB A system for the multiple, simultaneous synthesis of org. compds., primarily by the solid-phase method, is disclosed. The system includes: (a) a sealed reaction apparatus comprising a reservoir member with a plurality of reaction wells for holding reaction materials, a plurality of tubular members (usually gas dispersion tubes) for holding reaction materials, a holder member attached to the reservoir for holding the tubular members, and a manifold member attached to the holder member and enclosing a portion of the tubular members, (b) a sample processor, (c) a means on the sample processor for dispensing and aspirating materials at least into and from said tubular members, (d) a first controller for the operation of the sample processor, including the dispensing and aspirating of materials into and from the tubular members, (e) a multi-axis robot member for manipulating the reaction apparatus on the sample processor, and (f) a second controller, for operation of the multi-axis robot member, in order to manipulate the reaction apparatus on the sample processor. The manifold top wall has a plurality of apertures in axial alignment with the reaction tubes, and a gasket which allows penetration by a needle in order to dispense and aspirate materials from the reaction tubes. Sealing members, such as gaskets, are placed between the holder block, manifold, and reservoir rack, and the components are releasably fastened together. A robotic sample processor is used to automate the synthesis process using the reaction apparatus The apparatus is constructed from materials which will accommodate heating, cooling, agitation, or corrosive reagents. The apparatus provides in excess of 1 mg of each product with structural knowledge and control over each compound The apparatus can be adapted to manual, semiautomatic, or fully automatic performance. Using the apparatus, a series of building blocks are covalently attached to a solid support. These building blocks are then modified by covalently adding addnl. different building blocks or chemical modifying some existing functionality until the penultimate structure is achieved. This is then cleaved from the solid support by another chemical reaction into the solution within the well, yielding an array of newly synthesized individual compds., which after post-reaction modification, if necessary, are suitable for testing for activity. A variety of organic compds. with different functionalities may be prepared by the system, including peptides, cyclic peptides, hydantoins, benzodiazepines, keto-ureas, nucleosides or analogs, cyclic nucleotides, carbocyclic compds. (e.g. tocopherols and steroids) and other N-, O-, and S-containing heterocyclic compds. (e.g., β-lactams and cephalosporins). The system is suitable for synthesizing compds. in an array format based on a structure of known biol. activity, for the purpose of developing a structure activity relationship for biol. agents such as muscarinic agonists, antiepileptics, antidepressants, HMG CoA reductase inhibitors, antiinflammatories, etc. Among several groups of compds. prepared in examples, 16 dipeptides containing Ala or Ile were

prepared in 26-85% yield, 40 hydantoins were prepared in 5-81% yield, and 40 benzodiazepines were prepared <5% to quant. yield.
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 19 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:15623 CAPLUS Full-text
DOCUMENT NUMBER: 128:114966
ORIGINAL REFERENCE NO.: 128:22545a,22548a
TITLE: Apparatus and method for solid phase multiple simultaneous synthesis.
INVENTOR(S): Dewitt, Sheila H. H.; Kell, Michael; Pavia, Michael R.; Kiely, John S.; Schroeder, Mel C.; Stankovic, Charles J.; Ware, Steven
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: U.S., 52 pp., Cont.-in-part of U.S. 5,612,002.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5702672	A	19971230	US 1995-540512	19951010
US 5324483	A	19940628	US 1993-12557	19930202
US 5324483	B1	19960924		
US 5612002	A	19970318	US 1995-430696	19950428
US 5565173	A	19961015	US 1995-461998	19950605
US 5567391	A	19961022	US 1995-464161	19950605
US 5582801	A	19961210	US 1995-463545	19950605
US 5593642	A	19970114	US 1995-461475	19950605
US 5766556	A	19980616	US 1996-777270	19961231
PRIORITY APPLN. INFO.:			US 1992-958383	B2 19921008
			US 1993-12557	A3 19930202
			US 1994-217347	B3 19940324
			US 1995-430696	A2 19950428

AB An app. for multiple, simultaneous synthesis of compds. consists of a reservoir block having a plurality of wells; a plurality of reaction tubes, usually gas dispersion tubes, having filters on their lower ends; a holder block, having a plurality of apertures; and a manifold, which may have ports to allow introduction/maintenance of a controlled environment. The manifold top wall has apertures and a detachable plate with identical apertures. Apparatus operation involves placing the filters on the lower ends of the reaction tubes in the reservoir block wells, and the upper ends passing through the holder block apertures and into the manifold. Dipeptides, hydantoins, and benzodiazepines were prepared

L10 ANSWER 20 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:694374 CAPLUS Full-text
DOCUMENT NUMBER: 125:327717
ORIGINAL REFERENCE NO.: 125:61391a,61394a
TITLE: A method for the combinatorial synthesis of mixtures of compounds
INVENTOR(S): Becker, Katherine; Dewitt, Sheila Hobbs
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9630393	A1	19961003	WO 1995-US16332	19951208
W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9644244	A	19961016	AU 1996-44244	19951208
PRIORITY APPLN. INFO.:			US 1995-411040 A	19950327
			WO 1995-US16332 W	19951208

GI



I II

AB Described is a method of synthesizing a plurality of compds., such as dipeptides, hydantoins [I; R1 = H, Ph; R2 = H, Me, PhCH2, etc.; R3 = H, Bu, H2C:CHCH2, etc.], benzodiazepines [II; R1 = H, Me, iPr, 4-HOC6H4CH2, indol-3-ylmethyl; R2 = Ph, 4-MeOC6H4, cyclohexyl, 2-thienyl; R3 = H, Cl, Me, NO2; R4 = H, Me, iPr], etc., in a plurality of wells comprising the steps of: (a) providing a plurality of test wells in a plurality of arrays of the wells; (b) reacting in at least one step reaction a first reagent with a plurality of reagents called building blocks in the test well to obtain a unique product designed to be the same in each array; and (c) continuing to react reagents such that there are multiple reagents resulting in mixts. of multiple different products in each well. The resulting 40 benzodiazepines were tested for activity in a benzodiazepine receptor binding assay and their IC50 values were given.

L10 ANSWER 21 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:599190 CAPLUS Full-text
DOCUMENT NUMBER: 125:219625
ORIGINAL REFERENCE NO.: 125:41079a,41082a
TITLE: Inhibitor and anti-inhibitor monoclonal antibodies specific for horseradish peroxidase
INVENTOR(S): Gorman, Kevin M.; Daiss, John L.
PATENT ASSIGNEE(S): Johnson & Johnson Clinical Diagnostics, Inc., USA
SOURCE: Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 690071	A2	19960103	EP 1995-303657	19950530

EP 690071	A3	19961016		
EP 690071	B1	20001227		
R: BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5650324	A	19970722	US 1994-251496	19940531
CA 2150497	A1	19951201	CA 1995-2150497	19950530
CA 2150497	C	20061017		
PT 690071	T	20010430	PT 1995-303657	19950530
ES 2157294	T3	20010816	ES 1995-303657	19950530
AU 9520409	A	19951207	AU 1995-20409	19950531
JP 08053497	A	19960227	JP 1995-134031	19950531
JP 3745411	B2	20060215		
GR 3035547	T3	20010629	GR 2001-400388	20010309

PRIORITY APPLN. INFO.: US 1994-251496 A 19940531

AB Monoclonal antibodies have been prepd. which are of the IgG isotype and are highly specific for horseradish peroxidase. One group of antibodies inhibits at least about 95% of the normal activity of horseradish peroxidase when bound to the enzyme. A second group of antibodies inhibits less than about 20% of the enzymic activity when bound to the enzyme, but prevents the binding of the antibodies from the first group. The antibodies in either group can be conjugated to specific binding ligands such as drugs or hormones.

L10 ANSWER 22 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1996:115666 CAPLUS Full-text
DOCUMENT NUMBER:	124:260004
ORIGINAL REFERENCE NO.:	124:48171a,48174a
TITLE:	Combinatorial organic synthesis using Parke-Davis's diversomer method
AUTHOR(S):	DeWitt, Sheila Hobbs; Czarnik, Anthony W.
CORPORATE SOURCE:	Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI, 48105, USA
SOURCE:	Accounts of Chemical Research (1996), 29(3), 114-22 CODEN: ACHRE4; ISSN: 0001-4842
PUBLISHER:	American Chemical Society
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB Derivs. of 2,4-imidazolidinedione (hydantoin), 2H-1,4-benzodiazepin-2-one and 2,4-dihydro-3H-fluoreno[1,9-ef]-1,4-diazepin-3-one were prepared in a com. available Parke-Davis's Diversomer Apparatus and screened for biol. activity. The advantages of combinatorial synthesis were discussed.

L10 ANSWER 23 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1995:766526 CAPLUS Full-text
DOCUMENT NUMBER:	123:339894
ORIGINAL REFERENCE NO.:	123:61003a,61006a
TITLE:	Synthesis, structure and properties of 5,5-diphenyl-2,3,5,6-tetrahydroimidazo[2,1-b]imidazoline-3,6-dione
AUTHOR(S):	Kiec-Kononowicz, Katarzyna; Karolak-Wojciechowska, Janina; Mrozek, Agnieszka; Posel, Maciej
CORPORATE SOURCE:	Department of Chemical Technology of Drugs, Collegium Medicum of Jagiellonian University, Krakow, PL 30-688, Pol.
SOURCE:	Archiv der Pharmazie (Weinheim, Germany) (1995), 328(6), 517-21 CODEN: ARPMAS; ISSN: 0365-6233
PUBLISHER:	VCH
DOCUMENT TYPE:	Journal
LANGUAGE:	English

OTHER SOURCE(S): CASREACT 123:339894
AB Cyclization of N-(5,5-diphenyl-4-oxo-2-imidazolidinyl)glycine yielded 5,5-diphenyl-2,3,5,6-tetrahydroimidazo[2,1-b]imidazoline-3,6-dione (6) or its acetyl derivative 5, depending on the method used. The stabilities of 5 and 6 in acidic or alkaline solns. were examined The crystal structure of the hydrolysis products of 5 and 6 were solved by x-ray anal.

L10 ANSWER 24 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:746664 CAPLUS Full-text
DOCUMENT NUMBER: 123:142970
ORIGINAL REFERENCE NO.: 123:25449a,25452a
TITLE: Gas/Solid Reactions with Nitrogen Dioxide
AUTHOR(S): Kaupp, Gerd; Schmeyers, Jens
CORPORATE SOURCE: FB 9-Organic Chemistry I, University of Oldenburg, Oldenburg, D-26111, Germany
SOURCE: Journal of Organic Chemistry (1995), 60(17), 5494-503
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 123:142970
AB Virtually all primary reaction types of NO2 with org. substrates (electron transfer, oxygen atom transfer, H-abstraction, and O/C- and N/C-bond formation) have been demonstrated for gas/solid reactions. Atomic force microscopy (AFM) measurements on prominent faces of single crystals of nitroxyls, anthracene, and tetraphenylethylene reveal phase rebuildings with well-directed long-range mol. transports. Mol. interpretations of the AFM features are given.

L10 ANSWER 25 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:441042 CAPLUS Full-text
DOCUMENT NUMBER: 122:222646
ORIGINAL REFERENCE NO.: 122:40526h,40527a
TITLE: Dissolution behavior of phenytoin-bile salt complexes prepared by co-grinding
AUTHOR(S): Otsuka, Makoto; Matsuda, Yoshihisa
CORPORATE SOURCE: Kobe Pharm. Univ., Kobe, 658, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1994), 42(11), 2382-4
CODEN: CPBTAL; ISSN: 0009-2363
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The physicochem. properties of phenytoin (PHT)-bile salt complexes comprised of sodium dehydrocholate (DHCNa), sodium deoxycholate (DCNa) or sodium cholate (CNa) prepared by co-grinding were investigated by x-ray diffraction anal., DSC and dissoln. kinetics. All x-ray diffraction peak intensities of the co-ground PHT-bile salt [1:1] mixts. were decreased by grinding for 3 h, and showed a halo pattern of a noncryst. solid. The solubility of ground products with DCNa, DHCNa and CNa were 212-, 56-, 68-fold higher, resp., than those of phys. mixts.

L10 ANSWER 26 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:308615 CAPLUS Full-text
DOCUMENT NUMBER: 122:106536
ORIGINAL REFERENCE NO.: 122:20071a,20074a
TITLE: Apparatus and method for multiple simultaneous

	synthesis of peptides and other organic compounds
INVENTOR(S):	Cody, Donna Reynolds; Dewitt, Sheila Helen Hobbs; Hodges, John Cooke; Roth, Bruce David; Schroeder, Mel Conrad; Stankovic, Charles John; Moos, Walter Hamilton; Pavia, Michael Raymond; Kiely, John Steven
PATENT ASSIGNEE(S):	Warner-Lambert Co., USA
SOURCE:	PCT Int. Appl., 143 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9408711	A1	19940428	WO 1993-US9666	19931008
W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5324483	A	19940628	US 1993-12557	19930202
US 5324483	B1	19960924		
AU 9453558	A	19940509	AU 1994-53558	19931008
EP 663856	A1	19950726	EP 1993-923827	19931008
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08502482	T	19960319	JP 1993-510171	19931008

PRIORITY APPLN. INFO.:	US 1992-958383	A	19921008
	US 1993-12557	A	19930202
	WO 1993-US9666	W	19931008

AB An app. and method provide a suitable location for multiple, simultaneous synthesis of compds. by the solid phase method. The apparatus consists of (1) a reservoir block having a plurality of wells, (2) a plurality of reaction tubes, usually gas dispersion tubes, having filters on their lower ends, (3) a holder block having a plurality of apertures, and (4) a manifold, which may have ports to allow introduction/maintenance of a controlled environment. The manifold top wall has apertures and a detachable plate with identical apertures. The apparatus is constructed from materials which will accommodate heating, cooling, agitation, or corrosive reagents. Gaskets are placed between the components. Rods or clamps are provided for fastening the components together. Apparatus operation involves placing the filters on the lower ends of the reaction tubes in the reservoir block wells, and the upper ends passing through the holder block apertures and into the manifold. The apparatus provides in excess of 1 mg of each product with structural knowledge and control over each compound The apparatus can be adapted to manual, semiautomatic of fully automatic performance. Using the apparatus a series of building blocks are covalently attached to a solid support. These building blocks are then modified by covalently adding addnl. different building blocks or chemical modifying some existing functionality until the penultimate structure is achieved. This is then cleaved from the solid support by another chemical reaction into the solution within the well yielding an array of newly synthesized individual compds., which after post-reaction modification, if necessary, are suitable for testing for activity. A class of organic compds. with different functionalities including peptides, cyclic peptides, hydantoins, benzodiazepines, keto-ureas, nucleosides or analogs, cyclic nucleotides, carbocyclic compds. (e.g. tocopherols and steroids) and other N-, O-, and S-containing heterocyclic compds. (e.g. β-lactams and cephalosporins) are simultaneously prepared by this apparatus This apparatus is suitable for synthesizing a series of compds. simultaneously in an array format based on a structure of known biol. activity for the purpose of developing a structure activity relationship for biol. agents such as muscarinic agonists, antiepileptics, antidepressants, HMG CoA reductase inhibitors, antiinflammatories, etc.

L10 ANSWER 27 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:137709 CAPLUS Full-text
DOCUMENT NUMBER: 122:177662
ORIGINAL REFERENCE NO.: 122:32293a,32296a
TITLE: Phenytoin derivatives as potent σ ligands
AUTHOR(S): Hudkins, Robert L.; DeHaven-Hudkins, Diane L.
CORPORATE SOURCE: Albany Mol. Res., Albany, NY, 12203, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1994), 4(18), 2185-8
CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of 4-phenylpiperidinyl and 4-phenylpiperazinyl alkyl spaced 5,5-diphenylhydantoins was prepared and evaluated for affinity at σ sites. Increasing the alkyl spacer between the two pharmacophore recognition units resulted in a progressive increase in σ binding affinity. The pentyl 12 and hexyl 13 4-phenylpiperidine derivs. exhibited subnanomolar affinity (0.7 nM and 0.6 nM) for the PENT site.

L10 ANSWER 28 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:404529 CAPLUS Full-text
DOCUMENT NUMBER: 121:4529
ORIGINAL REFERENCE NO.: 121:999a,1002a
TITLE: Labeled drug hapten analogs for immunoassays
INVENTOR(S): Danielson, Susan J.; Brummond, Barbara A.; Oenick, Marsha D. B.; Ponticello, Ignazio S.; Hilborn, David A.
PATENT ASSIGNEE(S): Eastman Kodak Co., USA
SOURCE: U.S., 11 pp. Cont.-in-part of U.S. Ser. No. 712,330, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5298403	A	19940329	US 1992-851439	19920316
CA 2062240	A1	19921208	CA 1992-2062240	19920416
EP 517326	A2	19921209	EP 1992-201581	19920602
EP 517326	A3	19930407		
EP 517326	B1	20010816		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 204384	T	20010915	AT 1992-201581	19920602
JP 05172814	A	19930713	JP 1992-145980	19920605
JP 3190729	B2	20010723		
PRIORITY APPLN. INFO.:			US 1991-712330	B2 19910607
			US 1992-851439	A 19920316

AB The invention is directed to labeled drug hapten analogs comprising: (A) a label, of the type used in immunoassays, having an amine or sulfhydryl group; (B) a drug hapten nucleus selected from barbiturates or hydantoins; and (C) a linking chain linking the 3-position of the drug hapten nucleus to the label through a carbonyl bridge. 5-Ethyl-5-phenyl-1-{4-[4-(3-succinimidoxycarbonylpropionyl)-1-piperazinylcarbonyl]butyl}-2,4,6-(1H,3H,5H)pyrimidinetrione (I) was prepared from phenobarbital and Me 5-

bromovalerate in 7 steps. I was conjugated with amine-enriched horseradish peroxidase (L-lysine reaction products with peroxidase) to show improved antibody recognition.

L10 ANSWER 29 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:299113 CAPLUS Full-text
DOCUMENT NUMBER: 120:299113
ORIGINAL REFERENCE NO.: 120:52733a,52736a
TITLE: Part 1. Synthetic studies of some unsymmetrically substituted sulfamides and 5,5-diphenylhydantoin. Part 2. Photoinduced generation of glycosyl cations from thioglycosides for possible application in oligosaccharide synthesis
AUTHOR(S): Bandara, Nayanie Champika
CORPORATE SOURCE: Univ. New Orleans, New Orleans, LA, USA
SOURCE: (1992) 127 pp. Avail.: Univ. Microfilms Int., Order No. DA9230592
From: Diss. Abstr. Int. B 1992, 53(6), 2865
DOCUMENT TYPE: Dissertation
LANGUAGE: English
AB Unavailable

L10 ANSWER 30 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:656382 CAPLUS Full-text
DOCUMENT NUMBER: 119:256382
ORIGINAL REFERENCE NO.: 119:45625a,45628a
TITLE: Phenytoin-lipid conjugates: Chemical, plasma esterase-mediated, and pancreatic lipase-mediated hydrolysis in vitro
AUTHOR(S): Scriba, Gerhard K. E.
CORPORATE SOURCE: Dep. Pharm. Chem., Univ. Muenster, Muenster, 48149, Germany
SOURCE: Pharmaceutical Research (1993), 10(8), 1181-6
CODEN: PHREEB; ISSN: 0724-8741
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Phenytoin-lipid conjugates obtained by covalent binding of hydroxymethylphenytoin to diacyl glycerides and to 3-acyloxy-2-acyloxymethylpropionic acids formed dispersions with a particle size of 10-200 μM when briefly sonicated in a sodium taurodeoxycholate-containing ethanol-water mixture In contrast to the corresponding bis-deacyl derivs., the lipids were not significantly hydrolyzed in aqueous buffers and in plasma. Incubation with pancreatic lipase yielded primarily the bis-deacyl compds., which are comparable to monoglycerides, and subsequently liberated phenytoin. The glyceride-derived prodrugs were better substrates for the enzyme than the 3-acyloxy-2-acyloxymethylpropionic acid derivs. Thus, the phenytoin lipid conjugates are hydrolyzed by pancreatic lipase in a similar manner as natural triglycerides.

L10 ANSWER 31 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:617285 CAPLUS Full-text
DOCUMENT NUMBER: 119:217285
ORIGINAL REFERENCE NO.: 119:38477a,38480a
TITLE: Phenytoin-lipid conjugates as potential prodrugs of phenytoin
AUTHOR(S): Scriba, Gerhard K. E.
CORPORATE SOURCE: Dep. Pharm. Chem., Univ. Muenster, Muenster, D-48149,

Germany
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1993), 326(8), 477-81
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Phenytoin-1-triglycerides and phenytoin-2-triglycerides were synthesized as potential prodrugs of phenytoin by covalent binding of 3-hydroxymethylphenyltoin by succinic acid to the positions 1 and 2, resp., of diglycerides. The corresponding 1- and 2-monoglycerides were also prepared In addition, replacement of glycerol by 3-hydroxy-2- hydroxymethylpropionic acid furnished lipids that allowed direct coupling of 3-hydroxymethylphenytoin. The lipid conjugates proved to be substrates for pancreatic lipase in vitro.

L10 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:260830 CAPLUS Full-text
DOCUMENT NUMBER: 118:260830
ORIGINAL REFERENCE NO.: 118:45219a,45222a
TITLE: Optimization of phenytoin preparation
AUTHOR(S): Ponte, C. I. R. V.; Bacha, C. T. M.; Seixas, L. M. J.; Todeschini, A. R.; Cunha, A.; Carvalho, E.
CORPORATE SOURCE: Fac. Farm., UFRGS, Brazil
SOURCE: Revista Brasileira de Farmacia (1992), 73(1), 11-12
CODEN: RBFAAH; ISSN: 0370-372X
DOCUMENT TYPE: Journal
LANGUAGE: Portuguese
AB Improvements were made in the chem. processes to obtain phenytoin, a drug used in psychomotor epilepsy treatment. The processes can be adapted to pilot plant scale.

L10 ANSWER 33 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:633927 CAPLUS Full-text
DOCUMENT NUMBER: 117:233927
ORIGINAL REFERENCE NO.: 117:40459a,40462a
TITLE: A convenient preparation of symmetrical and unsymmetrical 1,2-diketones: application to fluorinated phenytoin synthesis
AUTHOR(S): Page, Philip C. Bulman; Graham, Andrew E.; Park, B. Kevin
CORPORATE SOURCE: Dep. Chem., Univ. Liverpool, Liverpool, L69 3BX, UK
SOURCE: Tetrahedron (1992), 48(35), 7265-74
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 117:233927
GI



I II

AB 1,2-Diketones RCOCOR1 (R = Ph, 2-, 3-, 4-FC6H4, R1 = Ph, 2-, 3-, 4-FC6H4, Et, Pr) are efficiently produced in two steps by reaction of R1CHO with anions derived from 2-substituted dithianes I followed by treatment of the resulting alcs. with NBS in aqueous acetone. Phenytoin derivs. II (Ph, 2-, 3-, 4-FC6H4, R1 = Ph, 2-, 3-, 4-FC6H4) were prepared from these diketones by a standard method involving treatment with urea and potassium hydroxide under reflux.

L10 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:187524 CAPLUS Full-text
DOCUMENT NUMBER: 116:187524
ORIGINAL REFERENCE NO.: 116:31511a,31514a
TITLE: Analysis of a clinically important interaction between phenytonin and Shankhapushpi, and Ayurvedic preparation
AUTHOR(S): Dandekar, U. P.; Chandra, R. S.; Dalvi, S. S.; Joshi, M. V.; Gokhale, P. C.; Sharma, A. V.; Shah, P. U.; Kshirsagar, N. A.
CORPORATE SOURCE: Dep. Pharmacol. Clin. Pharmacol., Seth Gordhandas Sunderdas Med. Coll., Bombay, 400-012, India
SOURCE: Journal of Ethnopharmacology (1992), 35(3), 285-8
CODEN: JOETD7; ISSN: 0378-8741
DOCUMENT TYPE: Journal
LANGUAGE: English
AB During the course of routine plasma drug level monitoring, an unexpected loss of seizure control and reduction in plasma phenytoin levels was noticed in 2 patients who were also taking Shankhapushi (SRC), an Ayurvedic preparation Therefore, the present study was undertaken in rats to investigate any SRC-phenytoin interaction from both pharmacokinetic (serum levels) and pharmacodynamic (electroshock seizure prevention) aspects. Single dose SRC and phenytoin (oral/i.p.) coadministration did not have any effect on plasma phenytoin levels but decreased the antiepileptic activity of phenytoin significantly. On multiple-dose coadministration, SRC reduced not only the antiepileptic activity of phenytoin but also lowered plasma phenytoin levels. SRC itself showed significant antiepileptic activity compared to placebo and is worth further investigation. However, the clin. combination of SRC with phenytoin is not advised.

L10 ANSWER 35 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:679900 CAPLUS Full-text
DOCUMENT NUMBER: 115:279900
ORIGINAL REFERENCE NO.: 115:47563a,47566a
TITLE: Reactions of carbonic acid diamides with α-hydroxy ketones and α-diketones. Part 4. Reactions of substituted biguanides with benzil in ethanol under the influence of sodium ethanolate
AUTHOR(S): Schramm, H. W.
CORPORATE SOURCE: Inst. Pharm. Chem., Karl-Franzens-Univ., Graz, A-8010, Austria
SOURCE: Scientia Pharmaceutica (1991), 59(2), 123-33
CODEN: SCPHA4; ISSN: 0036-8709
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 115:279900
GI



I



II

AB The imidazole derivs. I (R = Me, cyclohexyl, 4-MeC6H4, 4-MeOC6H4, 2-ClC6H4, 2,4-Cl(Me)C6H3, 4,2-Cl(Me)C6H3; R1 = H, Me; RR1 = (CH2)n, n = 4, 6) were prepared by treating benzil with H2NC(:NH)N:C(NH2)NRR1 in the presence of NaOEt. I reacted with Cu(II) to form lilac-colored diimidazolidinylguanidine complexes. I (R = 4-MeC6H4, R1 = H) was also prepared by aminolysis of 4-oxo-5,5-diphenyl-(3H)-1-imidazolin-2-ylcyanamide (II) and yielded 5,5-diphenylimidazolidine-2,4-dione upon hydrolysis. I (R = 4-MeC6H4, R1 = H) also exhibited anthelmintic activity (no data).

L10 ANSWER 36 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1991:228552 CAPLUS Full-text
DOCUMENT NUMBER:	114:228552
ORIGINAL REFERENCE NO.:	114:38533a,38536a
TITLE:	Preparation of (aminoalkyl)phenylacyl-derivatized drugs with improved solution stability and solubility
INVENTOR(S):	Bundgaard, Hans; Falch, Erik
PATENT ASSIGNEE(S):	Den.
SOURCE:	PCT Int. Appl., 109 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9008128	A1	19900726	WO 1990-DK20	19900119
W: AU, CA, FI, JP, KR, NO, US RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
CA 2045591	A1	19900721	CA 1990-2045591	19900119
AU 9050323	A	19900813	AU 1990-50323	19900119
EP 454773	A1	19911106	EP 1990-902624	19900119
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 04502918	T	19920528	JP 1990-502553	19900119
PRIORITY APPLN. INFO.:			DK 1989-240 A	19890120
			WO 1990-DK20 A	19900119

OTHER SOURCE(S): MARPAT 114:228552

GI



I

AB The title compds. [I; D = residue of an NH- or OH-contg. drug; R1 = H, alkyl, aryl, aralkyl, alkoxycarbonyl, carbamoyl; R2 = H, alkyl; R3, R4 = H, (substituted) alkyl, aralkyl, alkenyl, cycloalkyl; R3R4N = (substituted) heterocyclyl; R5 = halo, OH, alkyl, alkoxy; d = 0-4; m,p = 0,1; n = 1-4] were prepared as prodrugs having improved stability in aqueous solution Thus, hydrocortisone in CH2C12 was stirred with Et3N and 3-ClCH2C6H4COCl to give hydrocortisone 21-(3-chloromethyl)benzoate. The latter was stirred with NaI and N-methylpiperazine in Me2CO at 60° to give hydrocortisone 21-[3-(4-methylpiperazin-1-yl)methyl]benzoate, converted to the dihydrochloride. The latter had solubility of 3.5 mg/mL in H2O at 21°, vs. 0.40 mg/mL for hydrocortisone itself. I are preferably stored at pH 3-5. I derivs. of hydrocortisone showed t1/2 of 8-147 min in human plasma at pH 7.4.

L10 ANSWER 37 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:17446 CAPLUS Full-text
DOCUMENT NUMBER: 114:17446
ORIGINAL REFERENCE NO.: 114:2973a,2976a
TITLE: Sodium channel binding and anticonvulsant activities of hydantoins containing conformationally constrained 5-phenyl substituents
AUTHOR(S): Brouillette, Wayne J.; Brown, George B.; DeLorey, Timothy M.; Liang, Gang
CORPORATE SOURCE: Dep. Chem., Univ. Alabama, Birmingham, AL, 35294, USA
SOURCE: Journal of Pharmaceutical Sciences (1990), 79(10), 871-4
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English
GI


I


II

AB As a preliminary investigation of the importance of the arom. ring orientation in interactions of 5-phenylhydantoins with the anticonvulsant site on the neuronal voltage-sensitive Na channel, 2 isomeric hydantoins containing conformationally constrained Ph rings and their monocyclic analogs were synthesized. One, a spirohydantoin (I) derived from α-tetralone, contains the plane of the Ph ring in an orientation approx. perpendicular to that for the hydantoin ring. The other, a tricyclic hydantoin (II) derived from tetrahydroisoquinoline, contains the plane of the Ph ring in an orientation roughly coplanar with that for the hydantoin ring. These compds. were evaluated in Na channel binding and whole animal (mice) anticonvulsant assays. In both assays, II was significantly more perfect than I, suggesting that the anticonvulsant receptor site on the voltage-sensitive Na channel may require a specific aromatic ring orientation.

L10 ANSWER 38 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:478239 CAPLUS Full-text
DOCUMENT NUMBER: 113:78239

ORIGINAL REFERENCE NO.: 113:13239a,13242a
TITLE: The reactions of carbonic diamides α-hydroxy ketones and α-diketones. Part 1. The reaction of cyanoguanidine with benzil
AUTHOR(S): Schramm, H. W.
CORPORATE SOURCE: Inst. Pharm. Chem., Karl-Franzens-Univ., Graz, A-8010, Austria
SOURCE: Scientia Pharmaceutica (1989), 57(4), 385-90
CODEN: SCPHA4; ISSN: 0036-8709
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



I

AB Cyanoguanidine reacts with benzil in KOH/EtOH with 1,2-rearrangement to yield the imidazolinylcyanamide I. The isomeric 1- and 3-cyano-2-aminoimidazolidinones and are not formed in the reaction. The structure of I was proven by spectroscopic and chemical methods.

L10 ANSWER 39 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:154859 CAPLUS Full-text
DOCUMENT NUMBER: 112:154859
ORIGINAL REFERENCE NO.: 112:26083a,26086a
TITLE: Immobilization of haptens for measurement by immunoassay using surface plasmon resonance (SPR)
INVENTOR(S): Corrie, John; Fairclough, Lynne; Charles, Stephen Alexander; Finlan, Martin Francis
PATENT ASSIGNEE(S): Amersham International PLC, UK
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8908260	A1	19890908	WO 1989-GB156	19890223
W: JP, SU				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
EP 378594	A1	19900725	EP 1989-904150	19890223
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 03503679	T	19910815	JP 1989-503761	19890223
AU 8930774	A	19890831	AU 1989-30774	19890227
AU 616481	B2	19911031		

PRIORITY APPLN. INFO.: GB 1988-4669 A 19880227
WO 1989-GB156 W 19890223

AB A metal surface carries a coating comprising spacer units, e.g. protein mols., to which haptens are linked. These metal surfaces are useful for assays, e.g. in which dissolved haptens in a sample compete with immobilized haptens for

binding to antibodies. The coated metal surfaces are adapted for use in SPR techniques. Also included are immunoassays in which antibodies are immobilized on the metal surface with hapten conjugates reversibly bound to them, displacement of conjugate, as a result of addition of a sample containing the hapten, being monitored by SPR. Thus, a theophylline-7-propionyl-rabbit γ-globulin conjugate was prepared For theophylline determination, a glass microscope slide covered on 1 side by a thin (50-60 nm) film of Ag was immersed for 30-45 min in an 8 μM solution of the conjugate in buffer (10 mM Na phosphate, pH 7.4). The coated slide was then immersed for 30 min in a solution of 5 μM rabbit γ-globulin solution in the same buffer to block residual binding sites on the metal surface. The slide was incubated overnight in a solution of theophylline antiserum (raised in a rabbit against a theophylline-8- butyryl-bovine serum albumin conjugate, essentially as described by T. Nishikawa, et al. (1984)) diluted 1:500 in buffer (50 mM Na phosphate/0.154 M NaCl, pH 7.4, called PBS) which also contained 0.1% ovalbumin. The slide was then rinsed twice in PBS buffer containing 0.05% Tween 20, and twice in PBS, and stored until use in PBS. For use, the non-silvered surface was cleaned with isopropanol and the SPR properties of the slide were determined before and after exposure to theophylline. A graph of SPR reflectivity vs. time, showing results obtained on theophylline determination is presented.

L10 ANSWER 40 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:632664 CAPLUS Full-text
DOCUMENT NUMBER: 111:232664
ORIGINAL REFERENCE NO.: 111:38649a,38652a
TITLE: The stereochemical course of the Biltz reaction
AUTHOR(S): Mergen, F.; Poupaert, J. H.; De Keyser, J. L.; Dumont, P.
CORPORATE SOURCE: Med. Fak. Kathol., Univ. Lowen, Brussels, 1200, Belg.
SOURCE: Pharmazie (1989), 44(2), 110-12
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 111:232664
GI

I

AB The mechanism of the Biltz synthesis of phenytoin (I) has been investigated by chromatog. (HPLC) and spectroscopy (13C- and 15N-NMR) with special emphasis on the stereochem. course of the reaction of urea and benzil. The resulting data allowed the development of novel approaches in the synthesis of I derivs.; in this connection, phase-transfer catalysis proved to be extremely useful in terms of yield and selectivity.

L10 ANSWER 41 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:484010 CAPLUS Full-text
DOCUMENT NUMBER: 111:84010

ORIGINAL REFERENCE NO.: 111:14037a,14040a
TITLE: Low-melting phenytoin prodrugs: in vitro and in vivo correlations
AUTHOR(S): Martodihardjo, Suwaldi
CORPORATE SOURCE: Univ. Kansas, Lawrence, KS, USA
SOURCE: (1988) 248 pp. Avail.: Univ. Microfilms Int., Order No. DA8903134
From: Diss. Abstr. Int. B 1989, 49(11), 4831
DOCUMENT TYPE: Dissertation
LANGUAGE: English
AB Unavailable

L10 ANSWER 42 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:165383 CAPLUS Full-text
DOCUMENT NUMBER: 110:165383
ORIGINAL REFERENCE NO.: 110:27197a,27200a
TITLE: Enzyme-enhanced electrochemical immunoassay for phenytoin
AUTHOR(S): Umana, Mirtha; Waller, Jess; Wani, Mansukh; Whisnant, Carol; Cook, Edgar
CORPORATE SOURCE: Res. Triangle Inst., Research Triangle Park, NC, 27709-2194, USA
SOURCE: Journal of Research of the National Institute of Standards and Technology (1988), 93(6), 659-61
CODEN: JRITEF; ISSN: 1044-677X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB An enzyme-enhanced electrochem. immunoassay for phenytoin is described. This paper describes the optimum conditions for the assay. This paper also describes preliminary results on the electron-transfer mediation of ferrocene derivs. to polypyrrole-immobilized glucose oxidase (GOx). The goal of these expts. is to couple the polypyrrole-immobilized GOx to the ferrocene diphenylhydantoin system to produce a reagentless electrochem. immunoassay sensor, for easy and time-saving detns.

L10 ANSWER 43 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:37727 CAPLUS Full-text
DOCUMENT NUMBER: 108:37727
ORIGINAL REFERENCE NO.: 108:6311a,6314a
TITLE: Spirohydantoin aldose reductase inhibitors
AUTHOR(S): Sarges, Reinhard; Schnur, Rodney C.; Belletire, John L.; Peterson, Michael J.
CORPORATE SOURCE: Pfizer Cent. Res., Groton, CT, 06340, USA
SOURCE: Journal of Medicinal Chemistry (1988), 31(1), 230-43
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:37727
GI



I

AB Sorbitol formation from glucose, catalyzed by aldose reductase, is believed to play a role in the development of certain chronic complications of diabetes mellitus. Spiro hydantoins derived from five- and six-membered ketones fused to an aromatic ring or ring system were prepd by Bucherer-Bergs cyclocondensation with KCN and (NH4)2CO3, and were tested for inhibition of aldose reductase isolated from calf lens. In vivo these compds. are potent inhibitors of sorbitol formation in sciatic nerves of streptozotocinized rats. Optimum in vivo activity is reached in spiro hydantoins I (R = F, Cl, Br). In I (R = F), the activity resides exclusively in the 4S isomer. This compound is currently being used to test, in humans, the value of aldose reductase inhibitors in the therapy of diabetic complications.

L10 ANSWER 44 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:101551 CAPLUS Full-text
DOCUMENT NUMBER: 106:101551
ORIGINAL REFERENCE NO.: 106:16619a,16622a
TITLE: Reaction of bis-α-diketones with urea in alkaline media
AUTHOR(S): Savchenko, T. I.; Yatsimirskii, A. K.
CORPORATE SOURCE: Politekh. Inst., Tomsk, USSR
SOURCE: Zhurnal Organicheskoi Khimii (1986), 22(6), 1241-6
CODEN: ZORKAE; ISSN: 0514-7492
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 106:101551
GI



II III

AB Rate consts. were detd. for the cyclization of PhCOCOXCOCOPh (I; X = 4,4'-biphenylylene, 4,4'-oxydi-p-phenylene, 4-C6H4C.tplbond.CC6H4-4, etc.) with urea to give bishydantoins (II), and a linear Hammett relation yielded ρ = 1.13. Steric effects were more important than electronic effects in governing the reactivity of I. The reaction of I (X = p-phenylene) with urea gave III.

L10 ANSWER 45 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:435320 CAPLUS Full-text
DOCUMENT NUMBER: 105:35320

ORIGINAL REFERENCE NO.: 105:5693a,5696a
TITLE: Pharmacological properties of 3-aminoalkyl and amide derivatives of 5,5-diphenylhydantoin
AUTHOR(S): Kiec-Kononowicz, Katarzyna; Stypula, Ewa; Krupinska, Jolanta; Cebo, Barbara
CORPORATE SOURCE: Dep. Pharm. Chem., Med. Acad., Krakow, 31-065, Pol.
SOURCE: Polish Journal of Pharmacology and Pharmacy (1985), 37(5), 693-9
CODEN: PJPPAA; ISSN: 0301-0244
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The title compds. I (R = alkyleneheterocycles, CONHC6H4CO2H-4, etc; X = O, S) were prepared and evaluated for pharmacol. activity in animal models. In general, the compds. given in a dose of 50 mg/kg, did not affect cardiac bioelec. activity and, in contrast to diphenylhydantoin did not possess the antiarrhythmic properties and did not protect against pentetrazol seizures I(R = CONHC6H4CO2Et-4; X = O) [80688-82-0] showed weak antiarrhythmic and antiseizure activity.

L10 ANSWER 46 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1985:471246 CAPLUS Full-text
DOCUMENT NUMBER: 103:71246
ORIGINAL REFERENCE NO.: 103:11465a,11468a
TITLE: Reactions of 5,5-diphenylhydantoin and its 3-N-carboxylates with hydrazine and 2-morpholinoethylamine
AUTHOR(S): Kiec-Kononowicz, Katarzyna; Zejc, Alfred; Byrtus, Hanna
CORPORATE SOURCE: Dep. Pharm. Chem., Sch. Med., Krakow, 31065, Pol.
SOURCE: Polish Journal of Chemistry (1984), 58(4-5-6), 585-91
CODEN: PJCHDQ; ISSN: 0137-5083
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 103:71246
GI

I

AB Treating hydantoin I (R = CH2CO2Et) (II) with a 5-fold excess of N2H4·H2O 4 h at 130-140° gave 56% I (R = NH2) characterized by its Schiff bases with Me2CO and p-O2NC6H4CHO. Similarly, II treated with N2H4·H2O in refluxing EtOH 4 h gave 62% I (R = CH2CONHNH2) which was also converted to its hydrazide-hydrazones. Treating I (R = CO2Et) with N2H4·H2O gave 86% I (R = H) (III) which with N2H4·H2O gave I (R = NH2). Treating III with 2-morpholinoethylamine (IV) gave 68% I (R = 2-morpholinoethyl). Addnl. obtained were I (R = CH2CH2CO2Et) and its amide with IV, and the amide of I (R = CH2CO2Et).

L10 ANSWER 47 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1985:78766 CAPLUS Full-text
DOCUMENT NUMBER: 102:78766
ORIGINAL REFERENCE NO.: 102:12349a,12352a
TITLE: Phase-transfer catalysis by poly(ethyleneglycol) 600 in the Biltz synthesis of phenytoin.
AUTHOR(S): Poupaert, Jacques H.; De Keyser, Jean Luc; Vandervorst, Daniel; Dumont, Pierre
CORPORATE SOURCE: Brussels, B-1200, Belg.
SOURCE: Bulletin des Societes Chimiques Belges (1984), 93(6), 493-5
CODEN: BSCBAG; ISSN: 0037-9646
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 102:78766
GI



I

AB A reinvestigation of the Biltz synthesis of phenytoin (I) from benzil and urea was undertaken to selectively produce I instead of a mixture of I and the glycoluryl derivative This was accomplished by carrying out the reaction in a two-phase system (BuOH-H2O) and in the presence of a phase-transfer catalyst [poly(ethyleneglycol) 600]. Under these conditions, 87-93% I was obtained. This approach was also superior to one-phase conditions for the synthesis of other hydantoin derivs.

L10 ANSWER 48 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1985:32235 CAPLUS Full-text
DOCUMENT NUMBER: 102:32235
ORIGINAL REFERENCE NO.: 102:5117a,5120a
TITLE: Pharmaceutical complexes with cyclodextrin and glycol diglycidyl ether polymers
PATENT ASSIGNEE(S): Mitsubishi Petrochemical Co., Ltd., Japan; Mitsubishi Yuka Pharmaceutical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59164728	A	19840917	JP 1983-38473	19830309

PRIORITY APPLN. INFO.: JP 1983-38473 19830309

GI

I

AB Insol. or barely-sol. drugs are treated with reaction products of I (R = H or Me; n = 1-10) and cyclodextrin to give complexes that are soluble in H2O. Thus, soluble cyclodextrin-polymers were prepared by treating β-cyclodextrin with propylene glycol diglycidyl ether and polymerizing This product was treated with insol. drugs such as phenytoin and indomethacin to give soluble complexes.

L10 ANSWER 49 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1984:616279 CAPLUS Full-text
DOCUMENT NUMBER:	101:216279
ORIGINAL REFERENCE NO.:	101:32715a,32718a
TITLE:	Phenytoin prodrugs. IV: Hydrolysis of various 3-(hydroxymethyl)phenytoin esters
AUTHOR(S):	Varia, S. A.; Schuller, S.; Stella, V. J.
CORPORATE SOURCE:	Dep. Pharm. Chem., Univ. Kansas, Lawrence, KS, 66045, USA
SOURCE:	Journal of Pharmaceutical Sciences (1984), 73(8), 1074-80 CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE:	Journal
LANGUAGE:	English

GI

I

II, R=COCH2NMe2 ═ MeSO3H
III, R=COCH2CH2NEt2
IV, R=COCH2CH2NMe2 ═ MeSO3H
V, R=PO3Na2

AB The aq. chem. stability of various bioreversible derivs. or prodrugs of phenytoin (I) [57-41-0], a poorly water-soluble and erratically absorbed drug after both oral and i.m. parenteral dosing, was evaluated. This study, together with assessments of other physicochem. properties including cleavage in the presence of various animal tissues and anticonvulsant activity in mice, helped identify a number of promising candidate prodrugs. II [71919-15-8], III [92780-92-2], and IV [92135-00-7] were identified as potential orally and perhaps parenterally useful prodrugs, while V [92134-98-0] appears to be ideally suited as a parenteral form of phenytoin.

L10 ANSWER 50 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1984:490608 CAPLUS Full-text
DOCUMENT NUMBER: 101:90608
ORIGINAL REFERENCE NO.: 101:13879a,13882a
TITLE: Urea derivatives and their use
INVENTOR(S): Stransky, Werner; Schroeder, Ludwig; Mengel, Rudolf; Lust, Sigmund; Linden, Gerbert
PATENT ASSIGNEE(S): Celamerck G.m.b.H. und Co. K.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 16 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3236626	A1	19840405	DE 1982-3236626	19821004

PRIORITY APPLN. INFO.: DE 1982-3236626 19821004
OTHER SOURCE(S): CASREACT 101:90608; MARPAT 101:90608
GI



I

II

AB Aryl(carboxyalkyl)ureas and their derivs. (I) (R, R1 = CF3, halo, C1-4 alkyl, alkoxy; R2, R3 = C1-4 alkyl, alkenyl, C3-6 cycloalkyl, aryl, benzyl; R4 = H, C1-20 alkyl, alkenyl, alkoxyalkyl, etc.) were prepared as herbicides (no data). Thus, PrC(CHMe2)(NH2)CO2Me and 3,5-Me2C6H3NCO in THF gave 78% urea II.

L10 ANSWER 51 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:114425 CAPLUS Full-text
DOCUMENT NUMBER: 100:114425
ORIGINAL REFERENCE NO.: 100:17249a,17252a
TITLE: Radioimmunoassay of diphenylhydantoin
AUTHOR(S): Wu, Jianzhong; Jia, Liguo; Zhu, Yanzhen
CORPORATE SOURCE: Beijing Inst. Neurosurg., Beijing, Peop. Rep. China
SOURCE: Zhonghua Yixue Jianyan Zazhi (1983), 6(2), 65-7
CODEN: CHCCDO; ISSN: 0253-973X
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
AB Diphenylhydantoin (DPH) [57-41-0] was detd. in human blood serum by a RIA which uses rabbit antiserum to the immunogen DPH-bovine serum albumin and 125I-labeled DPH. The RIA for DPH was accurate, precise, and showed average recovery of 99.7% in conventionally used dosages; in addition, this RIA was sensitive (lowest limit 0.5 ng) and specific (did not cross-react with other therapeutic drugs, e.g. valium) with good reproducibility (intra- and interassay relative standard deviation 3.8-6.7 and 14%, resp.). The RIA required only 20 μL blood and could be used directly for DPH determination in other body fluids, including saliva and cerebrospinal fluids. The salivary level of DPH determined by this RIA correlated well with the serum DPH level. Apparently, this RIA is useful in monitoring of DPH in therapy of epileptics.

L10 ANSWER 52 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:22537 CAPLUS Full-text
DOCUMENT NUMBER: 100:22537
ORIGINAL REFERENCE NO.: 100:3541a,3544a
TITLE: Application of spin labeling to drug assays. III. 2,2,5,5-tetramethylpyrroline-15N,d13-1-oxyl-3-carboxylic acid coupled to phenytoin
AUTHOR(S): Yost, Yul; Polnaszek, Carl F.; Holtzman, Jordan L.
CORPORATE SOURCE: Res. Serv., VA Med. Cent., Minneapolis, MN, 55417, USA
SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals (1983), 20(6), 707-17
CODEN: JLCRD4; ISSN: 0362-4803
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Cycloaddn. reaction of [(R3C)2C:CR]2CO (R = H, D) with 15NH3 and 15ND3 followed by bromination gave the piperidines I (R = H, D). Ring contraction of I on treatment with concentrated NH4OH for 2 h gave pyrrolidines II which on oxidation with H2O2 gave the corresponding nitroxides. Basic hydrolysis of the doubly labeled nitroxide gave 2,2,5,5-tetramethyl-1- oxylpyrroline-3-carboxylic -15N-d13, -15N-d12, and -15N-d11 acid. When coupled to phenytoin these gave a spin-labeled drug of high sensitivity for detection by ESR.

L10 ANSWER 53 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:609278 CAPLUS Full-text
DOCUMENT NUMBER: 99:209278
ORIGINAL REFERENCE NO.: 99:32141a,32144a
TITLE: Assay method
INVENTOR(S): Allen, Gerald John
PATENT ASSIGNEE(S): Amersham International PLC, UK
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 92344	A1	19831026	EP 1983-301943	19830406
R: DE, FR, GB				
JP 58190762	A	19831107	JP 1983-66281	19830414

PRIORITY APPLN. INFO.: GB 1982-10928 A 19820415

AB Assays for analytes (esp. antigens) are described which employ a specific binding partner for the analyte (especially antibodies), a fluorescent compound-analyte conjugate, and solid particles which have a material which is

not a member of the binding pair but which controls the extent of binding of the labeled derivative The solid particles are preferably of C, either coated with albumin or carrying a receptor for the binding partner. The albumin coating acts as a mol. sieve to accept labeled analytes but not antiserums and complexes thereof. For example, phenytoin amine was determined with a phenytoin-fluorescein label, antiserum, and albumin-coated charcoal. Fluorescence was measured at 490 nm excitation and 520 nm emission. Serum phenytoin amine was determined in the range 0-100 μg/mL.

L10 ANSWER 54 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:435662 CAPLUS Full-text
DOCUMENT NUMBER: 99:35662
ORIGINAL REFERENCE NO.: 99:5573a,5576a
TITLE: Fluoroimmunoassay system
INVENTOR(S): Hendrix, John L.
PATENT ASSIGNEE(S): Bio-Diagnostics, Inc., USA
SOURCE: Eur. Pat. Appl., 60 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 71991	A2	19830216	EP 1982-107102	19820806
EP 71991	A3	19830907		
EP 71991	B1	19860514		
R: AT, DE, FR, GB, IT				
CA 1186621	A1	19850507	CA 1982-408817	19820805
AT 19828	T	19860515	AT 1982-107102	19820806
AU 8287024	A	19830512	AU 1982-87024	19820810
AU 565418	B2	19870917		
JP 58086459	A	19830524	JP 1982-139112	19820810
JP 03079665	B	19911219		
AU 8774987	A	19871022	AU 1987-74987	19870630

PRIORITY APPLN. INFO.: US 1981-291793 A 19810810
EP 1982-107102 A 19820806

AB An automated computer-controlled app. and improved reagent for fluoroimmunoassays are described in which the analyte (e.g., antibody, antigen, hormone, hapten, virus, drug) is conjugated to a fluorescent label that has a relatively high Stokes shift (not <150 nm) and fluoresces at wavelengths longer than those of autofluorescing substances in patient-serum samples (e.g., chlorophylls or porphyrins). The apparatus is relatively inexpensive, has simple optics, and includes an excitation light source, fiber optics, photodetectors, an analog-to-digital converter, and a display. The excitation light source is placed directly above the sample, such as a well in a microliter plate, and the light sensors are placed directly below the well. Thus, bacteriochlorophyllide b was purified from Rhodopseudomonas viridis by TLC and reversed-phase high-performance liquid chromatog., conjugated to T4 by using iso-Bu chloroformate in a solution of triethylamine and dioxane, and used for the determination of T4 in serum by an immunoassay procedure in anti-T4-coated test tubes.

L10 ANSWER 55 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:122427 CAPLUS Full-text
DOCUMENT NUMBER: 98:122427
ORIGINAL REFERENCE NO.: 98:18605a,18608a

TITLE: Stabilization of glucose oxidase apoenzyme
INVENTOR(S): Rupchock, Patricia A.; Tyhach, Richard J.
PATENT ASSIGNEE(S): Miles Laboratories, Inc. , USA
SOURCE: U.S., 17 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4366243	A	19821228	US 1981-255310	19810417
PRIORITY APPLN. INFO.:			US 1981-255310	19810417

AB Glucose oxidase apoenzyme is stabilized by poly(vinyl alc.) and serum albumin for ligand binding assays. The stabilized apoenzyme can be incorporated into test strips for immunoassays. In such assays an FAD-antigen conjugate is the label, and FAD-antigen conjugate which is not bound to the antibody is available for glucose oxidase apoenzyme activation. For example, test strips were prepared for dinitrophenyl caproate immunoassay which contained buffer, a glucose oxidase detection system, apoglucose oxidase, dinitrophenol antibody, and dinitrophenol-FAD conjugate. Inclusion of poly(vinyl alc.) and albumin increased the heat stability of the test strips. Test strips for theophylline and phenytoin are also described.

L10 ANSWER 56 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:68454 CAPLUS Full-text
DOCUMENT NUMBER: 98:68454
ORIGINAL REFERENCE NO.: 98:10421a,10424a
TITLE: Homogeneous specific binding assay test device having a copolymer enhancing substance
INVENTOR(S): Tabb, David L.; Tyhach, Richard J.
PATENT ASSIGNEE(S): Miles Laboratories, Inc. , USA
SOURCE: U.S., 15 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4362697	A	19821207	US 1981-255759	19810420
PRIORITY APPLN. INFO.:			US 1981-255759	19810420
OTHER SOURCE(S):	MARPAT 98:68454			

AB Test strips are described for ligand detn. by homogeneous specific binding assays with reflection spectrometric detection. The test strips are impregnated with the appropriate reagents and an enhancer substance (e.g. Gafquat). For example, N-(2,4-dinitrophenyl)-δ-aminocaproic acid was determined by test strips impregnated with apoglucose oxidase, 2,4-DNP-FAD conjugate, antibody, and a glucose oxidase detection reagents. This system responded to 2,4-DNP by exhibiting color due to the activation of apoglucose oxidase by the 2,4-DNP-FAD conjugate. The presence of Gafquat 734 markedly improved the color response. Theophylline and phenytoin were also determined by the title system.

L10 ANSWER 57 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:466393 CAPLUS Full-text

DOCUMENT NUMBER: 97:66393
ORIGINAL REFERENCE NO.: 97:10983a,10986a
TITLE: Fluorescent reagent and method for determining immunofluorescence.
INVENTOR(S): Tsay, Yuh Geng; Chen, Janet H.; Palmer, Richard J.
PATENT ASSIGNEE(S): International Diagnostic Technology, Inc., USA
SOURCE: Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 47459	A2	19820317	EP 1981-106776	19810829
EP 47459	A3	19820324		
EP 47459	B1	19841121		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AT 10399	T	19841215	AT 1981-106776	19810829
CA 1172560	A1	19840814	CA 1981-385220	19810904
DK 8103946	A	19820309	DK 1981-3946	19810907
FI 8102771	A	19820309	FI 1981-2771	19810907
FI 72394	B	19870130		
FI 72394	C	19870511		
NO 8103029	A	19820309	NO 1981-3029	19810907
NO 155516	B	19861229		
JP 57077963	A	19820515	JP 1981-140808	19810907

PRIORITY APPLN. INFO.: US 1980-185235 A 19800908
EP 1981-106776 A 19810829

GI

I

AB Fluorescent diagnostic reagents are prepd. which contain a hydrophobic hapten, a hydrophilic compound such as an aminoglycoside, peptide, protein, or polyacrylamide hydrazine [30601-03-7], and a hydrophobic fluorescent compound such as a derivative of fluorescein [2321-07-5], umbelliferone [93-35-6], or fluorescamine [38183-12-9]. The hydrophobic hapten and the hydrophobic fluorescent compound are both bound to the hydrophilic compound but separated from each other. The reagents are used in the solid-phase fluorescence immunoassay of e.g. diphenylhydantoin (I) [57-41-0], phenobarbital [50-06-6], and primidone [125-33-7] in blood serum and eliminate the disadvantages of previously used reagents. Thus, for the determination of the hydrophobic compound I, a reagent was prepared by coupling a carboxylated derivative of I and FITC [27072-45-3] with the hydrophilic compound gentamicin [1403-66-3]. The resulting hydrophilic conjugate has increased water solubility, less susceptibility to fluorescence quenching by albumin and other serum proteins, and improved antigenicity.

L10 ANSWER 58 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:104166 CAPLUS Full-text

DOCUMENT NUMBER: 96:104166
ORIGINAL REFERENCE NO.: 96:17109a,17112a
TITLE: The synthesis of some carbon-11-labeled antiepileptic drugs with potential utility as radiopharmaceuticals: hydantoins and barbiturates
AUTHOR(S): Roeda, D.; Westera, G.
CORPORATE SOURCE: Dep. Org. Chem., Vrije Univ., Amsterdam, 1081 HV, Neth.
SOURCE: International Journal of Applied Radiation and Isotopes (1981), 32(11), 843-5
CODEN: IJARAY; ISSN: 0020-708X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 11C-labeled phenytoin and 5-ethyl-5-phenylhydantoin were prepd. using 11COCl2 as the starting material. 11C-urea was used to produce 11C-phenobarbital and 11C-barbital. The methods developed are suitable for automation in a lead shielded cell.

L10 ANSWER 59 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:417983 CAPLUS Full-text
DOCUMENT NUMBER: 95:17983
ORIGINAL REFERENCE NO.: 95:3021a,3024a
TITLE: A nonmetabolized analog of phenytoin
AUTHOR(S): Henderson, James D.; Dayton, Peter G.; Israili, Zafar H.; Mandell, Leon
CORPORATE SOURCE: Dep. Med., Emory Univ., Atlanta, GA, 30322, USA
SOURCE: Journal of Medicinal Chemistry (1981), 24(7), 843-7
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Nine 5,5-diphenylhydantoin analogs I (R = m- or p-CF3; R1 = H or m- or p-Me or CF3) were synthesized and tested for anticonvulsant activity in mice. None of the I had any anticonvulsant activity against elec. or chemical shock at doses of ≤100 mg/kg. 14C-labeled I (R = R1 = m-CF3) (II) [62031-95-2] was synthesized and certain physiochem. properties and the 7-day LD50 (40 mg/kg, i.p.; 100 mg/kg, orally) were determined in mice. II exhibited neurotoxicity at 24 and 48 h after doses of 750 and 1000 mg/kg, but not after a dose of 500 mg/kg. The other 8 analogs did not demonstrate any neurotoxicity ≤4 h after doses of ≤300 mg/kg (i.p.). II was excreted unmetabolized in rat feces (94% in 18 days), with a urinary excretion of <0.5%. The half-life of elimination of II from plasma was 67-72 h in rats and 115 h in mice. Tissue distribution and biliary excretion studies indicated low tissue/plasma ratios due to high plasma binding (97%) and low biliary excretion. Possible explanations for the

lack of metabolism of II are given. Structure activity relations are discussed.

L10 ANSWER 60 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1980:506758 CAPLUS Full-text
DOCUMENT NUMBER: 93:106758
ORIGINAL REFERENCE NO.: 93:16909a,16912a
TITLE: A new metabolite of 5,5-diphenylhydantoin containing an epoxide-ol moiety
AUTHOR(S): Lhoest, G.; Poupaert, J. H.; Claesen, M.
CORPORATE SOURCE: Sch. Pharm., Univ. Cathol. Louvain, Louvain, Belg.
SOURCE: European Journal of Mass Spectrometry in Biochemistry, Medicine and Environmental Research (1980), 1(1), 57-9
CODEN: EJMRDJ; ISSN: 0379-8399
DOCUMENT TYPE: Journal
LANGUAGE: English
GI


I


II

AB Following the feeding of 5,5-diphenylhydantoin (I) [57-41-0] to rats and rabbits, a new metabolite was found in the urine which, by chromatog. and mass spectrometry, was identified as probably being the epoxide-ol structure II [74612-34-3].

L10 ANSWER 61 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:420399 CAPLUS Full-text
DOCUMENT NUMBER: 91:20399
ORIGINAL REFERENCE NO.: 91:3413a,3416a
TITLE: Synthesis of 5,5-diphenylhydantoin
AUTHOR(S): Chiang, Hung-Cheh; Li, Shyh-Yuan; Shih, Hsi-Pin
CORPORATE SOURCE: Inst. Chem., Natl. Taiwan Normal Univ., Taipei, Taiwan
SOURCE: Kexue Fazhan Yuekan (1979), 7(1), 21-31
CODEN: KHFKDF; ISSN: 0250-1651
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
GI


I

AB The title compd. (I) was prepd. most economically by refluxing PhCHO with NaCN, oxidizing benzoin by Larked and Dieger's method, and condensing benzil with urea using modified Klosa's method.

L10 ANSWER 62 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:197383 CAPLUS Full-text
DOCUMENT NUMBER: 90:197383
ORIGINAL REFERENCE NO.: 90:31255a,31258a
TITLE: Fluorinated phenytoin anticonvulsant analogs
AUTHOR(S): Nelson, Wendel L.; Kwon, Young G.; Marshall, Gary L.; Hoover, James L.; Pfeffer, Gary T.
CORPORATE SOURCE: Sch. Pharm., Univ. Washington, Seattle, WA, USA
SOURCE: Journal of Pharmaceutical Sciences (1979), 68(1), 115-17
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Of 6 title compds. I (R = F; R1 = H or F) evaluated for anticonvulsant activity 5-(2-fluorophenyl)-5-phenylhydantoin [70028-82-9], showed reasonable activity, being slightly less than 1/2 as potent as phenytoin in the maximum electroshock seizure assay. None of I were active in the s.c. pentylenetetrazol assay. The synthesis of I is given. Structure-activity relations are discussed.

L10 ANSWER 63 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:529930 CAPLUS Full-text
DOCUMENT NUMBER: 89:129930
ORIGINAL REFERENCE NO.: 89:20125a,20128a
TITLE: Labeled 5,5-diphenylhydantoin derivatives for radioimmunoassay
INVENTOR(S): Parsons, George H., Jr.; Eller, Thomas
PATENT ASSIGNEE(S): Baxter Travenol Laboratories, Inc., USA
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4092479	A	19780530	US 1976-673853	19760405
US 4145407	A	19790320	US 1977-835481	19770922
PRIORITY APPLN. INFO.:			US 1976-673853 A3	19760405
OTHER SOURCE(S):	MARPAT 89:129930			

GI



I



III

AB Radioiodinated derivs. of hydantoin I (R = R1 = H) (II), useful in radioimmunoassays, were prepared Thus, 5,5-diphenylhydantoin 3-Na salt was treated with Br(CH2)4CO2Me to give hydantoinvaleric acid ester III (R2 = Me), which was hydrolyzed to III (R2 = H),which was condensed with tyrosine via the ClCO2Et mixed anhydride method to give II. II was iodinated with Na125I to give I (R = 125I, R1 = H; R = R1 = 125I. The radioiodinated derivs. were used in the radioimmunoassay of 5,5-diphenylhydantoin in rabbits.

L10 ANSWER 64 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:151656 CAPLUS Full-text
DOCUMENT NUMBER: 88:151656
ORIGINAL REFERENCE NO.: 88:23885a,23888a
TITLE: Mechanistic studies in the chemistry of urea. Part 2. Reaction with benzil, 4,4'-dimethylbenzil, and 4,4'-dimethoxybenzil
AUTHOR(S): Butler, Anthony R.; Leitch, Elizabeth
CORPORATE SOURCE: Dep. Chem., Univ. St. Andrews, St. Andrews, UK
SOURCE: Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999) (1977), (14), 1972-6
CODEN: JCPKBH; ISSN: 0300-9580
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB Urea and N-methylurea with benzil, 4,4'-dimethyl-, and 4,4'-dimethoxybenzil in alkaline conditions gave the hydantoins I (R = H, Me, R1 = H, Me, OMe). The mechanism of the reaction, determined by a kinetic study, is rate-determining attack by the urea anion on benzil, rapid cyclization, and slow rearrangement. The benzils with N,N'-dimethylurea gave the diols II (R = H, Me, OMe).

L10 ANSWER 65 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:578887 CAPLUS Full-text
DOCUMENT NUMBER: 83:178887
ORIGINAL REFERENCE NO.: 83:28089a,28092a
TITLE: Chemistry of a novel 5,5-diphenylhydantoin prodrug
AUTHOR(S): Stella, V.; Higuchi, T.; Hussain, A.; Truelove, J.
CORPORATE SOURCE: Dep. Pharm. Chem., Univ. Kansas, Lawrence, KS, USA
SOURCE: ACS Symposium Series (1975), 14(Pro-drugs Novel Drug Delivery Syst., Sypm., 1974), 154-83
CODEN: ACSMC8; ISSN: 0097-6156
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB H2NCONHCPh2CO2CH2CH2N+HEt2 SO4= (I), an acyclic form of 5,5-diphenylhydantoin (II) was prepared by condensing H2NCPh2CO2H with ClCO2Et, treating HO2CCPh2NHCO2Et with SOCl2, reacting the oxazolidinedione III with HOCH2CH2NEt2, treating the resulting H2NCPh2CO2CH2CH2NEt2 with KNCO and H2SO4; I regenerated II in simulated physiological conditions in 7 min, suggesting that enzyme mediation was not necessary.

L10 ANSWER 66 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:497130 CAPLUS Full-text
DOCUMENT NUMBER: 83:97130
ORIGINAL REFERENCE NO.: 83:15253a,15256a
TITLE: Hydantoins, thiohydantoins, and glycocyamidines. 41. Reaction of N-cyano amines with 1-(tert-butyl)-3,3-diphenylaziridinone. General method for the synthesis of 1-alkyl-, 1-aralkyl-, and 1-aryl-5,5-diphenyl hydantoins and -glycocyamidines
AUTHOR(S): Simig, G.; Lempert, K.; Tamas, J.; Czira, G.
CORPORATE SOURCE: Res. Group Alkaloid Chem., Hung. Acad. Sci., Budapest, Hung.
SOURCE: Tetrahedron (1975), 31(9), 1195-200
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 83:97130
GI For diagram(s), see printed CA Issue.
AB RNHCN (I, R = Et, Me3C, PhCH2, Ph, p-MeC6H4, m-ClC6H4, p-MeOC6H4) reacted with aziridinone II to give 48-73% RN(CN)CPh2CONHCMe3 (III). Base-catalyzed ring closure of III gave 90-8% glycocyamidines IV. IV (R = Me) was prepared directly by reaction of I (R = Me) with II in C6H6. Acid-catalyzed de-tert-butylation, and deimination combined with de-tert-butylation, of IV gave V and VI, resp. Reaction of II with H2NCN gave (Me3CNHCOCPh2N:)2O (VII) which cyclized to give the corresponding glycocyamidine (VIII). The mass spectra of V (R = p-MeOC6H4, p-HOC6H4, VI (R = p-MeOC6H4, p-HOC6H4), VII, and VIII were discussed.

L10 ANSWER 67 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:95826 CAPLUS Full-text
DOCUMENT NUMBER: 80:95826
ORIGINAL REFERENCE NO.: 80:15411a,15414a
TITLE: Hydantoins, thiohydantoins, and glycocyamidines. 39. S-Demethylations and -debenzylations of hydantoin and thiohydantoin derivatives
AUTHOR(S): Domany, Gyorgy; Nyitrai, Jozsef; Zauer, Koroly; Lempert, Karoly; Bekassy, Sandor
CORPORATE SOURCE: Dep. Org. Chem., Tech. Univ., Budapest, Hung.

SOURCE: Acta Chimica Academiae Scientiarum Hungaricae (1974), 80(1), 101-10
CODEN: ACASA2; ISSN: 0001-5407
DOCUMENT TYPE: Journal
LANGUAGE: English
AB S-Methyl derivs. of 5,5-diphenyl-mono- and -dithiohydantoins are demethylated by the hydrogen sulfide anion, thiolate anions or phosphorus pentasulfide. The latter simultaneously converts carbonyl into thiocarbonyl groups. When the α-toluenethiolate anion is used as the demethylating agent, the S-benzyl analogs of the starting substances, formed by exchange thiation, can in several cases be isolated as the intermediates. The S-benzyl groups can also be removed by boiling with benzene in the presence of aluminum chloride. In order to remove N(3)-benzyl groups, more vigorous conditi0ns are required under which, in the presence of a 4-thioxo group, a rearrangement of the retrobenzilic acid type becomes the main reaction.

L10 ANSWER 68 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:140814 CAPLUS Full-text
DOCUMENT NUMBER: 76:140814
ORIGINAL REFERENCE NO.: 76:22867a,22870a
TITLE: 5,5-Diphenylhydantoin
INVENTOR(S): Kolbeck, Winfried; Bayerlein, Friedrich
PATENT ASSIGNEE(S): Diamalt A.-G.
SOURCE: U.S., 2 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3646056	A	19720229	US 1970-10317	19700210
PRIORITY APPLN. INFO.:			US 1970-10317 A	19700210

GI For diagram(s), see printed CA Issue.
AB Treatment of benzoin and NH2CONH2 with aq. KOH and S gave 67-83 5,5-diphenylhydantoin (I).

L10 ANSWER 69 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1971:130340 CAPLUS Full-text
DOCUMENT NUMBER: 74:130340
ORIGINAL REFERENCE NO.: 74:21015a,21018a
TITLE: Lepsiral composition
AUTHOR(S): Zieloff, K.
CORPORATE SOURCE: Berlin-Weissensee, Fed. Rep. Ger.
SOURCE: Zentralblatt fuer Pharmazie, Pharmakotherapie und Laboratoriumsdiagnostik (1970), 109(11), 1179-82
CODEN: ZPPLBF; ISSN: 0049-8696
DOCUMENT TYPE: Journal
LANGUAGE: German
AB Lepsiral (I) is used for treatment of epilepsy. Each tablet consists of 0.25 g primidone(5-phenyl-5-ethylhexahydro-4,6-pyrimidinedione) and of 0.1 g phenytoin(5,5-diphenylhydantoin). Some reports are made about the pharmacol. of I, its clin. use, its side effects, contraindications and dosage.

L10 ANSWER 70 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1968:402905 CAPLUS Full-text

DOCUMENT NUMBER: 69:2905
ORIGINAL REFERENCE NO.: 69:563a,566a
TITLE: Methoxy derivatives of 5,5-diphenylhydantoin and 5-phenyl-5-benzylhydantoin
AUTHOR(S): Novelli, Armando; De Santis, Alberto M.
CORPORATE SOURCE: Univ. Buenos Aires, Buenos Aires, Argent.
SOURCE: Journal of Medicinal Chemistry (1968), 11(1), 176-8
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Various MeO and dioxymethylene derivs. (I) of 5,5-diphenylhydantoin and MeO derivs. (II) of 5-phenyl-5-benzylhydantoin are prepared and evaluated pharmacol. II are prepared by treating the corresponding MeO derivative of deoxybenzoin (prepared by condensing the corresponding phenylacetic acid and methoxybenzene in the presence of P2O5/H3PO4) with (NH4)2CO3/KCN in aqueous HCONMe2. I are prepared by refluxing the appropriate methoxybenzil derivs. (prepared by condensing the appropriate aldehydes and oxidizing the products with CuSO4 in pyridine) with urea in a Na-EtOH solution The anti-convulsant action is lowered when a Ph group is replaced by a benzyl group and the introduction of MeO groups increases the drug efficacy. Increasing the number of MeO groups progressively delays the appearance of the anticonvulsant effect.

L10 ANSWER 71 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1968:39508 CAPLUS Full-text
DOCUMENT NUMBER: 68:39508
ORIGINAL REFERENCE NO.: 68:7675a,7678a
TITLE: Organic sulfur compounds. XCV. Base-catalyzed reaction of substituted benzils with urea and thiourea to give glycolurils, hydantoins, imidazolidinones, and dithioglycolurils and thiohydantoins, respectively
AUTHOR(S): Dietz, Werner; Mayer, Roland
CORPORATE SOURCE: Organ. Lab., VEB Fettchem., Karl-Marx-Stadt, Fed. Rep. Ger.
SOURCE: Journal fuer Praktische Chemie (Leipzig) (1968), 37(1-2), 78-90
CODEN: JPCEAO; ISSN: 0021-8383
DOCUMENT TYPE: Journal
LANGUAGE: German
GI For diagram(s), see printed CA Issue.
AB Methoxy-, halo-, and methylbenzils reacted with urea in the presence of KOH in EtOH to give the corresponding 3a,6a-diphenylglycolurils (I), 5,5-diphenylydantoins, and 4,5-dihydroxy-4,5-diphenyl-2-imidazolidinones. The reaction of the benzil derivs. with thiourea yielded 3a,6a-diphenyl-2,5-dithioglycolurils and 5,5-diphenyl-2-thiohydantoins. Hydroxybenzils did not react with urea. Methoxybenzils treated with KOH in EtOH in the absence of urea gave methoxybenzoic acids. The mechanism of reaction is discussed.

```
=> s L2/SPN
          2221 L2
       2009163 SPN/RL
L11           9 L2/SPN
                (L2 (L) SPN/RL)

=> d 1-9 l11
```

L11 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1300819 CAPLUS Full-text
DN 147:508387
TI An improved process for the preparation of phenytoin sodium
IN Rao, Siripragada Mahender; Ramar, Padmanabhan
PA Orchid Chemicals & Pharmaceuticals Limited, India
SO PCT Int. Appl., 8pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007129184	A2	20071115	WO 2007-IB1130	20070502
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	IN 2006CH00806	A	20080516	IN 2006-CH806	20060504
PRAI	IN 2006-CH806	A	20060504		

L11 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:430714 CAPLUS Full-text
DN 141:12272
TI Modified carbamate-containing prodrugs and methods of synthesizing same
IN Ekwuribe, Nnochiri N.; Riggs-Sauthier, Jennifer; Dyakonov, Tatyana
PA Nobex Corporation, USA
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004043396	A2	20040527	WO 2003-US35995	20031107
	WO 2004043396	A3	20040812		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003285200	A1	20040603	AU 2003-285200	20031107
	US 20040152769	A1	20040805	US 2003-703647	20031107
PRAI	US 2002-424796P	P	20021109		
	US 2003-483676P	P	20030630		
	WO 2003-US35995	W	20031107		

OS MARPAT 141:12272

L11 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:586184 CAPLUS Full-text
DN 122:314499
OREF 122:57197a,57200a
TI Modified synthetic process for phenytoin sodium
AU Yang, Shihao; Li, Liping; Yang, Jianwen
CS Guangdong Medical Coll., Zhanjiang, 524023, Peop. Rep. China
SO Zhongguo Yiyao Gongye Zazhi (1995), 26(1), 4-5
CODEN: ZYGZEA; ISSN: 1001-8255
PB Zhongguo Yiyao Gongye Zazhi Bianjibu
DT Journal
LA Chinese

L11 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1986:65419 CAPLUS Full-text
DN 104:65419
OREF 104:10413a,10416a
TI Ligand determination utilizing an immunoassay monitorable by biotin-containing enzymes, and compositions therefor
IN Bacquet, Cathy A.; Twumasi, Daniel Y.
PA Kallestad Laboratories, Inc., USA
SO U.S., 9 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4550075	A	19851029	US 1983-506889	19830622
PRAI US 1983-506889		19830622		

L11 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1983:422468 CAPLUS Full-text
DN 99:22468
OREF 99:3637a,3640a
TI 3-(γ-Amino-β-hydroxypropyl)-5,5-diphenylhydantoin derivatives
IN Zejc, Alfred; Kiec-Kononwicz, Katarzyna
PA Polska Akademia Nauk, Instytut Farmakologii, Pol.
SO Pol., 4 pp.
CODEN: POXXA7
DT Patent
LA Polish
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI PL 114751	B1	19810228	PL 1977-202530	19771130
PRAI PL 1977-202530	A	19771130		

OS CASREACT 99:22468

L11 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1983:78068 CAPLUS Full-text
DN 98:78068
OREF 98:11843a,11846a
TI Intravenous solution of sodium diphenyl hydantoin: preparation and stability control
AU Ibanez, S.; Mendoza, Maria L.; Sanchez-Morcillo, J.
CS Serv. Farm., C.S. "Virgen de las Nieves", Granada, Spain
SO Revista de la Asociacion Espanola de Farmaceuticos de Hospitales (1982),

```
     6(2), 133-7
     CODEN: RAEHDT; ISSN: 0210-6329
DT   Journal
LA   Spanish

L11  ANSWER 7 OF 9  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   1981:417983  CAPLUS Full-text
DN   95:17983
OREF 95:3021a,3024a
TI   A nonmetabolized analog of phenytoin
AU   Henderson, James D.; Dayton, Peter G.; Israili, Zafar H.; Mandell, Leon
CS   Dep. Med., Emory Univ., Atlanta, GA, 30322, USA
SO   Journal of Medicinal Chemistry (1981), 24(7), 843-7
     CODEN: JMCMAR; ISSN: 0022-2623
DT   Journal
LA   English

L11  ANSWER 8 OF 9  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   1977:529616  CAPLUS Full-text
DN   87:129616
OREF 87:20589a,20592a
TI   Preparation of iodine-131-labeled diphenylhydantoin and its organ
     distribution in rats
AU   Angelberger, Peter; Pils, Peter; Wiesinger, Franz; Tragl, Karl Heinz
CS   Oesterr. Studienges. Atomenerg. G.m.b.H., Vienna, Austria
SO   Ber. Oesterr. Studienges. Atomenerg. (1977), SGAE Ber. No. 2701, 14 pp.
     CODEN: BOAEBM
DT   Report
LA   English

L11  ANSWER 9 OF 9  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   1967:442154  CAPLUS Full-text
DN   67:42154
OREF 67:7879a,7882a
TI   Acute intoxication due to methsuximide and diphenylhydantoin
AU   Schulte, Charles J. A.; Good, Thomas A.
CS   Univ. of Maryland Med. School, Baltimore, MD, USA
SO   Journal of Pediatrics (St. Louis, MO, United States) (1966), 68(4), 635-7
     CODEN: JOPDAB; ISSN: 0022-3476
DT   Journal
LA   English


=> s L3/SPN
          140 L3
      2009163 SPN/RL
L12         5 L3/SPN
                (L3 (L) SPN/RL)

=> d 1-5 l12

L12  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2007:1213035  CAPLUS Full-text
DN   147:469462
TI   Process for preparing fosphenytoin
IN   Bhattacharya, Apurba; Bolugoddu, Vijayabhaskar; Vankawala, Pravinchandra
     Jayantilal; Elati, Chandrasekhar Ravi Ram; Gangula, Srinivas; Lekkala,
     Amarnath Reddy; Mallemula, Ramakrishna Venkata; Naredla, Anitha; Sigala,
     Ashok
PA   India
```

SO U.S. Pat. Appl. Publ., 25pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070249563	A1	20071025	US 2007-737783	20070420
	IN 2006CH00734	A	20071228	IN 2006-CH734	20060421
PRAI	IN 2006-CH734	A	20060421		
	IN 2006-CH1031	A	20060614		
	US 2006-820838P	P	20060731		
	US 2006-821444P	P	20060804		

OS CASREACT 147:469462

L12 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:547232 CAPLUS Full-text
DN 143:65482
TI Prodrug compositions including amino acids
IN Hilfinger, John
PA USA
SO U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050137141	A1	20050623	US 2004-972729	20041025
	US 20070167353	A1	20070719	US 2007-690528	20070323
PRAI	US 2003-514121P	P	20031024		
	US 2004-972729	A2	20041025		
	US 2006-785582P	P	20060324		

L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:738490 CAPLUS Full-text
DN 140:303852
TI preparation of fosphenytoin sodium heptahydrate
IN Wang, Pingbao; Liu, Dengke; Jiang, Qingfeng; Liu, Mo; Ren, Rong; Zhao, Baojuan; Zhao, Jian
PA Tianjin Institute of Pharmacy, State Supervision Bureau for Medicine, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 16 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1379032	A	20021113	CN 2002-103888	20020410
PRAI	CN 2002-103888		20020410		

OS CASREACT 140:303852

L12 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:488385 CAPLUS Full-text
DN 129:85936
OREF 129:17633a,17636a
TI Increased Shelf-Life of Fosphenytoin: Solubilization of a Degradant, Phenytoin, through Complexation with (SBE)7m-β-CD
AU Narisawa, Shinji; Stella, Valentino J.

CS Department of Pharmaceutical Chemistry and Higuchi Biosciences Center for Drug Delivery Research, University of Kansas, Lawrence, KS, 66047., USA
SO Journal of Pharmaceutical Sciences (1998), 87(8), 926-930
CODEN: JPMSAE; ISSN: 0022-3549
PB American Chemical Society
DT Journal
LA English
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1984:630412 CAPLUS Full-text
DN 101:230412
OREF 101:34989a,34992a
TI Phenytoin prodrugs. III: Water-soluble prodrugs for oral and/or parenteral use
AU Varia, S. A.; Schuller, S.; Sloan, K. B.; Stella, V. J.
CS Sch. Pharm., Univ. Kansas, Lawrence, KS, 66045, USA
SO Journal of Pharmaceutical Sciences (1984), 73(8), 1068-73
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	257.70	293.78

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-56.00	-56.00

FILE 'REGISTRY' ENTERED AT 12:02:10 ON 14 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 JUL 2008 HIGHEST RN 1033821-28-1
DICTIONARY FILE UPDATES: 13 JUL 2008 HIGHEST RN 1033821-28-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> sel chem l1 and l2 and l3
MULTIPLE L-NUMBERS SPECIFIED

Only one L-number may be specified on this command.

=> s chem l1
MISSING OPERATOR

=> sel chem l1
E1 THROUGH E28 ASSIGNED

=> file uspatall pctfull
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.28	295.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-56.00

FILE 'USPATFULL' ENTERED AT 12:03:35 ON 14 JUL 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 12:03:35 ON 14 JUL 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:03:35 ON 14 JUL 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 12:03:35 ON 14 JUL 2008
COPYRIGHT (C) 2008 Univentio

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.61	301.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-56.00

FILE 'REGISTRY' ENTERED AT 12:03:54 ON 14 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 JUL 2008 HIGHEST RN 1033821-28-1
DICTIONARY FILE UPDATES: 13 JUL 2008 HIGHEST RN 1033821-28-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> dup rem l1 l2 l3
DUPLICATE IS NOT AVAILABLE IN 'REGISTRY'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L1
PROCESSING COMPLETED FOR L2
PROCESSING COMPLETED FOR L3
L13 3 DUP REM L1 L2 L3 (0 DUPLICATES REMOVED)

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.46 302.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -56.00

FILE 'CAPLUS' ENTERED AT 12:04:34 ON 14 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Jul 2008 VOL 149 ISS 3
FILE LAST UPDATED: 13 Jul 2008 (20080713/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> dup rem l10 l11 l12
PROCESSING COMPLETED FOR L10
PROCESSING COMPLETED FOR L11
PROCESSING COMPLETED FOR L12
L14 83 DUP REM L10 L11 L12 (2 DUPLICATES REMOVED)

=> d l14

L14 ANSWER 1 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2008:91080 CAPLUS Full-text
DN 148:160147
TI Conjugates of psychotropic drugs or GABA agonists with organic acids for treatment of CNS diseases or disorders

```
IN   Nudelman, Abraham; Rephaeli, Ada; Gil-Ad, Irit; Weizman, Abraham
PA   Ramot at Tel Aviv University Ltd., Israel; Bar-Ilan University
SO   PCT Int. Appl., 76pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     --------------      ----   --------   -------------------    --------
PI   WO 2008010223       A2     20080124   WO 2007-IL903          20070717
     WO 2008010223       A3     20080320
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
              CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
              GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
              KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
              MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
              PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
              TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
          RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
              IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
              BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
              GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
              BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRAI US 2006-831192P     P      20060717
     US 2006-831195P     P      20060717


=> d l 14 1-83 ibib abs
'L' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
```

```
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):bib

L14  ANSWER 14 OF 83  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2003:271112  CAPLUS Full-text
DN   139:323872
TI   Synthesis and characterization of optically active poly(amide-imide)s with
     hydantoin and thiohydantoin derivatives in the main chain
AU   Faghihi, Khalil; Zamani, Khosrow; Mallakpour, Shadpour
CS   Department of Chemistry, Arak University, Arak, 38156, Iran
SO   Iranian Polymer Journal (2002), 11(5), 339-347
     CODEN: IPJOFF; ISSN: 1026-1265
PB   Iran Polymer Institute
DT   Journal
LA   English
RE.CNT  21    THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14  ANSWER 1 OF 83  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2008:91080  CAPLUS Full-text
DN   148:160147
TI   Conjugates of psychotropic drugs or GABA agonists with organic acids for
     treatment of CNS diseases or disorders
IN   Nudelman, Abraham; Rephaeli, Ada; Gil-Ad, Irit; Weizman, Abraham
PA   Ramot at Tel Aviv University Ltd., Israel; Bar-Ilan University
SO   PCT Int. Appl., 76pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
```

PI	WO 2008010223	A2	20080124	WO 2007-IL903	20070717
	WO 2008010223	A3	20080320		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRAI	US 2006-831192P	P	20060717		
	US 2006-831195P	P	20060717		

L14 ANSWER 2 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1215841 CAPLUS Full-text
DN 147:455613
TI Halide-free glucosamine-acidic drug complexes
IN Chopdekar, Vilas M.; Torntore, Michael J.
PA JF C Technologies, LLC, USA
SO U.S. Pat. Appl. Publ., 6pp., Cont.-in-part of U.S. Ser. No. 223,686.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070249735	A1	20071025	US 2007-731294	20070331
	US 20070259043	A1	20071108	US 2005-223686	20050909
PRAI	US 2004-611178P	P	20040917		
	US 2005-223686	A2	20050909		

L14 ANSWER 3 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1300819 CAPLUS Full-text
DN 147:508387
TI An improved process for the preparation of phenytoin sodium
IN Rao, Siripragada Mahender; Ramar, Padmanabhan
PA Orchid Chemicals & Pharmaceuticals Limited, India
SO PCT Int. Appl., 8pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007129184	A2	20071115	WO 2007-IB1130	20070502
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,				

GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

	IN 2006CH00806	A	20080516	IN 2006-CH806	20060504
PRAI	IN 2006-CH806	A	20060504		

L14 ANSWER 4 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1213035 CAPLUS Full-text
DN 147:469462
TI Process for preparing fosphenytoin
IN Bhattacharya, Apurba; Bolugoddu, Vijayabhaskar; Vankawala, Pravinchandra Jayantilal; Elati, Chandrasekhar Ravi Ram; Gangula, Srinivas; Lekkala, Amarnath Reddy; Mallemula, Ramakrishna Venkata; Naredla, Anitha; Sigala, Ashok
PA India
SO U.S. Pat. Appl. Publ., 25pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20070249563	A1	20071025	US 2007-737783	20070420
IN 2006CH00734	A	20071228	IN 2006-CH734	20060421
PRAI IN 2006-CH734	A	20060421		
IN 2006-CH1031	A	20060614		
US 2006-820838P	P	20060731		
US 2006-821444P	P	20060804		

OS CASREACT 147:469462

L14 ANSWER 5 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:254742 CAPLUS Full-text
DN 147:469270
TI A novel synthesis of some new imidazothiazole and glycocyamidine derivatives and studies on their antimicrobial activities
AU El-Din, Asmaa A. Magd; Roaiah, Hanaa F.; Elsharabasy, Salwa A.; Hassan, Aisha Y.
CS Natural Products Department, National Research Centre, Cairo, Egypt
SO Phosphorus, Sulfur and Silicon and the Related Elements (2007), 182(3), 529-536
CODEN: PSSLEC; ISSN: 1042-6507
PB Taylor & Francis, Inc.
DT Journal
LA English
OS CASREACT 147:469270
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1125928 CAPLUS Full-text
DN 146:274284
TI Evaluating the one-pot synthesis of hydantoins
AU Mahmoodi, Nosrat O.; Khodaee, Ziba
CS Department of Chemistry, University of Guilan, Rasht, Iran
SO ARKIVOC (Gainesville, FL, United States) (2007), (3), 29-36
CODEN: AGFUAR
URL: http://www.arkat-usa.org/ARKIVOC/JOURNAL_CONTENT/manuscripts/2007/EA-1914DP%20as%20published%20mainmanuscript.pdf
PB Arkat USA Inc.
DT Journal; (online computer file)
LA English

OS CASREACT 146:274284
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:547232 CAPLUS Full-text
DN 143:65482
TI Prodrug compositions including amino acids
IN Hilfinger, John
PA USA
SO U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050137141	A1	20050623	US 2004-972729	20041025
	US 20070167353	A1	20070719	US 2007-690528	20070323
PRAI	US 2003-514121P	P	20031024		
	US 2004-972729	A2	20041025		
	US 2006-785582P	P	20060324		

L14 ANSWER 8 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1294782 CAPLUS Full-text
DN 144:350594
TI Synthesis of hydantoin, thiohydantoin and desulfuration of thiohydantoin to hydantoin
AU Dubey, Vijay S.
CS Department of Chemistry, Hislop College, Nagpur, 440 001, India
SO Asian Journal of Chemistry (2005), Volume Date 2006, 18(1), 155-158
CODEN: AJCHEW; ISSN: 0970-7077
PB Asian Journal of Chemistry
DT Journal
LA English
OS CASREACT 144:350594
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:430714 CAPLUS Full-text
DN 141:12272
TI Modified carbamate-containing prodrugs and methods of synthesizing same
IN Ekwuribe, Nnochiri N.; Riggs-Sauthier, Jennifer; Dyakonov, Tatyana
PA Nobex Corporation, USA
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004043396	A2	20040527	WO 2003-US35995	20031107
	WO 2004043396	A3	20040812		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2003285200	A1	20040603	AU 2003-285200	20031107
	US 20040152769	A1	20040805	US 2003-703647	20031107
PRAI	US 2002-424796P	P	20021109		
	US 2003-483676P	P	20030630		
	WO 2003-US35995	W	20031107		

OS MARPAT 141:122772

L14 ANSWER 10 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:281814 CAPLUS Full-text
DN 141:33316
TI Block of human NaV1.5 sodium channels by novel α-hydroxyphenylamide analogues of phenytoin
AU Lenkowski, Paul W.; Ko, Seong-Hoon; Anderson, James D.; Brown, Milton L.; Patel, Manoj K.
CS Department of Chemistry, University of Virginia, Charlottesville, VA, 22904, USA
SO European Journal of Pharmaceutical Sciences (2004), 21(5), 635-644
CODEN: EPSCED; ISSN: 0928-0987
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 141:33316
RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 11 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:570317 CAPLUS Full-text
DN 141:410863
TI One-Pot Synthesis of Phenytoin Analogs
AU Mahmoodi, N. O.; Emadi, S.
CS Organic Research Laboratory, Department of Chemistry, University of Guilan, Rasht, 1914, Iran
SO Russian Journal of Organic Chemistry (Translation of Zhurnal Organicheskoi Khimii) (2004), 40(3), 377-382
CODEN: RJOCEQ; ISSN: 1070-4280
PB MAIK Nauka/Interperiodica Publishing
DT Journal
LA English
OS CASREACT 141:410863
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 12 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:91629 CAPLUS Full-text
DN 139:6807
TI A rapid and efficient microwave-assisted synthesis of hydantoins and thiohydantoins
AU Muccioli, Giulio G.; Poupaert, Jacques H.; Wouters, Johan; Norberg, Bernadette; Poppitz, Wolfgang; Scriba, Gerhard K. E.; Lambert, Didier M.
CS Faculte de Medecine, Ecole de Pharmacie, Laboratoire de Chimie pharmaceutique et de Radiopharmacie, Universite catholique de Louvain, UCL-CMFA 7340, Brussels, B-1200, Belg.
SO Tetrahedron (2003), 59(8), 1301-1307
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier Science Ltd.
DT Journal

LA English
OS CASREACT 139:6807
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 13 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:738490 CAPLUS Full-text
DN 140:303852
TI preparation of fosphenytoin sodium heptahydrate
IN Wang, Pingbao; Liu, Dengke; Jiang, Qingfeng; Liu, Mo; Ren, Rong; Zhao, Baojuan; Zhao, Jian
PA Tianjin Institute of Pharmacy, State Supervision Bureau for Medicine, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 16 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1379032	A	20021113	CN 2002-103888	20020410
PRAI CN 2002-103888		20020410		

OS CASREACT 140:303852

L14 ANSWER 14 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:271112 CAPLUS Full-text
DN 139:323872
TI Synthesis and characterization of optically active poly(amide-imide)s with hydantoin and thiohydantoin derivatives in the main chain
AU Faghihi, Khalil; Zamani, Khosrow; Mallakpour, Shadpour
CS Department of Chemistry, Arak University, Arak, 38156, Iran
SO Iranian Polymer Journal (2002), 11(5), 339-347
CODEN: IPJOFF; ISSN: 1026-1265
PB Iran Polymer Institute
DT Journal
LA English
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 15 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:893101 CAPLUS Full-text
DN 138:255591
TI Microwave-assisted rapid synthesis of novel optically active poly(amide-imide)s containing hydantoins and thiohydantoins in main chain
AU Faghihi, Khalil; Zamani, Khosrow; Mirsamie, Azizollah; Reza Sangi, Mohammad
CS Department of Chemistry, Arak University, Arak, 38156, Iran
SO European Polymer Journal (2002), Volume Date 2003, 39(2), 247-254
CODEN: EUPJAG; ISSN: 0014-3057
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 138:255591
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 16 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:708653 CAPLUS Full-text
DN 136:151368
TI Synthesis of hydantocidin and C-2-thioxo-hydantocidin

AU Shiozaki, M.
CS Exploratory Chemistry Research Laboratories, Sankyo Co. Ltd., Shinagawa-ku, Tokyo, 140-8710, Japan
SO Carbohydrate Research (2001), 335(3), 147-150
CODEN: CRBRAT; ISSN: 0008-6215
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 136:151368
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 17 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1999:412636 CAPLUS Full-text
DN 131:56144
TI Specific binding assay using enzyme inhibitor and anti-inhibitor antibodies
IN Contestable, Paul B.; Daiss, John L.; Groth, Holly L.; Grogan, Elizabeth A.; Snyder, Brian A.
PA Johnson & Johnson Clinical Diagnostics, Inc., USA
SO U.S., 16 pp., Cont. of U.S. Ser. No. 250,980, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5916757	A	19990629	US 1996-683247	19960717
PRAI US 1994-250980	B1	19940531		

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 18 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1999:536691 CAPLUS Full-text
DN 131:299402
TI 3-Alkyl-(5,5'-diphenyl)imidazolidinediones as new cannabinoid receptor ligands
AU Kanyonyo, Martial; Govaerts, Sophie J.; Hermans, Emmanuel; Poupaert, Jacques H.; Lambert, Didier M.
CS Unite de Chimie Pharmaceutique et de Radiopharmacie, Universite Catholique de Louvain, Brussels, 1200, Belg.
SO Bioorganic & Medicinal Chemistry Letters (1999), 9(15), 2233-2236
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 19 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1999:639650 CAPLUS Full-text
DN 131:346154
TI The influence of structure and lipophilicity of hydantoin derivatives on anticonvulsant activity
AU Scholl, S.; Koch, A.; Henning, D.; Kempter, G.; Kleinpeter, E.
CS Institut fur Organische Chemie und Strukturanalytik, Universitat Potsdam, Postdam, D-14415, Germany
SO Structural Chemistry (1999), 10(5), 355-366
CODEN: STCHES; ISSN: 1040-0400
PB Kluwer Academic/Plenum Publishers

DT Journal
LA English
RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 20 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:527297 CAPLUS Full-text
DN 129:161184
OREF 129:32803a,32806a
TI Preparation of fatty acyl and alkyl derivatives of drugs and agrochemicals
IN Myhren, Finn; Borretzen, Bernt; Dalen, Are; Sandvold, Marit Liland
PA Norsk Hydro Asa, Norway
SO PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9832718	A1	19980730	WO 1998-NO21	19980123
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	GB 2321455	A	19980729	GB 1997-1441	19970124
	ZA 9800579	A	19980723	ZA 1998-579	19980123
	CA 2276694	A1	19980730	CA 1998-2276694	19980123
	CA 2276694	C	20070522		
	AU 9857828	A	19980818	AU 1998-57828	19980123
	AU 733370	B2	20010510		
	EP 977725	A1	20000209	EP 1998-901593	19980123
	EP 977725	B1	20040616		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
	HU 2000000937	A2	20000928	HU 2000-937	19980123
	HU 2000000937	A3	20010129		
	HU 225664	B1	20070529		
	NZ 336724	A	20010629	NZ 1998-336724	19980123
	JP 2001522351	T	20011113	JP 1998-531863	19980123
	RU 2227794	C2	20040427	RU 1999-118313	19980123
	AT 269292	T	20040715	AT 1998-901593	19980123
	ES 2224356	T3	20050301	ES 1998-901593	19980123
	IL 130853	A	20050320	IL 1998-130853	19980123
	SK 284803	B6	20051103	SK 1999-1003	19980123
	TW 231209	B	20050421	TW 1998-87103693	19980313
	NO 9903563	A	19990917	NO 1999-3563	19990721
	US 20010006962	A1	20010705	US 1999-355111	19990927
	US 20030153544	A1	20030814	US 2002-116358	20020405
	US 6762175	B2	20040713		
	US 20040063677	A1	20040401	US 2003-662441	20030916
PRAI	GB 1997-1441	A	19970124		
	WO 1998-NO21	W	19980123		
	US 1999-355111	B1	19990927		
	US 2002-116358	A1	20020405		

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 21 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:79418 CAPLUS Full-text
DN 128:166998
OREF 128:32909a,32912a
TI System for multiple simultaneous synthesis of small-molecule organic compounds
IN Dewitt, Sheila H. H.; Kiely, John S.; Pavia, Michael R.; Schroeder, Mel C.; Stankovic, Charles J.
PA Warner-Lambert Co., USA
SO U.S., 67 pp., Cont.-in-part of U.S. Ser.5,612,002.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5714127	A	19980203	US 1995-475559	19950607
	US 5324483	A	19940628	US 1993-12557	19930202
	US 5324483	B1	19960924		
	US 5612002	A	19970318	US 1995-430696	19950428
	US 5565173	A	19961015	US 1995-461998	19950605
	US 5567391	A	19961022	US 1995-464161	19950605
	US 5582801	A	19961210	US 1995-463545	19950605
	US 5593642	A	19970114	US 1995-461475	19950605
	US 5766556	A	19980616	US 1996-777270	19961231
PRAI	US 1992-958383	B2	19921008		
	US 1993-12557	A3	19930202		
	US 1994-217347	B1	19940324		
	US 1995-430696	A2	19950428		

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1
AN 1998:488385 CAPLUS Full-text
DN 129:85936
OREF 129:17633a,17636a
TI Increased Shelf-Life of Fosphenytoin: Solubilization of a Degradant, Phenytoin, through Complexation with (SBE)7m-β-CD
AU Narisawa, Shinji; Stella, Valentino J.
CS Department of Pharmaceutical Chemistry and Higuchi Biosciences Center for Drug Delivery Research, University of Kansas, Lawrence, KS, 66047., USA
SO Journal of Pharmaceutical Sciences (1998), 87(8), 926-930
CODEN: JPMSAE; ISSN: 0022-3549
PB American Chemical Society
DT Journal
LA English
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 23 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:520228 CAPLUS Full-text
DN 129:245090
OREF 129:49905a,49908a
TI Superacid-activated condensation of parabanic acid and derivatives with arenes. A new synthesis of phenytoin and 5,5-diarylhydantoins
AU Klumpp, Douglas A.; Yeung, Ka Yeun; Prakash, G. K. Surya; Olah, George A.
CS Department Chemistry, California State Polytechnic University, Pomona, CA, 91768, USA
SO Synlett (1998), (8), 918-920
CODEN: SYNLES; ISSN: 0936-5214

PB Georg Thieme Verlag
DT Journal
LA English
OS CASREACT 129:245090

L14 ANSWER 24 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:15623 CAPLUS Full-text
DN 128:114966
OREF 128:22545a,22548a
TI Apparatus and method for solid phase multiple simultaneous synthesis.
IN Dewitt, Sheila H. H.; Kell, Michael; Pavia, Michael R.; Kiely, John S.; Schroeder, Mel C.; Stankovic, Charles J.; Ware, Steven
PA Warner-Lambert Co., USA
SO U.S., 52 pp., Cont.-in-part of U.S. 5,612,002.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5702672	A	19971230	US 1995-540512	19951010
	US 5324483	A	19940628	US 1993-12557	19930202
	US 5324483	B1	19960924		
	US 5612002	A	19970318	US 1995-430696	19950428
	US 5565173	A	19961015	US 1995-461998	19950605
	US 5567391	A	19961022	US 1995-464161	19950605
	US 5582801	A	19961210	US 1995-463545	19950605
	US 5593642	A	19970114	US 1995-461475	19950605
	US 5766556	A	19980616	US 1996-777270	19961231
PRAI	US 1992-958383	B2	19921008		
	US 1993-12557	A3	19930202		
	US 1994-217347	B3	19940324		
	US 1995-430696	A2	19950428		

L14 ANSWER 25 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1996:694374 CAPLUS Full-text
DN 125:327717
OREF 125:61391a,61394a
TI A method for the combinatorial synthesis of mixtures of compounds
IN Becker, Katherine; Dewitt, Sheila Hobbs
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9630393	A1	19961003	WO 1995-US16332	19951208
	W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9644244	A	19961016	AU 1996-44244	19951208
PRAI	US 1995-411040	A	19950327		
	WO 1995-US16332	W	19951208		

L14 ANSWER 26 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1996:599190 CAPLUS Full-text
DN 125:219625
OREF 125:41079a,41082a

TI Inhibitor and anti-inhibitor monoclonal antibodies specific for horseradish peroxidase
IN Gorman, Kevin M.; Daiss, John L.
PA Johnson & Johnson Clinical Diagnostics, Inc., USA
SO Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 690071	A2	19960103	EP 1995-303657	19950530
	EP 690071	A3	19961016		
	EP 690071	B1	20001227		
	R: BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5650324	A	19970722	US 1994-251496	19940531
	CA 2150497	A1	19951201	CA 1995-2150497	19950530
	CA 2150497	C	20061017		
	PT 690071	T	20010430	PT 1995-303657	19950530
	ES 2157294	T3	20010816	ES 1995-303657	19950530
	AU 9520409	A	19951207	AU 1995-20409	19950531
	JP 08053497	A	19960227	JP 1995-134031	19950531
	JP 3745411	B2	20060215		
	GR 3035547	T3	20010629	GR 2001-400388	20010309
PRAI	US 1994-251496	A	19940531		

L14 ANSWER 27 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1996:115666 CAPLUS Full-text
DN 124:260004
OREF 124:48171a,48174a
TI Combinatorial organic synthesis using Parke-Davis's diversomer method
AU DeWitt, Sheila Hobbs; Czarnik, Anthony W.
CS Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI, 48105, USA
SO Accounts of Chemical Research (1996), 29(3), 114-22
CODEN: ACHRE4; ISSN: 0001-4842
PB American Chemical Society
DT Journal
LA English

L14 ANSWER 28 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:746664 CAPLUS Full-text
DN 123:142970
OREF 123:25449a,25452a
TI Gas/Solid Reactions with Nitrogen Dioxide
AU Kaupp, Gerd; Schmeyers, Jens
CS FB 9-Organic Chemistry I, University of Oldenburg, Oldenburg, D-26111, Germany
SO Journal of Organic Chemistry (1995), 60(17), 5494-503
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 123:142970

L14 ANSWER 29 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:766526 CAPLUS Full-text
DN 123:339894
OREF 123:61003a,61006a
TI Synthesis, structure and properties of 5,5-diphenyl-2,3,5,6-

tetrahydroimidazo[2,1-b]imidazoline-3,6-dione
AU Kiec-Kononowicz, Katarzyna; Karolak-Wojciechowska, Janina; Mrozek, Agnieszka; Posel, Maciej
CS Department of Chemical Technology of Drugs, Collegium Medicum of Jagiellonian University, Krakow, PL 30-688, Pol.
SO Archiv der Pharmazie (Weinheim, Germany) (1995), 328(6), 517-21
CODEN: ARPMAS; ISSN: 0365-6233
PB VCH
DT Journal
LA English
OS CASREACT 123:339894

L14 ANSWER 30 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:586184 CAPLUS Full-text
DN 122:314499
OREF 122:57197a,57200a
TI Modified synthetic process for phenytoin sodium
AU Yang, Shihao; Li, Liping; Yang, Jianwen
CS Guangdong Medical Coll., Zhanjiang, 524023, Peop. Rep. China
SO Zhongguo Yiyao Gongye Zazhi (1995), 26(1), 4-5
CODEN: ZYGZEA; ISSN: 1001-8255
PB Zhongguo Yiyao Gongye Zazhi Bianjibu
DT Journal
LA Chinese

L14 ANSWER 31 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:308615 CAPLUS Full-text
DN 122:106536
OREF 122:20071a,20074a
TI Apparatus and method for multiple simultaneous synthesis of peptides and other organic compounds
IN Cody, Donna Reynolds; Dewitt, Sheila Helen Hobbs; Hodges, John Cooke; Roth, Bruce David; Schroeder, Mel Conrad; Stankovic, Charles John; Moos, Walter Hamilton; Pavia, Michael Raymond; Kiely, John Steven
PA Warner-Lambert Co., USA
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9408711	A1	19940428	WO 1993-US9666	19931008
	W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5324483	A	19940628	US 1993-12557	19930202
	US 5324483	B1	19960924		
	AU 9453558	A	19940509	AU 1994-53558	19931008
	EP 663856	A1	19950726	EP 1993-923827	19931008
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08502482	T	19960319	JP 1993-510171	19931008
PRAI	US 1992-958383	A	19921008		
	US 1993-12557	A	19930202		
	WO 1993-US9666	W	19931008		

L14 ANSWER 32 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1994:404529 CAPLUS Full-text
DN 121:4529
OREF 121:999a,1002a
TI Labeled drug hapten analogs for immunoassays

IN Danielson, Susan J.; Brummond, Barbara A.; Oenick, Marsha D. B.; Ponticello, Ignazio S.; Hilborn, David A.
PA Eastman Kodak Co., USA
SO U.S., 11 pp. Cont.-in-part of U.S. Ser. No. 712,330, abandoned. CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5298403	A	19940329	US 1992-851439	19920316
	CA 2062240	A1	19921208	CA 1992-2062240	19920416
	EP 517326	A2	19921209	EP 1992-201581	19920602
	EP 517326	A3	19930407		
	EP 517326	B1	20010816		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 204384	T	20010915	AT 1992-201581	19920602
	JP 05172814	A	19930713	JP 1992-145980	19920605
	JP 3190729	B2	20010723		
PRAI	US 1991-712330	B2	19910607		
	US 1992-851439	A	19920316		

L14 ANSWER 33 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:441042 CAPLUS Full-text
DN 122:222646
OREF 122:40526h,40527a
TI Dissolution behavior of phenytoin-bile salt complexes prepared by co-grinding
AU Otsuka, Makoto; Matsuda, Yoshihisa
CS Kobe Pharm. Univ., Kobe, 658, Japan
SO Chemical & Pharmaceutical Bulletin (1994), 42(11), 2382-4 CODEN: CPBTAL; ISSN: 0009-2363
PB Pharmaceutical Society of Japan
DT Journal
LA English

L14 ANSWER 34 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:137709 CAPLUS Full-text
DN 122:177662
OREF 122:32293a,32296a
TI Phenytoin derivatives as potent σ ligands
AU Hudkins, Robert L.; DeHaven-Hudkins, Diane L.
CS Albany Mol. Res., Albany, NY, 12203, USA
SO Bioorganic & Medicinal Chemistry Letters (1994), 4(18), 2185-8 CODEN: BMCLE8; ISSN: 0960-894X
DT Journal
LA English

L14 ANSWER 35 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1993:656382 CAPLUS Full-text
DN 119:256382
OREF 119:45625a,45628a
TI Phenytoin-lipid conjugates: Chemical, plasma esterase-mediated, and pancreatic lipase-mediated hydrolysis in vitro
AU Scriba, Gerhard K. E.
CS Dep. Pharm. Chem., Univ. Muenster, Muenster, 48149, Germany
SO Pharmaceutical Research (1993), 10(8), 1181-6 CODEN: PHREEB; ISSN: 0724-8741
DT Journal
LA English

L14 ANSWER 36 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1993:617285 CAPLUS Full-text
DN 119:217285
OREF 119:38477a,38480a
TI Phenytoin-lipid conjugates as potential prodrugs of phenytoin
AU Scriba, Gerhard K. E.
CS Dep. Pharm. Chem., Univ. Muenster, Muenster, D-48149, Germany
SO Archiv der Pharmazie (Weinheim, Germany) (1993), 326(8), 477-81
CODEN: ARPMAS; ISSN: 0365-6233
DT Journal
LA English

L14 ANSWER 37 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1994:299113 CAPLUS Full-text
DN 120:299113
OREF 120:52733a,52736a
TI Part 1. Synthetic studies of some unsymmetrically substituted sulfamides and 5,5-diphenylhydantoin. Part 2. Photoinduced generation of glycosyl cations from thioglycosides for possible application in oligosaccharide synthesis
AU Bandara, Nayanie Champika
CS Univ. New Orleans, New Orleans, LA, USA
SO (1992) 127 pp. Avail.: Univ. Microfilms Int., Order No. DA9230592
From: Diss. Abstr. Int. B 1992, 53(6), 2865
DT Dissertation
LA English

L14 ANSWER 38 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1992:633927 CAPLUS Full-text
DN 117:233927
OREF 117:40459a,40462a
TI A convenient preparation of symmetrical and unsymmetrical 1,2-diketones: application to fluorinated phenytoin synthesis
AU Page, Philip C. Bulman; Graham, Andrew E.; Park, B. Kevin
CS Dep. Chem., Univ. Liverpool, Liverpool, L69 3BX, UK
SO Tetrahedron (1992), 48(35), 7265-74
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA English
OS CASREACT 117:233927

L14 ANSWER 39 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1992:187524 CAPLUS Full-text
DN 116:187524
OREF 116:31511a,31514a
TI Analysis of a clinically important interaction between phenytonin and Shankhapushpi, and Ayurvedic preparation
AU Dandekar, U. P.; Chandra, R. S.; Dalvi, S. S.; Joshi, M. V.; Gokhale, P. C.; Sharma, A. V.; Shah, P. U.; Kshirsagar, N. A.
CS Dep. Pharmacol. Clin. Pharmacol., Seth Gordhandas Sunderdas Med. Coll., Bombay, 400-012, India
SO Journal of Ethnopharmacology (1992), 35(3), 285-8
CODEN: JOETD7; ISSN: 0378-8741
DT Journal
LA English

L14 ANSWER 40 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1993:260830 CAPLUS Full-text
DN 118:260830

OREF 118:45219a,45222a
TI Optimization of phenytoin preparation
AU Ponte, C. I. R. V.; Bacha, C. T. M.; Seixas, L. M. J.; Todeschini, A. R.; Cunha, A.; Carvalho, E.
CS Fac. Farm., UFRGS, Brazil
SO Revista Brasileira de Farmacia (1992), 73(1), 11-12
CODEN: RBFAAH; ISSN: 0370-372X
DT Journal
LA Portuguese

L14 ANSWER 41 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1991:679900 CAPLUS Full-text
DN 115:279900
OREF 115:47563a,47566a
TI Reactions of carbonic acid diamides with α-hydroxy ketones and α-diketones. Part 4. Reactions of substituted biguanides with benzil in ethanol under the influence of sodium ethanolate
AU Schramm, H. W.
CS Inst. Pharm. Chem., Karl-Franzens-Univ., Graz, A-8010, Austria
SO Scientia Pharmaceutica (1991), 59(2), 123-33
CODEN: SCPHA4; ISSN: 0036-8709
DT Journal
LA German
OS CASREACT 115:279900

L14 ANSWER 42 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1991:228552 CAPLUS Full-text
DN 114:228552
OREF 114:38533a,38536a
TI Preparation of (aminoalkyl)phenylacyl-derivatized drugs with improved solution stability and solubility
IN Bundgaard, Hans; Falch, Erik
PA Den.
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9008128	A1	19900726	WO 1990-DK20	19900119
	W: AU, CA, FI, JP, KR, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	CA 2045591	A1	19900721	CA 1990-2045591	19900119
	AU 9050323	A	19900813	AU 1990-50323	19900119
	EP 454773	A1	19911106	EP 1990-902624	19900119
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04502918	T	19920528	JP 1990-502553	19900119
PRAI	DK 1989-240	A	19890120		
	WO 1990-DK20	A	19900119		

OS MARPAT 114:228552

L14 ANSWER 43 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1991:17446 CAPLUS Full-text
DN 114:17446
OREF 114:2973a,2976a
TI Sodium channel binding and anticonvulsant activities of hydantoins containing conformationally constrained 5-phenyl substituents
AU Brouillette, Wayne J.; Brown, George B.; DeLorey, Timothy M.; Liang, Gang
CS Dep. Chem., Univ. Alabama, Birmingham, AL, 35294, USA

SO Journal of Pharmaceutical Sciences (1990), 79(10), 871-4
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English

L14 ANSWER 44 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1990:154859 CAPLUS Full-text
DN 112:154859
OREF 112:26083a,26086a
TI Immobilization of haptens for measurement by immunoassay using surface plasmon resonance (SPR)
IN Corrie, John; Fairclough, Lynne; Charles, Stephen Alexander; Finlan, Martin Francis
PA Amersham International PLC, UK
SO PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 8908260	A1	19890908	WO 1989-GB156	19890223
W: JP, SU				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
EP 378594	A1	19900725	EP 1989-904150	19890223
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 03503679	T	19910815	JP 1989-503761	19890223
AU 8930774	A	19890831	AU 1989-30774	19890227
AU 616481	B2	19911031		
PRAI GB 1988-4669	A	19880227		
WO 1989-GB156	W	19890223		

L14 ANSWER 45 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1990:478239 CAPLUS Full-text
DN 113:78239
OREF 113:13239a,13242a
TI The reactions of carbonic diamides α-hydroxy ketones and α-diketones. Part 1. The reaction of cyanoguanidine with benzil
AU Schramm, H. W.
CS Inst. Pharm. Chem., Karl-Franzens-Univ., Graz, A-8010, Austria
SO Scientia Pharmaceutica (1989), 57(4), 385-90
CODEN: SCPHA4; ISSN: 0036-8709
DT Journal
LA German

L14 ANSWER 46 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1989:632664 CAPLUS Full-text
DN 111:232664
OREF 111:38649a,38652a
TI The stereochemical course of the Biltz reaction
AU Mergen, F.; Poupaert, J. H.; De Keyser, J. L.; Dumont, P.
CS Med. Fak. Kathol., Univ. Lowen, Brussels, 1200, Belg.
SO Pharmazie (1989), 44(2), 110-12
CODEN: PHARAT; ISSN: 0031-7144
DT Journal
LA German
OS CASREACT 111:232664

L14 ANSWER 47 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1989:484010 CAPLUS Full-text

DN 111:84010
OREF 111:14037a,14040a
TI Low-melting phenytoin prodrugs: in vitro and in vivo correlations
AU Martodihardjo, Suwaldi
CS Univ. Kansas, Lawrence, KS, USA
SO (1988) 248 pp. Avail.: Univ. Microfilms Int., Order No. DA8903134
From: Diss. Abstr. Int. B 1989, 49(11), 4831
DT Dissertation
LA English

L14 ANSWER 48 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1989:165383 CAPLUS Full-text
DN 110:165383
OREF 110:27197a,27200a
TI Enzyme-enhanced electrochemical immunoassay for phenytoin
AU Umana, Mirtha; Waller, Jess; Wani, Mansukh; Whisnant, Carol; Cook, Edgar
CS Res. Triangle Inst., Research Triangle Park, NC, 27709-2194, USA
SO Journal of Research of the National Institute of Standards and Technology (1988), 93(6), 659-61
CODEN: JRITEF; ISSN: 1044-677X
DT Journal
LA English

L14 ANSWER 49 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1988:37727 CAPLUS Full-text
DN 108:37727
OREF 108:6311a,6314a
TI Spirohydantoin aldose reductase inhibitors
AU Sarges, Reinhard; Schnur, Rodney C.; Belletire, John L.; Peterson, Michael J.
CS Pfizer Cent. Res., Groton, CT, 06340, USA
SO Journal of Medicinal Chemistry (1988), 31(1), 230-43
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 108:37727

L14 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1987:101551 CAPLUS Full-text
DN 106:101551
OREF 106:16619a,16622a
TI Reaction of bis-α-diketones with urea in alkaline media
AU Savchenko, T. I.; Yatsimirskii, A. K.
CS Politekh. Inst., Tomsk, USSR
SO Zhurnal Organicheskoi Khimii (1986), 22(6), 1241-6
CODEN: ZORKAE; ISSN: 0514-7492
DT Journal
LA Russian
OS CASREACT 106:101551

L14 ANSWER 51 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1986:65419 CAPLUS Full-text
DN 104:65419
OREF 104:10413a,10416a
TI Ligand determination utilizing an immunoassay monitorable by biotin-containing enzymes, and compositions therefor
IN Bacquet, Cathy A.; Twumasi, Daniel Y.
PA Kallestad Laboratories, Inc., USA
SO U.S., 9 pp.
CODEN: USXXAM

DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4550075	A	19851029	US 1983-506889	19830622
PRAI US 1983-506889		19830622		

L14 ANSWER 52 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1986:435320 CAPLUS Full-text
DN 105:35320
OREF 105:5693a,5696a
TI Pharmacological properties of 3-aminoalkyl and amide derivatives of 5,5-diphenylhydantoin
AU Kiec-Kononowicz, Katarzyna; Stypula, Ewa; Krupinska, Jolanta; Cebo, Barbara
CS Dep. Pharm. Chem., Med. Acad., Krakow, 31-065, Pol.
SO Polish Journal of Pharmacology and Pharmacy (1985), 37(5), 693-9
CODEN: PJPPAA; ISSN: 0301-0244
DT Journal
LA English

L14 ANSWER 53 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1985:32235 CAPLUS Full-text
DN 102:32235
OREF 102:5117a,5120a
TI Pharmaceutical complexes with cyclodextrin and glycol diglycidyl ether polymers
PA Mitsubishi Petrochemical Co., Ltd., Japan; Mitsubishi Yuka Pharmaceutical Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 59164728	A	19840917	JP 1983-38473	19830309
PRAI JP 1983-38473		19830309		

L14 ANSWER 54 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1984:490608 CAPLUS Full-text
DN 101:90608
OREF 101:13879a,13882a
TI Urea derivatives and their use
IN Stransky, Werner; Schroeder, Ludwig; Mengel, Rudolf; Lust, Sigmund; Linden, Gerbert
PA Celamerck G.m.b.H. und Co. K.-G., Fed. Rep. Ger.
SO Ger. Offen., 16 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 3236626	A1	19840405	DE 1982-3236626	19821004
PRAI DE 1982-3236626		19821004		
OS CASREACT 101:90608; MARPAT 101:90608				

L14 ANSWER 55 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1984:616279 CAPLUS Full-text
DN 101:216279
OREF 101:32715a,32718a
TI Phenytoin prodrugs. IV: Hydrolysis of various 3-(hydroxymethyl)phenytoin esters
AU Varia, S. A.; Schuller, S.; Stella, V. J.
CS Dep. Pharm. Chem., Univ. Kansas, Lawrence, KS, 66045, USA
SO Journal of Pharmaceutical Sciences (1984), 73(8), 1074-80
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English

L14 ANSWER 56 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1984:630412 CAPLUS Full-text
DN 101:230412
OREF 101:34989a,34992a
TI Phenytoin prodrugs. III: Water-soluble prodrugs for oral and/or parenteral use
AU Varia, S. A.; Schuller, S.; Sloan, K. B.; Stella, V. J.
CS Sch. Pharm., Univ. Kansas, Lawrence, KS, 66045, USA
SO Journal of Pharmaceutical Sciences (1984), 73(8), 1068-73
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English

L14 ANSWER 57 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1985:471246 CAPLUS Full-text
DN 103:71246
OREF 103:11465a,11468a
TI Reactions of 5,5-diphenylhydantoin and its 3-N-carboxylates with hydrazine and 2-morpholinoethylamine
AU Kiec-Kononowicz, Katarzyna; Zejc, Alfred; Byrtus, Hanna
CS Dep. Pharm. Chem., Sch. Med., Krakow, 31065, Pol.
SO Polish Journal of Chemistry (1984), 58(4-5-6), 585-91
CODEN: PJCHDQ; ISSN: 0137-5083
DT Journal
LA English
OS CASREACT 103:71246

L14 ANSWER 58 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1985:78766 CAPLUS Full-text
DN 102:78766
OREF 102:12349a,12352a
TI Phase-transfer catalysis by poly(ethyleneglycol) 600 in the Biltz synthesis of phenytoin.
AU Poupaert, Jacques H.; De Keyser, Jean Luc; Vandervorst, Daniel; Dumont, Pierre
CS Brussels, B-1200, Belg.
SO Bulletin des Societes Chimiques Belges (1984), 93(6), 493-5
CODEN: BSCBAG; ISSN: 0037-9646
DT Journal
LA English
OS CASREACT 102:78766

L14 ANSWER 59 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1983:609278 CAPLUS Full-text
DN 99:209278
OREF 99:32141a,32144a
TI Assay method
IN Allen, Gerald John

PA Amersham International PLC, UK
SO Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 92344	A1	19831026	EP 1983-301943	19830406
	R: DE, FR, GB				
	JP 58190762	A	19831107	JP 1983-66281	19830414
PRAI	GB 1982-10928	A	19820415		

L14 ANSWER 60 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1983:435662 CAPLUS Full-text
DN 99:35662
OREF 99:5573a,5576a
TI Fluoroimmunoassay system
IN Hendrix, John L.
PA Bio-Diagnostics, Inc., USA
SO Eur. Pat. Appl., 60 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 71991	A2	19830216	EP 1982-107102	19820806
	EP 71991	A3	19830907		
	EP 71991	B1	19860514		
	R: AT, DE, FR, GB, IT				
	CA 1186621	A1	19850507	CA 1982-408817	19820805
	AT 19828	T	19860515	AT 1982-107102	19820806
	AU 8287024	A	19830512	AU 1982-87024	19820810
	AU 565418	B2	19870917		
	JP 58086459	A	19830524	JP 1982-139112	19820810
	JP 03079665	B	19911219		
	AU 8774987	A	19871022	AU 1987-74987	19870630
PRAI	US 1981-291793	A	19810810		
	EP 1982-107102	A	19820806		

L14 ANSWER 61 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1984:22537 CAPLUS Full-text
DN 100:22537
OREF 100:3541a,3544a
TI Application of spin labeling to drug assays. III. 2,2,5,5-tetramethylpyrroline-15N,d13-1-oxyl-3-carboxylic acid coupled to phenytoin
AU Yost, Yul; Polnaszek, Carl F.; Holtzman, Jordan L.
CS Res. Serv., VA Med. Cent., Minneapolis, MN, 55417, USA
SO Journal of Labelled Compounds and Radiopharmaceuticals (1983), 20(6), 707-17
CODEN: JLCRD4; ISSN: 0362-4803
DT Journal
LA English

L14 ANSWER 62 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1984:114425 CAPLUS Full-text
DN 100:114425
OREF 100:17249a,17252a
TI Radioimmunoassay of diphenylhydantoin

AU Wu, Jianzhong; Jia, Liguo; Zhu, Yanzhen
CS Beijing Inst. Neurosurg., Beijing, Peop. Rep. China
SO Zhonghua Yixue Jianyan Zazhi (1983), 6(2), 65-7
CODEN: CHCCDO; ISSN: 0253-973X
DT Journal
LA Chinese

L14 ANSWER 63 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1983:122427 CAPLUS Full-text
DN 98:122427
OREF 98:18605a,18608a
TI Stabilization of glucose oxidase apoenzyme
IN Rupchock, Patricia A.; Tyhach, Richard J.
PA Miles Laboratories, Inc. , USA
SO U.S., 17 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4366243	A	19821228	US 1981-255310	19810417
PRAI US 1981-255310		19810417		

L14 ANSWER 64 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1983:68454 CAPLUS Full-text
DN 98:68454
OREF 98:10421a,10424a
TI Homogeneous specific binding assay test device having a copolymer enhancing substance
IN Tabb, David L.; Tyhach, Richard J.
PA Miles Laboratories, Inc. , USA
SO U.S., 15 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4362697	A	19821207	US 1981-255759	19810420
PRAI US 1981-255759		19810420		
OS MARPAT 98:68454				

L14 ANSWER 65 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1982:466393 CAPLUS Full-text
DN 97:66393
OREF 97:10983a,10986a
TI Fluorescent reagent and method for determining immunofluorescence.
IN Tsay, Yuh Geng; Chen, Janet H.; Palmer, Richard J.
PA International Diagnostic Technology, Inc., USA
SO Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 47459	A2	19820317	EP 1981-106776	19810829
EP 47459	A3	19820324		
EP 47459	B1	19841121		

R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE

	AT 10399	T	19841215	AT 1981-106776	19810829
	CA 1172560	A1	19840814	CA 1981-385220	19810904
	DK 8103946	A	19820309	DK 1981-3946	19810907
	FI 8102771	A	19820309	FI 1981-2771	19810907
	FI 72394	B	19870130		
	FI 72394	C	19870511		
	NO 8103029	A	19820309	NO 1981-3029	19810907
	NO 155516	B	19861229		
	JP 57077963	A	19820515	JP 1981-140808	19810907
PRAI	US 1980-185235	A	19800908		
	EP 1981-106776	A	19810829		

L14 ANSWER 66 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1983:422468 CAPLUS Full-text
DN 99:22468
OREF 99:3637a,3640a
TI 3-(γ-Amino-β-hydroxypropyl)-5,5-diphenylhydantoin derivatives
IN Zejc, Alfred; Kiec-Kononwicz, Katarzyna
PA Polska Akademia Nauk, Instytut Farmakologii, Pol.
SO Pol., 4 pp.
CODEN: POXXA7
DT Patent
LA Polish
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	PL 114751	B1	19810228	PL 1977-202530	19771130
PRAI	PL 1977-202530	A	19771130		
OS	CASREACT 99:22468				

L14 ANSWER 67 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1983:78068 CAPLUS Full-text
DN 98:78068
OREF 98:11843a,11846a
TI Intravenous solution of sodium diphenyl hydantoin: preparation and stability control
AU Ibanez, S.; Mendoza, Maria L.; Sanchez-Morcillo, J.
CS Serv. Farm., C.S. "Virgen de las Nieves", Granada, Spain
SO Revista de la Asociacion Espanola de Farmaceuticos de Hospitales (1982), 6(2), 133-7
CODEN: RAEHDT; ISSN: 0210-6329
DT Journal
LA Spanish

L14 ANSWER 68 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2
AN 1981:417983 CAPLUS Full-text
DN 95:17983
OREF 95:3021a,3024a
TI A nonmetabolized analog of phenytoin
AU Henderson, James D.; Dayton, Peter G.; Israili, Zafar H.; Mandell, Leon
CS Dep. Med., Emory Univ., Atlanta, GA, 30322, USA
SO Journal of Medicinal Chemistry (1981), 24(7), 843-7
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English

L14 ANSWER 69 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1982:104166 CAPLUS Full-text
DN 96:104166

OREF 96:17109a,17112a
TI The synthesis of some carbon-11-labeled antiepileptic drugs with potential utility as radiopharmaceuticals: hydantoins and barbiturates
AU Roeda, D.; Westera, G.
CS Dep. Org. Chem., Vrije Univ., Amsterdam, 1081 HV, Neth.
SO International Journal of Applied Radiation and Isotopes (1981), 32(11), 843-5
CODEN: IJARAY; ISSN: 0020-708X
DT Journal
LA English

L14 ANSWER 70 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1980:506758 CAPLUS Full-text
DN 93:106758
OREF 93:16909a,16912a
TI A new metabolite of 5,5-diphenylhydantoin containing an epoxide-ol moiety
AU Lhoest, G.; Poupaert, J. H.; Claesen, M.
CS Sch. Pharm., Univ. Cathol. Louvain, Louvain, Belg.
SO European Journal of Mass Spectrometry in Biochemistry, Medicine and Environmental Research (1980), 1(1), 57-9
CODEN: EJMRDJ; ISSN: 0379-8399
DT Journal
LA English

L14 ANSWER 71 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1979:197383 CAPLUS Full-text
DN 90:197383
OREF 90:31255a,31258a
TI Fluorinated phenytoin anticonvulsant analogs
AU Nelson, Wendel L.; Kwon, Young G.; Marshall, Gary L.; Hoover, James L.; Pfeffer, Gary T.
CS Sch. Pharm., Univ. Washington, Seattle, WA, USA
SO Journal of Pharmaceutical Sciences (1979), 68(1), 115-17
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English

L14 ANSWER 72 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1979:420399 CAPLUS Full-text
DN 91:20399
OREF 91:3413a,3416a
TI Synthesis of 5,5-diphenylhydantoin
AU Chiang, Hung-Cheh; Li, Shyh-Yuan; Shih, Hsi-Pin
CS Inst. Chem., Natl. Taiwan Normal Univ., Taipei, Taiwan
SO Kexue Fazhan Yuekan (1979), 7(1), 21-31
CODEN: KHFKDF; ISSN: 0250-1651
DT Journal
LA Chinese

L14 ANSWER 73 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1978:529930 CAPLUS Full-text
DN 89:129930
OREF 89:20125a,20128a
TI Labeled 5,5-diphenylhydantoin derivatives for radioimmunoassay
IN Parsons, George H., Jr.; Eller, Thomas
PA Baxter Travenol Laboratories, Inc., USA
SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4092479	A	19780530	US 1976-673853	19760405
	US 4145407	A	19790320	US 1977-835481	19770922
PRAI	US 1976-673853	A3	19760405		

OS MARPAT 89:129930

L14 ANSWER 74 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1977:529616 CAPLUS Full-text
DN 87:129616
OREF 87:20589a,20592a
TI Preparation of iodine-131-labeled diphenylhydantoin and its organ distribution in rats
AU Angelberger, Peter; Pils, Peter; Wiesinger, Franz; Tragl, Karl Heinz
CS Oesterr. Studienges. Atomenerg. G.m.b.H., Vienna, Austria
SO Ber. Oesterr. Studienges. Atomenerg. (1977), SGAE Ber. No. 2701, 14 pp.
CODEN: BOAEBM
DT Report
LA English

L14 ANSWER 75 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1978:151656 CAPLUS Full-text
DN 88:151656
OREF 88:23885a,23888a
TI Mechanistic studies in the chemistry of urea. Part 2. Reaction with benzil, 4,4'-dimethylbenzil, and 4,4'-dimethoxybenzil
AU Butler, Anthony R.; Leitch, Elizabeth
CS Dep. Chem., Univ. St. Andrews, St. Andrews, UK
SO Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999) (1977), (14), 1972-6
CODEN: JCPKBH; ISSN: 0300-9580
DT Journal
LA English

L14 ANSWER 76 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1975:497130 CAPLUS Full-text
DN 83:97130
OREF 83:15253a,15256a
TI Hydantoins, thiohydantoins, and glycocyamidines. 41. Reaction of N-cyano amines with 1-(tert-butyl)-3,3-diphenylaziridinone. General method for the synthesis of 1-alkyl-, 1-aralkyl-, and 1-aryl-5,5-diphenyl hydantoins and -glycocyamidines
AU Simig, G.; Lempert, K.; Tamas, J.; Czira, G.
CS Res. Group Alkaloid Chem., Hung. Acad. Sci., Budapest, Hung.
SO Tetrahedron (1975), 31(9), 1195-200
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA English
OS CASREACT 83:97130

L14 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1975:578887 CAPLUS Full-text
DN 83:178887
OREF 83:28089a,28092a
TI Chemistry of a novel 5,5-diphenylhydantoin prodrug
AU Stella, V.; Higuchi, T.; Hussain, A.; Truelove, J.
CS Dep. Pharm. Chem., Univ. Kansas, Lawrence, KS, USA
SO ACS Symposium Series (1975), 14(Pro-drugs Novel Drug Delivery Syst., Sypm., 1974), 154-83

CODEN: ACSMC8; ISSN: 0097-6156
DT Journal
LA English

L14 ANSWER 78 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1974:95826 CAPLUS Full-text
DN 80:95826
OREF 80:15411a,15414a
TI Hydantoins, thiohydantoins, and glycocyamidines. 39. S-Demethylations and -debenzylations of hydantoin and thiohydantoin derivatives
AU Domany, Gyorgy; Nyitrai, Jozsef; Zauer, Koroly; Lempert, Karoly; Bekassy, Sandor
CS Dep. Org. Chem., Tech. Univ., Budapest, Hung.
SO Acta Chimica Academiae Scientiarum Hungaricae (1974), 80(1), 101-10
CODEN: ACASA2; ISSN: 0001-5407
DT Journal
LA English

L14 ANSWER 79 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1972:140814 CAPLUS Full-text
DN 76:140814
OREF 76:22867a,22870a
TI 5,5-Diphenylhydantoin
IN Kolbeck, Winfried; Bayerlein, Friedrich
PA Diamalt A.-G.
SO U.S., 2 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3646056	A	19720229	US 1970-10317	19700210
PRAI US 1970-10317	A	19700210		

L14 ANSWER 80 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1971:130340 CAPLUS Full-text
DN 74:130340
OREF 74:21015a,21018a
TI Lepsiral composition
AU Zieloff, K.
CS Berlin-Weissensee, Fed. Rep. Ger.
SO Zentralblatt fuer Pharmazie, Pharmakotherapie und Laboratoriumsdiagnostik (1970), 109(11), 1179-82
CODEN: ZPPLBF; ISSN: 0049-8696
DT Journal
LA German

L14 ANSWER 81 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1968:402905 CAPLUS Full-text
DN 69:2905
OREF 69:563a,566a
TI Methoxy derivatives of 5,5-diphenylhydantoin and 5-phenyl-5-benzylhydantoin
AU Novelli, Armando; De Santis, Alberto M.
CS Univ. Buenos Aires, Buenos Aires, Argent.
SO Journal of Medicinal Chemistry (1968), 11(1), 176-8
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English

L14 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1968:39508 CAPLUS Full-text
DN 68:39508
OREF 68:7675a,7678a
TI Organic sulfur compounds. XCV. Base-catalyzed reaction of substituted benzils with urea and thiourea to give glycolurils, hydantoins, imidazolidinones, and dithioglycolurils and thiohydantoins, respectively
AU Dietz, Werner; Mayer, Roland
CS Organ. Lab., VEB Fettchem., Karl-Marx-Stadt, Fed. Rep. Ger.
SO Journal fuer Praktische Chemie (Leipzig) (1968), 37(1-2), 78-90
CODEN: JPCEAO; ISSN: 0021-8383
DT Journal
LA German

L14 ANSWER 83 OF 83 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1967:442154 CAPLUS Full-text
DN 67:42154
OREF 67:7879a,7882a
TI Acute intoxication due to methsuximide and diphenylhydantoin
AU Schulte, Charles J. A.; Good, Thomas A.
CS Univ. of Maryland Med. School, Baltimore, MD, USA
SO Journal of Pediatrics (St. Louis, MO, United States) (1966), 68(4), 635-7
CODEN: JOPDAB; ISSN: 0022-3476
DT Journal
LA English

=> exit
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	104.77	406.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-56.00

STN INTERNATIONAL LOGOFF AT 12:06:57 ON 14 JUL 2008